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Summary 
Buruli ulcer (BU) is a chronic debilitating disease of the skin and soft tissues caused by 
Mycobacterium ulcerans. It is one of the 17 neglected tropical diseases according to the World 
Health Organization and has been reported in over 30 countries with tropical and sub-tropical 
conditions globally. M. ulcerans is traditionally considered as an environmental pathogen and even 
though BU was discovered over half a century ago, the environmental reservoir and exact mode of 
transmission of this pathogen remain obscure. This makes it challenging to formulate strategies for 
its prevention. As such, control strategies geared towards the early detection and treatment of cases 
are vital to minimize morbidity, disability and the socio-economic burden associated with the 
disease. The introduction of antibiotic therapy for treatment in 2004 to replace surgery as first-line 
therapy has brought about an improvement in the management of the disease. However, despite 
reported successful outcomes with the antibiotic treatment, the healing process is still characterized 
by long hospitalizations as a result of delayed wound closure. 
In this thesis, we explored the factors which could contribute to the observed delayed wound 
healing in two BU treatment centers in Ghana; the Ga-West Municipal Hospital and the Obom 
Health Center. Through a combination of clinical, microbiological and histopathological analysis, 
we identified secondary infection of BU lesions by other bacteria as a major cause of delayed 
healing. Through quantitative microbiological studies, we analysed the evolution of the bacterial 
burden and identified increased loads of bacteria post treatment which could negatively impact on 
the healing potential of the wounds. Furthermore, we explored co-infection with Human 
immunodeficiency virus (HIV) in the Ga-West Municipal Hospital as a challenge to the 
management of BU and described challenges associated with the management of this co-infection. 
Studying the isolated bacterial species through phenotypic, molecular and whole genome 
approaches helped to identify health-care associated transmission through health workers and 
equipment as well as self transmission as potential sources of wound infection within the health 
centers. With these results, we made recommendations for the improvement of wound management 
in the health centers and made a case for the need for wound management guidelines which were 
absent in the health centers. We followed this up with the development of local guidelines for 
wound care and the implementation of several interventions in the health centers. We also 
identified antibiotic resistance as an increasing problem and described in detail through whole 
genome sequencing, a recently emerged and rapidly spreading clone of community acquired 
methicillin resistant Staphylococcus aureus with sequence type 88 in Ghana which has the potential 
to become a serious public health threat with implications for healthcare. This alarming result 
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therefore calls for the urgent establishment of a surveillance system to monitor the use and 
distribution of antibiotics in Ghana and the emergence of antibiotic resistant pathogens. 
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Zusammenfassung 
Das Buruli-Ulkus (BU) ist eine chronische, verheerende Erkrankung der Haut und des 
Weichgewebes, die durch Mycobacterium ulcerans hervorgerufen wird. Das BU gehört gemäss 
Weltgesundheitsorganisation zu den 17 vernachlässigten Tropenkrankheiten und das Auftreten der 
Krankheit wurde aus mehr als 30 tropischen und sub-tropischen Ländern weltweit gemeldet. Bisher 
wurde allgemein angenommen, dass M. ulcerans ein Umwelterreger ist, doch obwohl das BU seit 
über einem halben Jahrhundert bekannt ist, bleiben die Infektionsquellen und der genaue 
Übertragungsweg des Erregers unklar. Dadurch ist es schwierig Präventionsmassnahmen zu 
entwickeln. Strategien zur Kontrolle der Krankheit, die eine frühe Erkennung und Behandlung von 
Patienten anstreben, sind entscheidend, um die mit der Krankheit verbundene Morbidität, 
Invalidität und wirtschaftlich-soziale Belastung möglichst gering zu halten. Die Einführung der 
Antibiotika-Therapie für die Behandlung der Krankheit im Jahre 2004, die die operative 
Behandlung als Erstlinientherapie abgelöst hat, hat wesentlich zur Verbesserung des 
Krankheitsmanagements beigetragen. Obwohl mit der Antibiotikabehandlung Berichten zufolge 
erfolgreiche Ergebnisse erzielt werden, ist der Heilungsprozess infolge von verzögerter 
Wundheilung noch immer von langen Krankenhausaufenthalten geprägt. 
In dieser Doktorarbeit haben wir in zwei Behandlungszentren für das BU in Ghana (das 
kommunale Ga-West Krankenhaus und das Gesundheitszentrum in Obom) die Faktoren erforscht, 
die zur beobachteten verzögerten Wundheilung beitragen könnten. Mit Hilfe einer Kombination 
aus klinischen, mikrobiologischen und histopathologischen Analysen, haben wir die 
Sekundärinfektion von BU Läsionen durch andere Bakterien als den Hauptgrund für die verzögerte 
Heilung bestimmt. Durch quantitative, mikrobiologische Analysen, haben wir die Entwicklung der 
bakteriellen Belastung untersucht und eine erhöhte Belastung durch Bakterien nach der 
Behandlung festgestellt, was einen negativen Einfluss auf das Heilungsvermögen der Wunden 
haben könnte. Des Weiteren haben wir im kommunalen Ga-West Krankenhaus erforscht, dass eine 
Ko-Infektion mit dem Humanen Immundefizienz-Virus (HIV) eine Herausforderung für die 
Bewältigung des BU darstellt und mit der Behandlung dieser Ko-Infektion verbundene 
Schwierigkeiten beschrieben. Die Analyse von isolierten Bakterienspezies mit Hilfe von 
phänotypischen, molekularen und genomumfassenden Ansätzen, hat dazu beigetragen sowohl die 
mit der Gesundheitspflege verbundene Übertragung durch das Gesundheitspersonal und die Geräte 
als auch die Selbstübertragung als mögliche Quelle für die Wundinfektion innerhalb der 
Gesundheitszentren zu identifizieren. Mit diesen Resultaten, konnten wir Empfehlungen für die 
Verbesserung der Wundversorgung in den Gesundheitszentren geben und für die Notwendigkeit 
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von Richtlinien für die Wundversorgung, die bisher in den Gesundheitszentren gefehlt haben, 
plädieren. Wir haben dies durch die Entwicklung von lokalen Richtlinien für die Wundbehandlung 
und die Durchführung von mehreren Massnahmen in den Gesundheitszentren weiterverfolgt. 
Zudem haben wir Antibiotikaresistenz als ein zunehmendes Problem identifiziert und mit Hilfe der 
Sequenzierung von Gesamtgenomen einen in Ghana unlängst aufgetretenen und sich rasch 
ausbreitenden Klon von im Krankenhaus erworbenen methicillinresistenten Staphylococcus aureus 
Bakterien mit dem Sequenztyp 88, der das Potential hat eine schwerwiegende Bedrohung für die 
öffentliche Gesundheit darzustellen, im Detail beschrieben. Dieses besorgniserregende Ergebnis 
macht daher deutlich, dass eine dringende Einrichtung eines Kontrollsystems notwendig ist, das 
den Gebrauch und die Verteilung von Antibiotika in Ghana und das Auftreten von 
Antibiotikaresistenzen  überwacht. 
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Introduction 
Buruli Ulcer Disease 
Buruli ulcer (BU), a disease caused by the bacteria Mycobacterium ulcerans is known as one of the 
17 neglected tropical diseases according to the World Health Organization (WHO) [1]. This 
disease was first clinically described in 1948 by MacCallum et al [2]; however earlier reports of the 
existence of a disease marked by large ulcerations in Africa and Australia had been made as far 
back as the second half of the nineteenth century [3-4]. It is the third most common mycobacterial 
disease of non-immunocompromised humans after tuberculosis and leprosy and the least 
understood [5].  Though it is thought to have a low mortality rate, it has great socioeconomic 
impact on the affected and their communities in terms of morbidity and its stigmatizing 
complications [6]. This prompted the WHO to name it as an emerging public health problem with 
the launch of a Global Buruli ulcer Initiative in 1998 [7] and the subsequent signing of the 
Yamoussoukro declaration on Buruli ulcer by representatives of more than 20 countries as a pledge 
to control the disease [8].  Since then, global efforts have intensified to improve control and 
accelerate research into the many unknowns of this disease.  
 
Etiology and Clinical Features  
The etiologic agent is a slow-growing acid fast bacillus similar to Mycobacterium tuberculosis 
(Mtb). In contrast to Mtb, it has an optimal growth temperature of 30-32
0
C and is sensitive to 
temperatures of 37
0
C or higher [9]. It also produces a necrotizing and immunosuppressive 
polyketide toxin called mycolactone as its virulence factor which plays an important role in its 
pathogenesis [10-12]. Genomic analysis of MU showed that it diverged from Mycobacterium 
marinum about a million years ago by horizontal gene transfer and reductive evolution [13]. While 
evolving, this bacterium acquired a 174-kb virulent plasmid pMUM001 and it has been 
hypothesized that this plasmid aided its adaptation to a new environment [14-17]. This plasmid 
carries a cluster of genes encoding giant polyketide synthases and polyketide-modifying enzymes 
responsible for the production of the macrolide toxin mycolactone. Mycolactone diffuses into 
subcutaneous tissues inducing necrosis and ulceration by its cytotoxic properties.  
The disease presents with a spectrum of forms, which can be either non-ulcerative or ulcerative. 
The non-ulcerative forms are characterized by nodules, papules, plaques and oedema. The nodule 
is a painless, firm and palpable subcutaneous form frequently found in Africa (Figure 1a) while the 
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papule is a painless raised skin lesion with erythema in the surrounding skin observed mainly in 
Australia (Figure 1b). Disseminated forms of the disease may present as a plaque (Figure 1c), 
which is a hardened, raised and dry painless lesion usually covered with discoloured skin or an 
oedema characterized by a firm and diffuse non-pitting swelling with nonspecific edges (Figure 
1d). If left untreated, these forms can evolve into severe large ulcerated lesions with rugged 
undermined, hyperpigmented edges and bases which contain a whitish necrotic slough (Figure 1e). 
The different presentations of the disease have also been classified into categories by the WHO, 
taking into account the size of the lesions, number of lesions and the site of lesion presentation. 
Thus, there are three categories: category I for single lesions less than 5cm in diameter, category II 
for lesions between 5-15cm in diameter and category III for single lesions above 15cm, multiple 
lesions, lesions found at critical sites and cases of osteomyelitis.  In about 85% of cases [18], the 
disease presents mainly on the limbs but the infection can also traverse the deep fascia and affect 
muscles, blood vessels, bones and joints finally leading to dramatic functional limitations in the 
affected.  
       
   
Figure 1: Clinical Presentations of Buruli ulcer disease, A= nodule, B=papule, C=plaque, 
D=oedema, E=ulcer  
 
 
  
A B C 
D E 
 
 
14 
 
Epidemiology and Diagnosis 
BU has been reported in 34 countries (Figure 2) globally with tropical, subtropical and temperate 
climates near areas of stagnant or slow flowing rivers and marshlands; an association that has been 
shown to be a risk factor for infection [19-20]. Geographically, the disease has been described in 
Africa, Asia, the Americas and Australia [21]. Africa is the worst affected continent with the 
highest incidence reported in Western African countries of Ghana, Cote d’Ivoire and Benin [22-
27]. It is estimated that over 5000-6000 cases are reported yearly; though a decline has been seen 
recently with only 2,251 new cases reported in 2014 [28]. All age groups are affected by the 
disease but in Africa the greatest burden is in children below the age of 15 years [28]. 
 
Figure 2: Global Distribution of Buruli ulcer, 2013  
BU can be clinically diagnosed and experienced health workers in endemic areas may be able to 
make an accurate clinical diagnosis of the disease [29-30]. However, in practice, misdiagnosis is 
common [22, 31-32] with reported rates up to about 50% [33] and the proportion of false negatives 
is usually not accessed, since patients are sent away and not followed up.  Clinical diagnosis should 
therefore be confirmed by laboratory tests, either by conventional or molecular methods. 
Misdiagnosis is stemming from the large number of organisms which also cause cutaneous 
infections and other non-infectious pathologies which may resemble BU [34]. Laboratory diagnosis 
also helps to confirm the accurate prevalence and incidence, helps to identify new foci, aids in the 
management of the disease and facilitates the differentiation of relapses from re-infection after 
treatment.  
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Tests available for the confirmation of BU diagnoses are; direct examination of acid fast bacilli in 
Ziehl-Neelson stained smears, in vitro culture, histopathology and the polymerase chain reaction 
(PCR) amplification of the insertion sequence 2404 elements (IS2404) found in multiple copies in 
the genome of M. ulcerans. Smear microscopy is the simplest and most widely used method which 
is also available in most endemic areas as a first line diagnostic test. It however has a low 
sensitivity with reported rates of about 50% even with strong clinical suspicion. Culture is not 
readily available in many endemic areas and is precluded as a rapid diagnostic method because of 
the slow-growing nature of the bacilli though sensitivity rates of up to 60% have been reported. 
Histopathological analysis is highly sensitive; confirming 90% of all cases but unavailable in many 
endemic settings. Molecular diagnostic methods are fast with a high sensitivity but unavailable in 
many endemic areas. PCR amplification of IS2404 is considered the gold standard diagnostic 
method with sensitivity around 96% and WHO recommends that at least 70% of all clinically 
suspected cases be confirmed by a PCR positive result [35]. This test however presents technical 
difficulties with implementation in a field setting, is expensive and also requires a high level of 
technical expertise. It is therefore restricted to only a few well-equipped and specialized reference 
laboratories.  
 
Treatment  
Spontaneous healing of BU lesions has been reported by several research groups [36-38] especially 
for early non-ulcerative forms [37].  Historically however, surgery was the standard treatment of 
choice for management of the disease and involved the removal of dead tissues through 
debridement or excision, followed by skin grafting. With this method, wide margins including 
healthy tissue had to be excised to stop the infection, ensure the complete removal of all affected 
tissue and prevent recurrence or relapse at the affected site. This treatment modality however 
presented with a number of challenges including long hospital stays [6] by patients and its effect on 
the health centers which were ill-equipped and lacked the capacity to accommodate patients for 
long periods of time. Surgery was also accessible to only a fraction of affected patients and the 
dramatic nature of the procedure leading to wide and traumatizing excisions and skin grafting often 
involving multiple operations impacted poorly on control efforts as affected patients will be 
reluctant to report at health facilities for treatment for fear of surgery. Also, lesions would finally 
heal at the expense of more severe sequelae than would result from simple surgical interventions 
consequently resulting in more functional disabilities in the absence of physiotherapy. In addition, 
though there was success with this method, recurrence was not uncommon and rates ranged 
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between 16%-28% [39-40]. In a retrospective comparative study, 47% of patients from one 
treatment center had either ulcers that never healed or healed, but had a recurrence, supporting the 
hypothesis that wider surgical excision improves the chance of healing of BU[41].  
To minimize or circumvent surgical interventions, several other approaches involving chemical and 
physical topical treatments have been explored and proposed. These include the use of 6% nitrogen 
oxides which was reported to kill M. ulcerans in vitro and also in a small randomized control trial 
[42-43], hyperbaric oxygen, phenytoin powder which appeared promising in accelerating healing 
and showed ulcer surface reduction of more than 50% in a randomised control trial [44-45] and 
clay which was shown to allow quick resolution of oedemas and vigorous debriding of ulcers [46]. 
Application of heat, taking advantage of the temperature sensitivity of M. ulcerans has also been 
documented with its efficacy demonstrated in several studies [9, 47-49]. Some of these other 
methods however have limited practicality in remote areas where most of the cases are reported 
from, because of the complicated nature of the devices and dressings needed for their 
implementation, high costs and the discomfort it brought for patients [5]. 
Finding a drug treatment regimen thus represented a major research priority for the WHO and with 
it the search for the appropriate antibiotic combination to combat this disease. Many antibiotics 
were found to show excellent results in vitro against M. ulcerans with various combinations 
inhibiting its growth in animal models [37, 50-56]. High sensitivity of M. ulcerans to rifampicin 
[50], aminoglycosides [51], macrolides [52] and quinolones [51]  was reported and studies in 
animal models showed that monotherapies of rifampicin and aminoglycosides was highly 
efficacious by exerting a strong bactericidal effect on M. ulcerans [54-55]. Monotherapy was 
however discouraged because M. ulcerans could become resistant to rifampicin and resistant 
mutants had been observed after monotherapy in mice [57]. The aminoglycosides on the other hand 
have long term side effects as they are known to cause ototoxic damage, vestibule-toxic 
impairments, nephrotoxicity and encephalopathy [58-61]  
Based on these results and clinical trials performed in Ghana [62], the WHO issued guidelines with 
a combination of rifampicin and streptomycin for 8 weeks as the treatment of choice for 
management of  the disease with the hope of minimizing indications of surgery and hopefully also 
decrease relapse rates [63].  Evidence accumulating after the implementation of these guidelines 
shows treatment success with recurrence rates of less than 3% [64].   
 
  
 
 
17 
 
Wound healing 
Wound healing is a complex process made up of four main stages, hemostasis, inflammation, 
proliferation and tissue remodeling or resolution. These phases are integrated and highly overlap. 
Interference with one or more of these phases leading to the inability of the wound to progress 
through the normal stages of healing results in the formation of a chronic wound. Such wounds 
would not respond normally to traditional wound management practices and standard protocols of 
care [65]. Factors that can affect wound healing could be either local or systemic. Local factors 
such as oxygenation, infection, venous sufficiency and foreign bodies affect the characteristics of 
the wound itself [66-67]. Systemic factors such as age, gender, sex hormones, stress, ischemia, 
diseases, medications, alcoholism and smoking, immunocompromised conditions and nutrition 
affect the overall health and disease state of the affected individual, consequently affecting the 
ability of the wound to heal [66]. 
Wound microbiology 
The human body is estimated to contain 10
14
 microbial cells playing various roles in the 
maintenance of health. Some of these microbes however, have the potential to cause disease and 
this is seen under opportunistic circumstances such as a breach in skin integrity leading to an 
injury. When a wound occurs, microorganisms which are normally found at the skin surface gain 
access into the underlying tissues, contaminating the wound. Other sources of wound contaminants 
are the environment and endogenous sources involving mucous membranes of the gastrointestinal, 
oropharyngeal and the genitourinary mucosa [68]. The establishment of a wound microbiota goes 
through several stages called a wound infection continuum. First is the contamination stage 
characterized by the presence of non-replicating microorganisms [65, 67]. At this stage, the 
microorganisms are suppressed or regulated by appropriate host defenses if the affected individual 
is not immunocompromised or physiologically challenged. Next is a colonization stage consisting 
of reversible and irreversible adhesion stages and characterized by the presence of replicating 
microorganisms in the absence of tissue damage. In the reversible adhesion stage, microorganisms 
access the wound environment using chemical receptors and either attach to the wound surface or 
remain planktonic based on the environmental signals [65]. At this stage of colonization, they can 
be detached by the application of low levels of force and are sensitive to host defenses and 
antimicrobial agents. As this stage progresses, stronger surface interactions are created leading to 
the formation of an irreversible attachment, biofilms and the production of intracellular and 
extracellular substances for polymeric encasement. Multiplication begins and an inherent resistance 
to antimicrobial agents develops. Continuous multiplication leads to the creation of micro-colonies 
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and a complex environment is created leading to decreased oxygen availability and hypoxia at 
certain sites in the wound. This will encourage the proliferation of anaerobic organisms further 
complicating the microbial community and increasing microbial diversity. Subsequently, critical 
colonization occurs where the microorganisms may colonize and multiply within the wound, 
inducing a non-healing state without clinical signs of infection or a visible host reaction. A mature 
biofilm is created when the microbial ecosystem climaxes and stabilizes. Exponential 
multiplication of bacteria within this mature biofilm leads to local infection driven by the bacterial 
burden exceeding a certain level and inducing host immune responses. If local infection is not 
managed properly and microbial burdens are uncontrolled, systemic infection may develop where 
bacteria invade new tissues and can find their way into the bloodstream causing bacteremia leading 
to septicemia, organ failure and death in severe cases [65]. 
 
Figure 2: The wound infection continuum 
Figure adapted from Percival et al [65] 
The quantitative and qualitative microbiology of a wound is important as it impacts on wound 
healing. Quantitatively, the role of microorganisms in the clinical course of many diseases and 
infections has been found to be related to its load. Bendy et al [69] reported that wound healing in 
decubitus ulcers progressed only when the microbial load of wound fluid was below 10
6
cfu/ml and 
Majewski [70] also demonstrated that patients with wound contamination < 5 x10
4
 cfu/cm
2
 had 
more successful skin grafts. Other studies also found that the risk of wound infection increased 
with bacterial loads above 10
5
cfu/ml and this has led to the conclusion that the determination of 
bacterial loads could be useful in the prediction of wound healing and infection. One exception 
however is where a wound is contaminated with ß-haemolytic streptococci which have been found 
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to cause disease even at levels lower than 10
5
cfu/g of tissue. Chronic wounds may have a 
polymicrobial etiology involving both aerobic and anaerobic microorganisms. Microbial pathogens 
frequently isolated from wounds include Enterococcus spp, Staphylococcus aureus, coagulase 
negative Staphylococci, Escherichia coli, Pseudomonas aeruginosa, Proteus sp, Enterobacter sp.  
However, S. aureus, P. aeruginosa and ß-haemolytic Streptococci have been commonly implicated 
in wound infection and delayed wound healing due to their ability to produce destructive virulence 
factors notably enzymes and toxins. 
Wound Healing in Buruli ulcer disease 
The evolution of BU disease varies with its severity which depends on the form, extent and 
localization. Early limited lesions and small ulcers have been shown to heal with antibiotic therapy 
alone without the need for surgery in 81% of cases [71]. In a proportion of affected patients, wound 
healing is delayed [72] and the end of antimycobacterial therapy is followed by a period of 
monitoring and wound management often ending with some form of surgical intervention if the 
lesions do not show signs of healing by secondary intention. Management of BU disease may be 
complicated by secondary bacterial infection [73] or Human immunodeficiency virus (HIV) co-
infection [74-75] which affect the healing potential of wounds ultimately impacting treatment 
outcome. 
 
Secondary Bacterial Infection  
According to the World Health Organization (WHO) [76], secondary infection in BU should be 
suspected when a wound develops cellulitis or becomes painful. Secondary infection is not well 
characterized and recognized in BU disease as it is assumed to be uncommon [76]; therefore, only 
few studies have documented the occurrence of secondary infection in BU disease [73, 77-79]. It is 
assumed that secondary infections may result in severe complications such as sepsis, tetanus and 
death [77]. In the two studies that described the microbial flora of BU wounds, the isolated 
organisms included S. aureus, P. aeruginosa, P. mirabilis, Group A Streptococci, coagulase 
negative Staphylococci and several species of Enterobaceriaceae and other Gram negative 
pathogens [73, 79]. S. aureus and P. aeruginosa were the dominant isolates in both studies [73, 
79]. These two organisms are well known as common causes of infection of other wound types 
[65-68], are frequently implicated in health-care associated infections and exhibit increased 
resistance to antimicrobials through both intrinsic and acquired mechanisms [80-81]. They also 
form biofilms contributing to antibiotic tolerance [80] and persistence and thus infection by either 
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of these organisms can result in worse patient outcomes [82]. Of concern in these studies was the 
high frequency of methicillin resistant S. aureus (MRSA) isolation. In the Ghanaian study, 33% of 
isolated S. aureus were MRSA while 38% MRSA was reported by the study in Benin. An MRSA 
frequency of 13% was also reported by a recent study in Ghana [83]. MRSA infection is one of the 
current global threats to public health. The organisms were first detected in hospitals but the recent 
emergence of MRSA strains with a community origin has created a greater challenge in the fight 
against antimicrobial resistant pathogens.  
Though standard guidelines for the management of secondary infections in BU are currently 
unavailable, it behooves all stake holders in the health sector to optimize wound management 
practices and actively implement all strategies necessary to prevent or reduce the occurrence of 
secondary infection. 
BU-HIV Co-infection  
A high prevalence of HIV exists within areas of Africa burdened by BU, where adult HIV 
prevalences between 1-5% have been reported [84]. Thus, co-infection between HIV and BU has 
been increasingly recognized [84-85]. This co-infection presents an important challenge in the 
management of BU disease with studies suggesting that HIV may affect clinical presentation and 
result in multiple and larger lesions and also slower wound healing [74-75, 86]. Disseminated 
disease has been reported in individuals presenting with BU-HIV co-infection [86-89]. Though 
similar presentations were also reported in HIV negative BU cases [90], HIV infection was found 
to be a risk factor for disseminated disease and a significant predictor of bone involvement in the 
clinical course of the disease [91-92]. It is also thought to result in more severe BU [75, 84-85] and 
a study by Vincent et al reported that over 70% of HIV positive BU patients developed more 
severe disease in comparison with 50% of HIV negative patients [85]. HIV has been considered as 
a risk factor for BU disease [74-75] and its prevalence was reportedly three times higher among 
BU patients in an endemic area in Akonolinga, Cameroon compared with the regional prevalence 
[75]. Also, similar results have been obtained from Ghana and Benin where BU patients are 4 and 8 
times more likely to have HIV than non-BU patients [74, 93]. BU-HIV co-infected patients often 
present with severe immunosuppression [75, 84]. In a study conducted in a BU endemic area in 
Cameroon, 70% of BU-HIV infected patients were found to have CD4 counts ≤ 500 cells/mm3 at 
diagnosis, needing antiretroviral therapy [75]. Data from this study also found a higher mortality in 
BU-HIV co-infected individuals as compared with BU patients without HIV [75].  
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Preliminary guidelines have been issued by the WHO on the management of this co-infection [94]. 
Despite these guidelines, lack of information still exists with regards to the best way to manage 
HIV patients with active BU, optimal ART regimens, when to start ART, the impact of HIV on BU 
treatment outcomes, drug-drug interactions between BU treatment drugs and ART regimens and 
whether ART influences the occurrence of paradoxical reactions in BU patients and more scientific 
studies are needed to better understand the epidemiological, clinical and treatment implications of 
BU-HIV co-infection [84].  
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Goal 
The goal of this PhD study was to gain an understanding into the evolution of BU wounds during 
the course of treatment and wound healing delay. 
 
Objectives 
1. Identify causes of wound healing delay in BU disease in treatment centers in the Ga-South 
and Ga-West municipalities in Ghana. 
2. Explore challenges associated with the management of BU disease. 
3. Gain an understanding into possible routes of secondary infection of BU lesions. 
4. Provide information on the genetic background of Staphylococcus aureus species isolated 
from BU lesions. 
5. Characterize the antibiotic resistance profiles of bacteria isolated from BU lesions. 
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Abstract 
 
Buruli ulcer (BU), caused by Mycobacterium ulcerans is a chronic necrotizing skin disease. 
It usually starts with a subcutaneous nodule or plaque containing large clusters of 
extracellular acid-fast bacilli. Surrounding tissue is destroyed by the cytotoxic macrolide 
toxin mycolactone produced by microcolonies of M. ulcerans. Skin covering the destroyed 
subcutaneous fat and soft tissue may eventually break down leading to the formation of large 
ulcers that progress, if untreated, over months and years. Here we have analyzed the 
bacterial flora of BU lesions of three different groups of patients before, during and after 
daily treatment with streptomycin and rifampicin for eight weeks (SR8) and determined drug 
resistance of the bacteria isolated from the lesions. Before SR8 treatment, more than 60% of 
the examined BU lesions were infected with other bacteria, with Staphylococcus aureus and 
Pseudomonas aeruginosa being the most prominent ones. During treatment, 65% of all 
lesions were still infected, mainly with P. aeruginosa. After completion of SR8 treatment, 
still more than 75% of lesions clinically suspected to be infected were microbiologically 
confirmed as infected, mainly with P. aeruginosa or Proteus mirabilis. Drug susceptibility 
tests revealed especially for S. aureus a high frequency of resistance to the first line drugs 
used in Ghana. Our results show that secondary infection of BU lesions is common. This 
could lead to delayed healing and should therefore be further investigated. 
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   Author Summary 
 
Buruli ulcer (BU) can lead to large ulcerative lesions due to extensive skin loss caused by the 
necrotizing effect of the main virulence factor mycolactone. For a long time the general 
perception was that BU lesions are not infected by other bacteria because of a postulated 
antimicrobial effect of the macrolide toxin, mycolactone. In this study, we analyzed laboratory 
confirmed BU lesions before, during, and after streptomycin/rifampicin treatment. Contrary to 
popular belief, our findings show that BU lesions are frequently co-colonized with other 
potential bacterial pathogens before, during, and after antibiotic treatment. For example, 75% 
of cases that were clinically indicative of being infected after treatment were microbiologically 
confirmed as infected. Most microbiologically infected cases were also confirmed by 
histopathological analysis. The most prominent bacterial species isolated included 
Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis. When we tested the 
isolates against first line drugs used in Ghana, the isolates were found to be resistant to most of 
these drugs. This study indicates that wound care practices need to be improved and that wound 
infection may be a common cause of wound healing delay in BU. 
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Introduction 
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a necrotizing skin disease that affects 
mainly impoverished communities in Western and Central Africa. It is the third most common 
mycobacterial disease of humans after tuberculosis and leprosy. BU lesions are characterized by 
extensive necrosis and minimal pain and inflammation [1,2]. The pathogenesis of the disease is 
believed to be initiated by the inoculation of M. ulcerans into the subcutaneous layer of the skin, 
which may be facilitated by trauma or an insect vector. Most BU lesions are found at the 
extremities and contain extracellular clusters of acid-fast bacilli (AFB) in the subcutaneous fat 
tissue. The incubation period seems to be highly variable, and has been estimated to range from 
two weeks to three years, with an average of two to three months [3]. The disease begins typically 
as a painless nodule under the skin and gradually enlarges and erodes through the skin surface, 
leaving a well-demarcated ulcer with a necrotic slough in the base and widely undermined edges [3 
,4]. 
Traditionally, the mainstay treatment of BU was surgical removal of infected tissues followed by 
skin grafting [1]. This led to long hospital stays with the accompanied social problems of losses of 
school time by children and a large economical burden directly and indirectly to the affected 
families. Since 2006, after a pilot study in Ghana, the first line treatment of BU is SR8 (eight weeks 
of streptomycin daily injections and oral therapy with rifampicin) [5–7]. This has reduced surgery 
to an adjunct procedure in BU management. The general perception is that this treatment modality 
will reduce the length of stay in health facilities, since it removes the fear of surgery and 
encourages early reporting to the formal health sector for treatment. SR8 makes a decentralization 
of treatment possible, since staff of peripheral health facilities can administer streptomycin 
injections. 
The pathogenesis of BU is mediated mainly by a polyketide derived macrolide toxin, named 
mycolactone, with potent tissue necrotizing [8] and immunosuppressive activities [9,10]. 
Mycolactone produced by clusters of M. ulcerans leads to the destruction of the surrounding soft 
skin tissue and to the formation of devitalized, avascular tissue and ‘necrotic slough’ at the wound 
bed, which is very characteristic of BU [11]. The necrotic tissue could provide an ideal medium for 
bacterial growth and may disturb and delay wound healing. While there is a popular belief that 
secondary infections of BU lesions are rare, because mycolactone has antimicrobial activities, there 
is no published evidence base for this. 
It is controversial, whether bacteria present in wounds contribute to delays in wound healing, 
because wounds generally harbor transient microorganisms (contamination) [12]. The surfaces of 
wounds have microbial populations at each stage of healing and some of the bacteria may be 
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involved in mutually beneficial relationships with the host preventing more virulent organism from 
infecting deeper tissues. Such beneficial organisms include coagulase negative Staphylococcus and 
Corynebaceria species [12–14]. These contaminating organisms are derived from the normal flora 
of the surrounding skin, mucous membranes or from external environmental sources. Usually the 
immune defense mechanisms of the host can contain these contaminants with no harm and negative 
consequence to wound healing. However, some of the contaminating organisms can also go on to 
colonize, massively multiply and delay wound healing. Only when a critical concentration of these 
microorganisms is reached, signs of infection including erythema, pain, increase in temperature, 
odor and discoloration of granulation tissue are observed. Therefore assessment of wound infection 
has to be based both on the density of microorganisms as well as on the presence of specific 
pathogenic species [15,16]. Staphylococcus aureus, Pseudomonas aeruginosa, and beta-hemolytic 
streptococci are regarded as primary indicators for a delayed healing and infection in both acute 
and chronic wounds. Bacterial loads exceeding 10
6
 colony forming units (CFU)/g of tissue or tissue 
fluid, accumulations of pus cells and presence of specific pathogenic organisms are being used as 
indicators for wound infection in contrast to wound contamination [16–19]. Factors predisposing a 
wound to infection include the non-observance of principles of good hygienic procedures during 
dressing and the presence of necrotic tissue or slough within the wound margin [13], which is 
commonly found in BU lesions. The extent of secondary infections in BU and their contribution to 
frequently observed delays in healing has not been studied so far. Here we have analyzed BU 
lesions before, during and after antimicrobial treatment for the presence of secondary infection. 
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Materials and Methods 
 
Study participants and sample collection 
 
The participants involved in the study were recruited from the Amasaman District Hospital and the 
Obom Health Centre in the Ga-West and Ga South Municipality, respectively. The participants 
were all laboratory confirmed BU cases and the analyzed samples fall into three main categories: 1) 
samples from 53 BU patients recruited consecutively before treatment; 2) samples from 20 BU 
patients recruited consecutively between four and six weeks after start of SR8 and 3) samples from 
31 BU patients whose lesions were clinically suspected of secondary infection after SR8 treatment. 
Some of the participants overlapped in some of the categories: 71 of the participants were sampled 
once for analysis, 12 twice and 3 thrice within the study period, thus in total 104 individual 
samples, 84 swabs and 20 tissue samples, from 86 participants were analyzed. The swabs were 
obtained from 52 cases before treatment, 20 cases during and 12 cases after treatment and analyzed 
microbiologically (Table S1). The tissue samples for histopathological analysis were obtained from 
one case before treatment and 20 cases after treatment. Except for one sample taken after treatment, 
all tissue samples were also analyzed microbiologically (Table S1). 
A detailed questionnaire was used to obtain standard demographic data, document the clinical 
presentation of lesions and other lesion characteristics. Altogether the study involved 86 
participants comprising 32 (37%) females and 54 (63%) males. The females’ age ranged between 
two and 72 years and the males were between four months and 82 years. Median age for both 
groups was 33 years. Seventy-seven of the cases had lesions located on the limbs, three in the head 
and neck region, and one each located on the buttocks, armpit and back respectively; the lesion 
location of three participants was not documented. 
Only 2/86 patients were pre-ulcerative. These lesions, one nodule and one plaque, were sampled 
later during surgery. The remaining 84 patients had ulcers; 78 of them had only ulcers, one had an 
ulcer and a nodule, three had ulcers with edema, and two had ulcers with osteomyelitis. Based on 
the judgment of the responsible clinician, surgical debridement was performed for 1 patient prior to 
treatment and for 20 patients after completion of SR8. Biopsy samples were collected in each 
instance for histopathological analysis (Figure 1). 
Laboratory confirmation of BU disease was done by IS2404 PCR and Ziehl-Neelsen microscopy as 
previously described [20,21]. Three swab samples were collected from clinically suspected 
ulcerative cases before treatment; one for IS2404-PCR based confirmation of BU, one for 
preparation of a direct smear for microscopic examination for the detection of bacteria and 
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neutrophils after Gram staining (Figure S1), and the third was inserted into a sterile tube containing 
3 ml of PBS for enumeration of the bacterial burden and the isolation of specific bacterial species. 
All swab specimens were collected from the undermined edges of lesions by first moistening the 
swab with sterile PBS using the Levine method of collecting swab specimen [22]. This has been 
found to be the best method for taking swabs as it is more reflective of tissue bioburden as 
compared to other methods [23]. After cleaning the wound surface with normal saline, a swab was 
rotated over a 1 cm
2
 area with sufficient pressure to collect the fluid from within the wound tissue. 
From cases that were sampled during treatment and those that were clinically suspected of having a 
bacterial infection after completion of SR8, three swab specimens were collected before surgery, 
and treated as above, except for the procedures for the laboratory confirmation of BU disease by 
PCR, since all cases had been previously confirmed as BU within the framework of a bigger study. 
From SR8 treated patients that underwent surgical management, tissue sample were analyzed if 
there was clinical suspicion of a secondary bacterial infection. While one sample was aseptically 
transferred into a clean sterile tube for enumeration of the bacterial load and species identification, 
a second sample was directly transferred into 10% neutral buffered formalin for histopathological 
analysis. 
The samples for bacteriological analysis were placed in an ice chest with ice packs to prevent 
bacterial multiplication and transported to the Bacteriology Department of the Noguchi Memorial 
Institute for Medical Research (NMIMR) for analysis, Tissue samples for were shipped to the 
Swiss Tropical and Public Health Institute for histopathological analysis. 
 
Ethics statement 
Ethical clearance was obtained from the institutional review board of the Noguchi Memorial 
Institute for Medical Research (Federal-wide Assurance number FWA00001824). The procedures 
for sampling in this study were essentially the same as those used in routine management of BU in 
Ghana. However, written informed consent was collected from all participants before study 
inclusion. In the case of children below sixteen years, written informed consent was collected from 
their parents or guardians. Patients were assured of the confidentiality of all information collected 
during the study. 
 
Enumeration of the bacterial load and isolation of bacteria 
When swab samples reached the microbiology laboratory, the volume of PBS was topped up to 5 
ml and both the swab and the PBS were transferred into a sterile glass tissue culture tube 
containing glass beads. The tubes were vortexed for about two minutes to dislodge any particles 
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that were sticking to the swabs. Using the resulting stock suspension, serial dilutions from 10
-2
 to 
10
-6
 were prepared. Hundred microlitres of serial dilutions of the swab or tissue suspensions were 
transferred into sterile Petri dishes and inoculated by the pour plate method using Plate Count Agar 
for total aerobic counts. The agar was left on the lab bench to set after which it was incubated at 
37
0
C for 18–24 hours. The remaining 10-1 dilution of the suspension was centrifuged at 8,000 g for 
25 minutes and after decanting, the pellet was inoculated onto MacConkey, Blood and Chocolate 
agar and incubated under aerobic conditions. The aerobic agar plates were examined after 24 hours 
and growing colonies were subcultured on Blood and MacConkey agar plates to obtain pure 
cultures. After incubation, the plates were examined using a colony counting chamber 
(Gallenkamp, UK) and those with colony counts between 30 and 300 were selected for computing 
CFU/ml or CFU/g, respectively, by multiplying the counts by the dilution factors. The lesion from 
which the sample was taken was classified as clean, contaminated or infected as indicated in the 
data analysis section. For tissue specimen, one gram of sample was weighed in a sterile plastic 
stomacher bag. Nine milliliters of PBS were added, samples were macerated in a stomacher and the 
resulting suspension was transferred into a sterile test-tube. Using this stock suspension, serial 
dilutions were prepared and plated out. 
 
 
Species identification of bacterial isolates 
Distinct bacterial colonies from the Blood and MacConkey agar plates were purified on Nutrient 
agar plates for identification. Bacterial isolates were Gram stained [24] and identified by 
biochemical tests as well as by molecular methods. Gram negative rod isolates were characterized 
by cytochrome oxidase analysis, and with Analytical Profile Index (API 20E) strips (bio-Me´rieux 
SA, Marcy-l’E’toile, France) according to the manufacturer’s instructions. Gram positive cocci 
were analyzed after Gram staining using the catalase test to differentiate between Staphylococcus 
spp. and Streptococcus spp. In order to further discriminate the catalase positive Gram positive 
cocci and especially to identify Staphylococcus spp., the Staphylase kit Prolex Latex Agglutination 
System (Pro-Lab Diagnostics) was used. Gram positive bacteria were further characterized using 
the Hain Lifescience Genotype Product series for Gram positive bacteria Genotype BC Gram 
positive version 3.0 and Genotype staphylococcus version 2 test kits (Hain Lifescience, Germany). 
Where species identification failed with the analytical profile index and the other biochemical 
assays, identification was achieved by MALDI-TOF mass spectrometry [25]. 
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Drug susceptibility testing 
Susceptibility of isolates to specific drugs was tested using the Kirby-Bauer disc diffusion method 
on Mueller Hinton agar [26]. Sensitivity was tested against antibiotics such as cotrimoxazole, 
ampicillin, tetracycline, ciprofloxacin, amikacin, gentamicin, penicillin, erythromycin, cefuroxime, 
cefixime, ceftriaxone, chloramphenicol and flucloxacillin. In addition, Gram positive cocci were 
tested against methicillin and vancomycin. The results of isolation and drug sensitivity tests were 
provided to the treating clinician at the collaborating health facility. Since the locally available disc 
systems varied in coverage, some antibiotics were only tested with a subset of isolates. One 
limitation of this study is that we did not test for susceptibility against streptomycin and rifampicin. 
 
Histopathology 
Histopathological analysis was done for all SR8 treated patients needing surgical management and 
presenting with a lesion clinically suspicious for secondary infection. Surgically excised tissue 
samples were immediately fixed after excision in 10% neutral-buffered formalin for 24 h at room 
temperature to maintain tissue structures. Afterwards samples were directly transferred to 70% 
ethanol for storage and transport. Tissue specimens were subsequently dehydrated, embedded into 
paraffin, and cut into 5 µm sections. After deparaffinization and rehydration, sections were stained 
with Ziehl-Neelsen/Methyleneblue (ZN) according to WHO standard protocols [3]. In this staining 
AFB appear pink and other bacteria are stained blue. Tissue sections were analyzed with a Leica 
DM2500 Microscope and pictures were either taken with a Leica DFC 420C camera or with an 
Aperio ScanScope XT. 
 
Analysis of recycled bandages 
Recycled bandages from fifteen confirmed BU cases were collected conveniently before wound 
dressing for microbiological analysis. Ten grams bandage was weighed, added to 90 ml of sterile 
PBS and macerated with a laboratory blender to give a 10
-1
 dilution. Using this suspension, serial 
dilutions from 10
-2
 to 10
-6
 were prepared. Hundred microlitres of these serially diluted suspensions 
were transferred into sterile Petri dishes and inoculated by the pour plate method using Plate Count 
Agar for total aerobic counts. Bacterial enumerations were performed as described above. In 
addition the left over suspension was centrifuged at 3,000 g for 20 mins and the resulting pellet was 
plated for bacterial isolation. 
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Data analysis 
The values obtained from plate counts were computed into CFU/ml for wound exudates (swabs) or 
CFU/g for tissue sample. The antibiogram of each isolate was interpreted according to the 
manufacturer’s specification as resistant, intermediate or susceptible. The percentages of cases in 
each category were then computed. 
 
Classification of wounds 
Lesions were classified microbiologically as clean if no bacteria were isolated, as contaminated if 
bacterial counts were < 10
6
 CFU/g or ml and as infected if counts were > 10
6
 CFU/g or ml of 
specimen. Lesions were clinically classified as infected based on the following criteria: 1. friable, 
bleeding granulation tissue despite appropriate care and management; 2. purulent discharge (yellow 
or green) from wound or drain placed in wound; 3. pain or tenderness, localized swelling (edema), 
or redness/heat; 4. tissue necrosis; 5. skin grafting failure; abnormal odor coming from the wound 
site; delayed healing not previously anticipated. Twenty-four of the patients clinically classified as 
infected were in-patients and seven were out-patients, who were reporting twice a week for wound 
dressing. During wound dressing, the wounds were cleaned with normal saline to wash away 
debris. Wounds that appeared necrotic or had an offensive odor were cleaned again with vinegar 
and dressed with povidine iodine. 
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Results 
Bacterial infection of lesions from PCR-confirmed BU patients before and during SR8 
treatment 
Swab samples of 52 consecutively recruited IS2404 PCR confirmed BU cases with ulcerative 
lesions were sampled before the commencement of SR8 treatment. Samples from three participants 
(5.7%) did not yield any aerobic growth on plate count agar (Table 1). Seventeen (32.1%) of the 
lesions with total CFU counts of 1.7 x 10
3
 to 9.0 x 10
5
 CFU/ml (average 3.2 x 10
5
 CFU/ml) were 
microbiologically classified as contaminated. Microbiologically Infected lesions were observed in 
33/52 patients (63.5%); aerobic counts from this group ranged between 1.0 x 10
6 
to 3.5 x 10
9
 
CFU/ml with an average value of 1.1 x 10
9
 CFU/ml. The most frequently identified bacterial 
species from the infected lesions prior to start of treatment (Table 1) were S. aureus (n = 9; 21.4%), 
P. aeruginosa (n = 7; 16.7%) and P. mirabilis (n = 6; 14.3%). 
The responsible clinician decided to perform wound debridement of one of the lesions prior to SR8 
initiation, since it showed clinical signs of a strong secondary infection (Figure 1D). A biopsy 
specimen was taken and the histopathological analysis of the tissue sample (Figure 1A–C) 
revealed, typical hallmarks of BU, such as fat cell ghosts, tissue necrosis and epidermal hyperplasia 
(Figure 1A). In addition, clusters of cocci were observed in the subcutaneous tissue between the fat 
cells (Figure 1A box, B, C). This area probably represents the tissue base of the undermined edges. 
These findings correlated well with the microbiological analysis, since S. aureus was isolated in 
large numbers from the lesion (1.2 x 10
9
 CFU/g). 
Twenty laboratory-confirmed BU cases were consecutively sampled between four and six weeks 
after start of SR8 treatment and analyzed for infection of the lesions. Of these lesions, 7/20 (35.0%) 
and 13/20 (65.0%) were microbiologically classified as contaminated or infected, respectively; 
clean wounds were not observed (Table 1). The aerobic bacterial load ranged between 1.5 x 10
6
 
and 3.5 x 10
9
 CFU/ml, with an average value of 5.6 x 10
8
 CFU/ml for the microbiologically 
infected lesions. The contaminated lesions had counts between 5.2 x 10
3
 and 7.3 x 10
5
 CFU/ml 
(average 3.3 x 10
5
 CFU/ml). Also here P. aeruginosa (n = 6; 35.3%) and P. mirabilis (n = 2; 
11.8%), but not S. aureus (n = 0), were the most frequently identified bacterial species isolated 
from the infected lesions (Table 1). 
 
Bacterial infection of BU lesions with clinical signs of infection after completion of SR8 
treatment 
Thirty-one BU lesions with clinical signs of secondary bacterial infection after completion of SR8 
treatment were sampled for laboratory investigation. Clinical signs indicative for secondary 
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infection were documented for 28 of them and included: localized pain (28/28), viscous/purulent 
discharge (28/28), edema (5/28) and localized heat (4/28). In addition, delayed healing not 
previously anticipated (17/28), offensive odor (15/28) and discoloration of tissues both within and 
at the wound margins (3/28) were regarded as signs of secondary infection (Table 2). The time at 
which infection was detected ranged from a few weeks to fifteen months after completion of SR8. 
Seven (22.6%) of the 31 lesions clinically suspected to be infected were not confirmed 
microbiologically by aerobic bacterial count analysis, as the total plate count ranged only between 
1.3 x 10
3
 and 8.9 x 10
5
 CFU/ml (average 2.7 x 10
5
 CFU/ml). The remaining twenty-four (77.4%) 
lesions that were microbiologically confirmed as infected had plate counts ranging between 1.2 x 
10
6
 and 3.5 x 10
9
 CFU/ml (average value of 1.2 x 10
9
). P. aeruginosa (n = 8; 32%), P. mirabilis (n 
= 5; 20%) and S. aureus (n = 3; 12%) dominated among the isolates. 
The bacterial load observed in cases analyzed within four weeks post SR8 ranged between 1.3 x 
10
3
 and 4.0 x 10
9
 CFU/ml; that between five and 12 weeks was between 9.3 x 10
4
 and 1.2 x 10
9
 
CFU/ml; and that between 9 and 15 months post SR8 ranged between 2.7 x 10
6
 and 1.8 x 10
9
 
CFU/ml. Nineteen tissue samples and 12 swab samples were analyzed (Table S1) and the bacterial 
load ranged between 1.3 x 10
3
 and 4.0 x 10
9
 CFU/ml for tissues and between 5.2 x 10
7
 and 2.1 x 
10
9
 for swabs. 
Tissue samples from 20/31 of the microbiologically analyzed lesions showing clinical signs of 
secondary infection after completion of SR8 were also analyzed by histopathology, since the 
responsible clinicians decided to perform a wound debridement. Microbiological analysis had 
categorized 16 of these lesions as infected and four as contaminated. None of the microbiologically 
contaminated wounds presented in the histopathological analysis with a detectable secondary 
infection. In contrast 12/16 (75%) of the lesions classified microbiologically as infected presented 
with an infection either with cocci, rods or both (Table 2). Infection was mainly observed in the 
stratum corneum (6/12; 50%) or on the open ulcer surface (3/12; 25%) and only rarely (3/12; 25%) 
deeper inside the excised tissue (Table 2). Histopathological analysis of specimen from patient 9 
(Figure 2 A– D) revealed a layer of densely packed rods at the open ulcer surface visible already at 
low magnification as an intensely blue stained band (Figure 2B) At higher magnification, clusters 
of rod shaped bacteria were observed (Figure 2 C,D). Microbiological analysis confirmed the 
presence of P. aeruginosa. Tissue excised from patient 16 (Figure 2E–H) showed a double 
infection: cocci being present inside the stratum corneum (data not shown) as well as an extensive 
infection of the dermal and subcutaneous tissue with rods (Figure F–H). Microbiological analysis 
isolated S. aureus as well as Gram-negative rods. In most of our analysis, histopathological and 
microbiological results showed a good correlation for most of the patients (Table 2). 
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Drug susceptibility pattern of bacterial isolates 
Using the disc diffusion assay, a total of 98 Gram-negative rods and Gram-positive cocci obtained 
from BU wounds were tested for resistance against antibiotics commonly used in Ghana. None of 
the isolates tested was sensitive to all drugs included in the analysis (Table 3). Five Gram-negative 
rods were resistant to all tested drugs. More than 70% of the 18 S. aureus isolates obtained from 
infected (n = 12) or contaminated (n = 6) lesions were resistant to flucloxacillin, ampicillin and 
penicillin. In contrast, 15/18 (83%) were susceptible to gentamicin. The prevalence of S. aureus 
isolates resistant to methicillin (MRSA) and vancomycin (VRSA) was 33% and 17%, respectively. 
Likewise most of the P. aeruginosa strains were resistant to most of the tested drugs. However, 
most isolates (18/22; 82%) were susceptible to gentamicin. Results for the other Gram-negative 
and -positive bacteria are provided in Table 3. 
 
 
Microbiological analysis of recycled bandages 
When monitoring wound management procedures, it was realized that patients and care-givers 
were instructed by health workers to wash and recycle dressing bandages. We therefore 
conveniently sampled dressings that have been used and washed for the next dressing. Seventeen 
bandages from fifteen BU cases were analyzed and as shown in Table 4, all of them had some 
bacterial contamination with total aerobic plate counts ranging between 2.2 x 10
3
 and 3.2 x 10
8
 
CFU/g with an average count of 2.8 x 10
7
 and a median value of 1.2 x 10
5
 CFU/g. While bacterial 
species identified included commensals such as staphylase negative Staphylococcus spp., also 
potential pathogens including S. aureus, P. aeruginosa, Flavibacterium oryzihabitans, 
Enterobacter agglomerans and Enterobacter cloacae were isolated. The drug susceptibility 
patterns of isolates are indicated in Table 4. Similar isolates were also isolated from patients’ 
wounds. 
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Discussion 
Mycolactone, the cytotoxic macrolide toxin of M. ulcerans plays a key role in the pathology of BU. 
It causes apoptosis of mammalian cells [8,27] and has immunomodulatory activity [28,29]. Since a 
number of macrolides have antibiotic activity against a broad spectrum of bacteria, including 
streptococci, pneumococci, staphylococci, enterococci, mycoplasma, mycobacteria, rickettsia, and 
chlamydia [30], it has been speculated that mycolactone secreted by M. ulcerans during active 
disease prevents secondary bacterial infections of BU lesions. The goal of this study was to find out 
whether ulcerative BU lesions are indeed rarely colonized or infected by other bacterial species. To 
address this, BU wounds were characterized before SR8 treatment by both direct smear 
microscopic analysis for the presence of bacteria and neutrophils [20] and by pour plate 
determination of aerobic CFU counts. More than 60% of the lesions tested before treatment had 
bacterial counts ≥106 CFU/ml and direct smear examination frequently showed large numbers of 
bacteria and neutrophils (Figure S1). A broad spectrum of bacterial species was isolated from the 
lesions with S. aureus, P. aeruginosa and P. mirabilis being the most frequently found species. 
This suggests that M. ulcerans infection and mycolactone secretion does not prevent secondary 
bacterial infections. 
Chronic wounds often have a bacterial burden that is massively exceeding levels used to define 
lower limits for the definition of infection in acute surgical wounds (i.e. 10
6
 CFU/g of tissue). 
However, many chronic wounds go on to closure despite levels of infecting microorganisms ≥108 
CFU/g of tissue, with infection by Group B streptococci being one exception to this rule 
[12,13,16]. Because of the intrinsic differences in the way acute and chronic wounds respond to the 
burden of microorganisms, emphasis is currently being placed on holistic assessments, with clinical 
signs and symptoms playing key roles in the diagnosis of chronic wound infection. Clinical signs 
usually employed for diagnosis include erythema, edema, heat, purulent exudates with concurrent 
inflammation, pain, delayed healing, discoloration of granulation tissue, friable granulation tissue, 
pocketing at the base of the wound, foul odor, and wound breakdown [13,14,17]. In particular 
increasing pain and wound breakdown have been shown to be good predictors of infection in 
chronic wounds. In this study we combined clinical, histopathological, qualitative and quantitative 
microbiological methods to analyze BU lesions for the presence of infections after completion of 
SR8 treatment. Lesions from 28 patients showing clinical signs of infection were included in this 
analysis. 75% of these lesions yielded CFU counts >10
6
 CFU/ml (average value of 1.2 x 10
9
) and 
frequently species with pathogenic potential, such as S. aureus, P. aeruginosa, S. haemolyticus, E. 
cloacae and K. pneumonia were isolated. Pain and yellow discharge turned out to be highly 
predictive clinical indicators for infection. For the patients that had clinical signs of infection after 
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SR8, culture and drug susceptibility testing results were submitted to the treating officer. However 
documentation of the treatment and subsequent follow-up of patients was beyond the scope of this 
study. 
A study analyzing the microbial flora of healing and non-healing decubitus ulcers [31] found S. 
aureus, Streptococcus spp., E. coli, Klebsiella spp., Proteus spp. and P. aeruginosa as the main 
organisms that caused infection of the ulcers. Chronic venous ulcers have been found to be infected 
with S. aureus, P. aeruginosa, Coagulase-negative staphylococci, Proteus spp. and anaerobic 
bacteria [32]. Thus most of the organisms isolated in this study from BU lesions have also been 
found associated with infection of other types of wounds. Similar to what has been reported in 
other studies [33], lesions were in many cases infected with more than one bacterial species (Table 
2). Our data on the microflora of lesions upon admission indicate that BU lesions may be 
contaminated from the communities as a result of improper wound care practices by the patients in 
their quest to treat the infection either on their own or with the help of traditional healers or 
herbalists. There is major concern about subsequent acquisition of antibiotic resistant organisms 
from the hospital settings. After the present pilot study demonstrating colonization and infection 
during and after SR8 treatment, we plan to perform longitudinal studies with patient cohorts to 
study the influence of BU wound management practices on secondary bacterial infections. 
The method used for collecting wound specimens can influence the data obtained from 
microbiological culturing. Currently, collection of a biopsy specimen is the gold standard for 
determining the presence and identity of microorganisms within the wound bed tissue [12,16,34–
37]. However, there are limitations as to which healthcare providers can collect biopsies, the 
availability of laboratories offering microbiological culture testing on biopsies, the expenses 
involved with the performance of these tests, and the potential for further tissue damage and delay 
of wound healing when biopsies are taken. In the present study we employed swabbing [22,36] as 
the main sampling procedure and performed histopathological studies with tissue specimen only 
from 20 cases that underwent surgical intervention. The histopathological analysis detected 
bacterial populations in 75% (12/16) of the analyzed lesions classified as infected and in none (0/4) 
of the lesions classified as contaminated. This strong correlation between results obtained with 
tissue and swab samples confirms results of previous studies [23] indicating that microbiological 
swabbing is a good sampling procedure for the determination of infection of wounds. 
Histopathological analysis detected infecting bacteria populations only rarely deeper inside the 
excised tissue and mainly in the stratum corneum or on the open ulcer surface, where bacteria are 
accessible for the swabs. 
Contamination of BU lesions prior to SR8 treatment may be a result of wound care practices by the 
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patients. Also during SR8 treatment a range of bacterial species, with Gram-negative rods 
dominating, were isolated from the lesions. This indicates that SR8 does not necessarily eliminate 
contamination or secondary infection of lesions. Bacterial species, such as P. aeruginosa, K. 
pneumoniae and S. aureus isolated from infected lesions after completion of SR8 treatment, may 
however also have been acquired from the hospital setting. A detailed characterization of isolates is 
required to address this important issue further. Both mono and multiple antibiotic resistant strains 
were isolated with high frequency from the BU lesions. For example all the tested S. aureus strains 
were resistant to penicillin, 22% were methicillin resistant and 17% vancomycin resistant. 
Dependent on the setting, both lower (Nigeria, [38]) or higher (South Africa, [39]) frequencies 
have been reported in Africa. Most worrying in this context is the high (83%) level of resistance of 
S. aureus isolates to flucloxacillin, which is in Ghana the main antibiotic in use for treating skin 
infections such as boils and cellulitis. In addition, we acknowledge that true VRSA is rare, and that 
the occurrence of apparent VRSA is being followed up through referral of isolates to an 
international reference laboratory. 
Postoperative infections of wounds represent the commonest surgical complication causing 
substantial increases in the duration and costs of hospital stays [40]. Our pilot study involving BU 
patients at different time points of SR8 treatment indicates that secondary bacterial infection may 
be a prominent cause for delays in wound healing and skin grafting failures. These findings call for 
an optimization of BU wound management and hygiene procedures to better control secondary 
infections. Also the choice of treatment of secondary infections with locally available antimicrobial 
agents requires a better understanding of the infecting flora and of drug susceptibility patterns. Our 
study did not follow the same patients from beginning of treatment till they were healed and this 
has limited the ability to determine causes and consequences of wound infection. More studies are 
required to ascertain the impact and source of wound infection in SR8 treatment of BU and to 
support development of guidelines for wound care in BU case management. In addition to wounds 
we also analyzed bandages that have been washed by the patients themselves to be re-used for 
wound dressing. From these bandages we isolated potential wound pathogens including S. aureus, 
P. aeruginosa, Flavibacterium oryzihabitans, Enterobacter agglomerans and Enterobacter 
cloacae; thus the bacteria profile of the wound samples was comparable to that of the bandages. 
These findings indicate that the recycling of bandages may not be a good practice as it may be one 
of the sources of wound infection. We recommend that if for economical reasons bandages need to 
be recycled, they must be washed well with an appropriate disinfectant. 
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Figures 
 
 
 
Figure 1: Histopathological analysis of tissue excised before start of SR8 treatment.  
Histological sections were stained with Ziehl-Neelsen (acid fast bacteria) and methylene blue (DNA, 
secondary infection). A: Overview over excised tissue specimen revealing infection at the lower end of the 
specimen (box), as well as BU characteristic histopathological features, including fat cell ghosts, necrosis 
and epidermal hyperplasia. B/C: higher magnification revealing the presence of cocci. D: clinical 
presentation of the lesion on the belly. 
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Figure 2: Histopathological analysis of tissue from two patients excised weeks after SR8 treatment 
respectively.  
Histological sections were stained with Ziehl-Neelsen (acid fast bacteria) and methylene blue (DNA, 
secondary infection). A: clinical presentation of patient 9 presenting with a large lesion on the right foot. B: 
overview over excised tissue specimen (open ulcer surface) revealing the presence of an infection (blue 
band, box). C/D: higher magnification confirming the presence of densely packed rods. E: clinical 
presentation of patient 16 presenting with a large lesion covering the left leg. F: overview over excised 
tissue specimen revealing an epidermal hyperplasia as well as a strong edema. G/H: secondary infection 
with rods of the dermal and subcutaneous tissue. 
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Tables 
Table 1: Spectrum of bacterial species isolated from BU lesions before, during or after SR8 treatment. 
 
 
Time of sampling Clean 
wounds 
Contaminated 
wounds    
Infected 
wounds 
Spectrum of bacteria isolates from infected 
cases n (%) 
Before SR8 Treatment 
(n = 53) 
3 (6%) 17 (32%) 33 (62%) 9 (22%) Staphylococcus aureus 
   7 (17%) Pseudomonas aeruginosa 
   6 (15%) Proteus mirabilis 
   3 (7%) Coagulase negative Staph. 
   3 (7%) Chryseomonas luteola 
   2 (5%) Enterobacter cloacae 
   2 (5%) Klebsiella pneumonia 
   2 (5%) Escherichia coli 
   1 (2%) Streptococcus dysgalactia 
   1 (2%) Providencia stuartii 
   1 (2%) Staphylococcus haemolyticus 
   1 (2%) Morganella morganii 
   1 (2%) Streptococcus agalactia 
   1 (2%) Staphylococcus warneri 
   1 (2%) Proteus vulgaris 
 During SR8 
Treatment (n = 20) 
 
0 (0%) 7 (35%) 13(65%) 6        (38%) Pseudomonas aeruginosa 
   2 (13%) Proteus mirabilis 
   1 (6%) Staphylococcus warneri 
   1 (6%) Coagulase negative Staph. 
   1 (6%) Enterobacter cloacae 
   1 (6%) Providencia stuartii 
   1 (6%) Staphylococcus haemolyticus 
   1 (6%) Enterococcus gallinum 
   1 (6%) Flavibacterium oryzihabitans 
   1 (6%) Chryseomonas luteola 
After SR8 Treatment 
(n = 31; 
clinically diagnosed 
for 
secondary infection) 
0 (0%) 7 (23%) 24(77%) 8       (32%) Pseudomonas aeruginosa 
   5 (20%) Proteus mirabilis 
   3 (12%) Staphylococcus aureus 
   2 (8%) Escherichia coli 
   2 (8%) Providencia stuartii 
   2 (8%) Klebsiella pneumoniae 
   1 (4%) Coagulase negative Staph. 
   1 (4%) Alcaligenes faecalis 
   1 (4%) Acinetobacter sp 
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Table 2: Presentation of wounds that were clinically infected after SR8 compared to microbiology and histology findings. 
BU 
Case 
Clinical Presentation Microbiological 
category 
Species Histopathology Location (in the 
tissue) 
Odor Pain Green 
discharge 
Yellow 
discharge 
Necrotic 
tissue 
Bloody 
discharge 
WHD
1
 Edema SGF
2
     
01 Yes Yes No Yes Yes No Yes No Yes Infected Mixed growth Rods/Cocci Stratum corneum 
02 Yes Yes No Yes Yes No Yes No Yes Infected Providencia stuartii None  
03 No Yes No Yes Yes No Yes Yes No Infected Klebsiella pneumoniae Rods Stratum corneum 
04 No Yes No Yes No No No No No Infected Mixed growth/S. aureus Rods/Cocci Stratum corneum 
05 No Yes No Yes Yes No No No No Infected Pseudomonas aeruginosa n/d  
06 Yes Yes No Yes Yes No Yes No No Infected Klebsiella pneumoniae, 
Coagulase negative 
Staphylococcus species 
n/d  
07 Yes Yes No Yes Yes Yes Yes Yes No Infected E. coli, Pseudomonas 
aeruginosa, S. aureus 
n/d  
08 No Yes No Yes Yes No No No No Contaminated Pseudomonas aeruginosa None  
09 Yes Yes Yes Yes Yes No Yes No No Infected Pseudomonas aeruginosa Rods Ulcer surface 
10 Yes Yes No Yes Yes No No No No Infected Proteus mirabilis None  
11 Yes Yes No Yes Yes No Yes Yes No Infected Proteus mirabilis, 
Enterobacter cloaccae 
n/d  
12 Yes Yes No Yes Yes No Yes No No Infected Proteus mirabilis, mixed 
growth 
None  
13 No Yes No Yes Yes  No Yes No No Infected Proteus mirabilis n/d  
14 Yes Yes No Yes Yes Yes Yes No No Infected Enterobacter cloacae, 
Gram positive cocci 
Rods/Cocci Ulcer surface 
15 Yes Yes No Yes Yes No Yes No No Infected S. aureus, Pseudomonas 
aeruginosa 
Rods Ulcer surface 
16 Yes Yes Yes Yes Yes No Yes No No Infected S. aureus, gram negative 
rods 
Rods/Cocci Stratum corneum 
(cocci), Dermis, 
Subcutis (rods) 
17 No Yes No Yes Yes No No No Yes Infected Gram negative rods Rods Dermis, subcutis 
18 Yes Yes No Yes Yes No Yes No No Infected Pseudomonas aeruginosa Rods/Cocci Stratum corneum 
 
19 No Yes No Yes Yes No No No Yes Infected Mixed growth Rods/Cocci Stratum 
corneum 
 
20 Yes Yes No Yes Yes Yes No No No Contaminated Gram negative rods None  
21 No Yes No Yes Yes No Yes No No Contaminated Candida sp, Klebsiella None  
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pneumonia 
22 No Yes No Yes Yes No No No No Contaminated Pseudomonas aeruginosa n/d  
23 No Yes No Yes No No Yes No No Contaminated Coagulase negative  
Staphylococcus species  
n/d  
24 Yes Yes Yes Yes Yes No Yes Yes Yes Infected Acinetobacter sp. Rods/Cocci Subcutis 
25 Yes Yes No Yes Yes No Yes No No Infected S. aureus Rods Subcutis 
26 No Yes No Yes No No No No Yes Infected Pseudomonas aeruginosa None  
27 No Yes No Yes No Yes No Yes No Contaminated Providencia stuartii None  
28 No Yes No Yes No No No No No Contaminated Enterobacter cloacae n/d  
 
We compared the clinical presentation to microbiological categorization based on quantification and histological findings. Lesions with a bacterial load less than 106 CFU/ml (or CFU/g) were 
categorized as contaminated, while lesions with bacterial loads above were considered as infected. 
1WHD = Wound healing delay. 
2SGF = Skin grafting failure. n/d = 
not done. 
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Table 3: Antibiotic susceptibility pattern of different bacterial species isolated from BU wounds. 
 
Pathogen  Drug Tested Number Tested  Susceptible, n(%)  Int. Resistant, n(%)  Resistant n(%) 
 
          
 
Pseudomonas aeruginosa  Gentamicin 22  18(81.9)  1(4.5)  3(13.6)        
 
  Ceftriaxone 13 3(23.1) 7(53.8) 3(23.1) 
 
        
  Cefotaxime 20  1(5.0)  1(5.0)  18(90)         
 
  Ampicillin 22 0(0) 0(0) 22(100) 
 
        
  Tetracycline 22  3(13.6)  1(4.5)  18(81.9)          
  Cotrimoxazole 22 3(13.6) 2(0) 17(77.3) 
 
        
  Cefuroxime 22  0(0)  0(0)  22(100)          
  Chloramphenicol 21 2(9.5) 2(9.5) 17(81) 
 
        
Staphylococcus aureus  Tetracycline 18  12(66.7) 0(0)  6(33.3) 
 
          
 
  Cotrimoxazole 18 16(88.9) 0(0) 2(11.1) 
 
        
  Erythromycin 18  9(50)  9(50)  0(0)          
  Ampicillin 18 2(11.1) 1(5.6) 15(83.3) 
 
        
  Flucloxacillin 18  3(16.7)  0(0)  15(83.3)          
  Cefuroxime 18 9(50) 1(5.6) 8(44.4) 
 
        
  Gentamicin 18  15(83.3)  0(0)  3(16.7)         
 
  Methicillin 18 12(66.7) 0(0) 6(33.3) 
 
        
  Vancomycin 18  15(83.3)  0(0)  3(16.7)          
  Penicillin 18  0(0) 0(0)  18(100) 
 
         
Other gram positive  Tetracycline 13  6(46.2)  0(0)  7(53.8)        
  Cotrimoxazole 13 7(53.8) 0(0) 6(46.2) 
 
        
  Erythromycin 13  6(46.2)  3(23.1)  4(30.7)          
  Ampicillin 13 3(23.1) 1(7.7) 9(69.2) 
 
        
  Flucloxacillin 13  2(15.4)  0(0)  11(84.6)         
 
  Cefuroxime 13 6(46.2) 0(0) 7(53.8) 
 
        
  Gentamicin 13  11(84.6)  0(0)  2(15.3)         
 
  Penicillin 13 2(15.4) 0(0) 11(84.6) 
 
       
Other gram negatives  Gentamicin 45  37(82.2)  1(2.2)  7(15.6)        
  Ceftriaxone 17 10(58.8) 2(11.8) 5(29.4) 
 
        
  Cefotaxime 39  16(41.0)  4(10.3)  19(48.7)          
  Ampicillin 45 0(0) 1(2.2) 44(97.8) 
 
        
  Tetracycline 45  1(2.3)  0(0)  44(97.8)          
  Cotrimoxazole 45 7(15.6) 0(0) 38(84.4) 
 
        
  Cefuroxime 45  5(11.1)  10(22.2)  30(66.7)         
 
  Chloramphenicol 39 6(15.4) 2(5.1) 31(79.5) 
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Table 4:  Microbiological analysis of recycled bandages 
 
 
 BACTERIAL LOAD  
ANTIBIOTIC SUSCEPTIBILITY 
  
 
CASE (CFU/g) ORGANISM ISOLATED    
     
        
   SENSITIVE INTERMEDIATE  RESISTANT 
 
       
 
CASE 1 9.56107 Enterobacter agglomerans CTX, TET, AMK, COT,  AMP, CRX 
 
   GEN, CHL    
 
        
CASE 2 5.36107 Staphylococcus warneri COT, CRX, GEN ERY  PEN, AMP, FLX, TET 
 
       
 
CASE 3 5.56104 Staphylase negative Staphylococcus TET, COT, CRX, GEN ERY  PEN, AMP, FLX 
 
        
CASE 4 1.106106 N/D     
 
       
 
CASE 5 3.26108 Staphylase positive Staphylococcus TET, COT, CRX, GEN   PEN, AMP, FLX, TET 
 
        
CASE 6 1.226105 N/D     
 
       
 
CASE 7 1.676106 Flavibacterium oryzihabitans TET, AMK, GEN CRX, CTX  AMP, COT, CHL 
 
        
CASE 8 8.66105 Staphylase negative Staphylococcus GEN   PEN, AMP, FLX, ERY, 
 
      TET, COT, CRX 
 
  Pseudomonas sp CTX, TET, COT, CHL   AMP, CRX, 
 
     AMK,GEN 
 
        
CASE 9 4.1610
3 Staphylase negative Staphylococcus TET, COT, CRX, GEN   PEN, AMP, FLX, ERY       
 
CASE 10 3.36105 Staphylase negative Staphylococcus GEN CRX PEN, AMP, FLX, ERY, 
 
     TET, COT 
 
        
CASE 11 3.16103 Staphylase negative Staphylococcus TET, GEN CRX  PEN, AMP, FLX, ERY, 
 
      COT 
 
CASE 12 6.36104 Staphylase negative Staphylococcus TET, COT, CRX, GEN ERY  PEN, AMP, FLX 
 
        
CASE 13 1.656105 Enterobacter cloacae CTX, TET, COT, GEN, CHL AMK  AMP, CRX 
 
       
 
CASE 14A 4.46104 Staphylase positive Staphylococcus TET, GEN CRX  PEN, AMP, FLX, ERY, 
 
     COT 
 
       
CASE 14B 5.36103 Staphylase negative Staphylococcus GEN   PEN, AMP, FLX, ERY, 
 
      TET, COT, CRX 
 
       
 
CASE 15A NEGLIGIBLE Staphylase negative Staphylococcus GEN ERY, CRX  PEN, AMP, FLX, TET, 
 
      COT 
 
        
CASE 15B NEGLIGIBLE N/D      
       
        
        
 
AMP = Ampicillin, CXM = Cefixime, CXC = Cloxacillin, COT = Cotrimoxazole, ERY = Erythromycin, GEN = Gentamicin, TET = Tetracycline, PEN = 
Penicillin, CRX = Cefuroxime, CHL = Chloramphenicol, CTR = Ceftriaxone, CTX = Cefotaxime. 
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Supplementary materials  
 
 
 
 
 
 
 
Figure S1: Direct smear examination of infected wounds and Kirby-Bauer plate of a VRSA 
isolate. 
Exudates from infected wounds were smeared directly over clean microscopic slides. The slides were 
then stained by the Gram procedure and viewed under oil immersion. While the exudate on Plate A is 
derived from the lesion of the patient whose biopsy was analyzed by histopathology before SR8 
(Figure 1), the smears on plate B and C were taken from cases after SR8 treatment. Plate D depicts the 
drug susceptibility result of two S. aureus isolates. While one strain is both methicillin and 
vancomycin resistant, the other is methicillin resistant, but vancomycin susceptible. 
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Table S1: Samples taken and types of analysis conducted at various stages of treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Types of  samples and analysis 
performed  
Before 
treatment 
During 
treatment 
After 
treatment 
Swab samples used for 
microbiology 
52 20 12 
Biopsy samples used both for 
histopathology and  microbiology 
1 0 19 
Biopsy samples used only for 
histopathology  
0 0 1 
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Abstract 
Introduction: Bacterial contamination is common to all wounds. The bacterial burden of 
wounds has been found to have an inverse relationship with chronic wound healing. In 
seeking to develop a better understanding of the evolution of Buruli ulcer (BU) wounds, we 
performed a longitudinal study to quantify the bacterial burden of BU wounds during the 
course of Streptomycin/Rifampicin (SR) treatment. 
 Materials and Methods: Twenty-one IS2404 PCR confirmed patients were longitudinally 
followed during the course of their treatment. Swab or tissue samples obtained from the 
lesions were quantitatively analysed to determine the bacterial burden pre, during and post 
SR treatment. Also the species of bacterial isolates obtained at these time-points were 
identified.  
Results: Based on the determination of the bacterial burden18/22 (81.8%) pre-treatment, 
15/25 (57.7%) during treatment and 36/48 (75.0%) post-treatment samples were classified as 
super-infected, respectively. Thirty distinct bacterial species including two species of 
anaerobic Clostridia (Clostridium perfringens and Clostridium sporogenes) were identified 
among 114 isolates. While Enterococcus faecalis, Pseudomonas aeruginosa and 
Chryseomonas luteola dominated pre-treatment, P. aeruginosa dominated during and post 
treatment.  
Conclusion: Most BU patients presented with lesions with a high bacterial load which 
increased significantly post treatment. Therefore good wound care is necessary to control the 
microbial burden of BU wounds especially post treatment to minimise complications.  
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Introduction 
Buruli ulcer (BU), a chronic debilitating disease caused by Mycobacterium ulcerans (Mu) 
affects mainly the soft tissues of the skin. If non-ulcerative stages of the disease (nodules, 
papules, oedema or plaques) are not treated, extensive tissue destruction by the macrolide 
toxin mycolactone can lead to large rugged ulcers, which are the hallmark of BU [1]. The 
first line treatment for BU; daily administration of oral rifampicin (10 mg/kg) and 
intramuscular streptomycin (15 mg/kg) for 8 weeks (SR8) was introduced by the World 
Health Organisation (WHO) in 2004 [2-3]. Early stages, especially nodules and papules, heal 
in most cases shortly after completion of the SR8 treatment without the need for adjunct 
surgical interventions. Large ulcerative lesions, however can take as long as a year or more to 
heal and bacterial superinfection may occur if wound care is not optimal.  
Localized wound infection has been identified as a significant cause of impaired healing and 
wound chronicity [4]. Wound infection occurs when the growth of microorganisms within the 
wound is uncontrolled by host defence mechanisms and can lead to deeper and more severe 
pathology and sepsis. Through biofilm formation, the pathogenic effects of bacteria may be 
increased. Endotoxin release by Gram-negative bacteria in wounds leads to elevated levels of 
proinflammatory cytokines (IL-1 and tumour necrosis factor).  Additionally, factors including 
the release of free radicals, degradation of growth factors, production of metabolic products, 
consumption of local oxygen and interference with collagen formation may result in a non-
conducive wound environment. With high bacterial loads, the effects of these mechanisms 
will be increased, thereby leading to impaired wound healing. 
Diagnosing wound infection is very challenging and optimally requires clinical signs and 
symptoms as well as quantitative and qualitative microbiological investigations involving 
direct microscopy and cultures. Bacterial loads above 10
5
cfu/g are the accepted gold standard 
in diagnosing localised infection [5-7]. The quantity of bacteria in wounds has been found to 
have an inverse relationship with the healing of chronic wounds [5, 8-10] with studies 
showing that wound healing progresses only when bacterial counts are below 10
6
cfu/ml [11-
13].  
In a previous cross sectional study, we identified wound infection as a probable cause of 
healing delay [14]. The study reported a good correlation between clinically suspected 
infected lesions and results of microbiological cultures. In seeking to have a better 
understanding of the evolution of the wounds we conducted a longitudinal study to quantify 
the bacterial burden of BU wounds during the course of SR8 treatment.  
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Methodology   
Ethics Statement 
Ethical clearance was obtained from the Institutional Review Board of the Noguchi Memorial 
Institute (Federal-wide Assurance number FWA00001824). Informed consent was obtained 
from the patients at their first hospital attendance after the objectives of the project had been 
explained to them in a language they understand. Sampling and confirmation of BU followed 
the approved WHO recommendations [15].  
 
Study participants and clinical presentation of lesions 
The study was conducted at the Ga West Municipal Hospital (GWMH) in the Greater Accra 
Region of Ghana; one of the main BU treatment facilities in the country. Participants were 
recruited into the study after the clinical BU diagnosis had been confirmed by at least IS2404 
PCR before commencement of SR8 treatment. Twenty-one (21) patients were recruited into 
the study out of which 17 were in-patients while four were outpatients who took the treatment 
at other health centers but reported at the GWMH periodically for review.  The male to 
female ratio was 8:13. Their ages ranged from 5 to 69 years with a mean of 35 ± 18, and their 
weights ranged from 18-115kg.  At their first hospital attendance, 14 patients presented with 
single lesions and seven presented with multiple lesions out of which three presented with an 
oedema and an ulcer, two presented with two ulcers and two others presented with a nodule, 
plaque and ulcer. The lesions of two were classified as category I lesions (size of <5 cm at the 
widest diameter), four as category II lesions (size between 5 and 15 cm at the widest 
diameter) and fifteen as category III lesions (size >15 cm at the widest diameter or multiple 
lesions). Nineteen of the lesions were found on the lower limbs and two on the upper limbs. 
Of the lesions on the lower limbs, 12 were found on the leg, four on the ankle and three on 
the foot; whilst on the upper limb, one each was found on the arm and the elbow. Three 
patients had other co-morbidities; HIV, hypertension and diabetes mellitus. Out of the 21 
cases, 17 took the SR treatment for 8 weeks and three took the treatment for 12 weeks 
because the treating clinician suspected the lesions to still be active after 8 weeks of 
treatment. One patient who had previously had BU and had undergone the 8 weeks of 
treatment a year before was prescribed a four-week treatment course after a new lesion 
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appeared at another location. During the course of treatment, one patient, who was positive 
for HIV, developed disseminated lesions on other parts of the lower limb.  
Clinical assessment 
The wounds were clinically accessed for signs of infection using a wound assessment chart. 
The clinical features assessed were the appearance of the wound (necrotic, granulation, 
epithelialisation, and slough), the wound exudate level (low, high, medium, serous, 
serosanguineous, purulent, malodour) and the appearance of the surrounding skin (macerated, 
oedematous, erythematous, indurated, dry scaling, healthy/intact). Category II and III lesions 
were assessed at two week intervals whilst category I lesions were assessed at weekly 
intervals.  
 
Sample collection 
Samples were taken from the lesions of patients for microbiological analysis to determine the 
bacterial burden and were also cultured to isolate and identify infecting bacteria, as 
previously described [14]. During the course of SR treatment, the bacterial burden of lesions 
was investigated bi-weekly. Post SR treatment, wound cultures were done upon advice from 
the responsible clinician when the lesion was suspected to be infected. Microbiological 
assessments were also made when patients underwent excision and debridement. A total of 
ninety-six (96) samples were collected from the patients. These included 85 swabs and 11 
tissue samples. Swab samples were collected by the Levine method [16] pre, during and post 
treatment from the undermined edges of lesions whilst tissue samples were collected post 
treatment after patients had undergone surgical procedures. Two swabs were taken from each 
lesion; one was placed in 5ml Phosphate buffered saline (PBS) for enumeration of the 
bacterial burden and isolation of aerobic infecting bacteria and the second was inserted into 
Robertson’s Cooked meat media for the isolation of anaerobic bacteria. Two tissue samples 
were taken from patients and one was aseptically transferred into Robertson’s Cooked meat 
media while the second was transferred into sterile transport containers. The samples were 
transported cold from the hospital to the laboratory at the Noguchi Memorial Institute for 
Medical Research and processed there.  
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Quantitative and qualitative cultures 
Quantitative cultures were carried out by the pour plate method, as previously described [14]. 
Values obtained from the enumeration of bacterial colonies were computed as colony 
forming units per ml (cfu/ml) for swabs and colony forming units per gram (cfu/g) for tissues. 
Wounds were classified as infected, if bacterial counts of >10
6
cfu/g or ml were obtained, 
contaminated if bacterial counts were <10
6
cfu/g or ml and clean if no bacterial colonies grew 
on the agar plates. Comparison between bacterial loads was done by t tests and one-way 
ANOVA calculations in SPSS v 24.0 [17]  
For the isolation of infecting bacterial species, 10
-1
 dilutions of the sample suspensions were 
pelleted and the sediments cultured on Blood, MacConkey and Mannitol Salt agars (Oxoid 
Ltd, Basingstoke, UK). Biochemical oxidase, catalase and coagulase tests were performed to 
presumptively identify bacteria species. Further characterization of Gram-negative rods was 
done using Analytical profile index (API20E) strips (bio-Merieux SA, Marcy-l’E’toile, 
France). The Staphylase Kit, Prolex latex agglutination system (Pro-Lab Diagnostics) was 
used to differentiate the catalase positive Gram positive bacteria, Staphylococcus aureus from 
other Staphylococcus species. 
The Robertson’s cooked meat medium containing the sample was incubated anaerobically in 
a glass jar with an anaerobic gas pack at 37°C for 48-73 hours. Tubes with signs of growth 
were subcultured on blood agar and incubated anaerobically with a metronidazole antibiotic 
disc to check for resistance. The Gram reaction of positive cultures was determined and 
identification of isolated microorganisms by MALDI-TOF mass spectrometry was 
outsourced to Mabritec AG, Riehen, Switzerland. 
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Results  
Clinical assessment of wounds 
Pre treatment, the majority of the lesions had clinical indications of infection, seemed to be in 
the proliferative stage of wound healing by having granulation tissue and epithelialisation, 
had undermined edges, and high wound exudates (Table 1). Changes in clinical presentation 
during treatment are shown in Table 1. Post treatment, all 15 assessed lesions presented with 
some granulation tissue and slough, 4/15 (26.6%) had necrotic tissues, 3/15 (20%) presented 
with epithelialisation whilst the edges of 5/15 (33.3%) were still undermined (Table 1).  
 
Bacterial burden and assessment of infection  
The bacterial burden of 22 lesions from 20 patients was determined pre SR. The bacterial 
load ranged from 0 to 3.00 x 10
9
cfu/ml, with a mean of 2.79 x 10
9
cfu/ml and a median of 
8.05 x 10
6
cfu/ml. Two (9.1%), two (9.1%) and eighteen (81.8%) samples were classified 
microbiologically as clean, contaminated and infected, respectively (Figure 1).  
During treatment, 26 samples were collected from the lesions of 20 patients (four patients 
were sampled twice and two patients had two lesions each). The bacterial load of the samples 
ranged from 0 to 2.06 x 10
9
cfu/ml, with a mean of 1.5 x 10
8
cfu/ml and a median of 1.13 x 
10
6
cfu/ml. Two (7.7%) samples were clean, eight (30.8%) were contaminated and fifteen 
(57.7%) were infected (Figure 1). The load of one of the samples could not be determined as 
the culture got contaminated.  
Post treatment, 48 samples were collected between weeks 8 and 75 from 25 lesions of 20 
patients. Ten lesions were sampled once, nine lesions twice, four lesions thrice and two 
lesions four times. The bacterial load of the samples ranged from 0 to 3.00 x 10
9
 cfu/ml, with 
a mean of 3.49 x 10
8
 cfu and a median of 1.69 x 10
8
cfu/ml. One (2.1%), eleven (22.9%), and 
thirty-six (75.0%) samples were classified as clean, contaminated and infected respectively 
(Figure 1).  
Bacterial loads were obtained for 17 patients (18 lesions) at all three stages. During treatment 
the bacterial load of 12 lesions decreased and that of six lesions increased compared to the 
values obtained pre-treatment. Post treatment, the loads of 16 lesions increased from the 
values obtained during treatment while that of two lesions decreased. Overall, most patients 
 
 
66 
 
thus presented with bacterial loads which reduced during treatment but increased 
dramatically post treatment (Figure 2). The difference between the bacterial loads at all three 
time points was significant (p<0.05). Pairwise comparison of the bacterial loads however 
showed that a statistically significant difference existed only between the loads during and 
post treatment.    
 
Isolated bacterial flora   
One hundred and fourteen bacterial isolates were recovered from qualitative cultures made up 
of 28 different species of aerobic bacteria and two species of Clostridia (Clostridium 
sporogenes and Clostridium perfringens). At pre-treatment, 14 distinct species were 
identified among 28 isolates, dominated by Enterococcus faecalis (5/28, 17.8%), 
Pseudomonas aeruginosa (4/28, 14.3%) and Chryseomonas luteola (4/28, 14.3%) (Table 2, 
S1 Table). Twelve species were identified among 29 isolates recovered during treatment and 
the main species was P. aeruginosa (12/29, 41.4%). Fifty-seven bacterial isolates were 
recovered post treatment out of which 20 distinct bacterial species, dominated by P. 
aeruginosa (16/57, 28.1%), were identified (Table 2, S1 Table).  
Post SR8 treatment follow-up 
After antibiotic treatment, twelve of the patients underwent surgical interventions. Three of 
them had excisions only, whilst nine patients underwent excision and skin grafting. The 
grafts of three of the patients failed and two had a second skin grafting. The lesions of 
thirteen patients got healed with an average healing time of 27-28 weeks post treatment. The 
rest of the patients were still dressing their wounds at the time of preparation of this 
manuscript and the time of dressing ranged at that time between 4 weeks to 75 weeks post 
treatment.  
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Discussion 
We investigated the bacterial burden of PCR confirmed BU wounds to gain an understanding 
into the evolution of microbial flora in BU wounds during treatment, which could have 
implications on the healing process. Our findings show that bacterial loads and bacterial 
diversity are high prior to S/R treatment, decrease during treatment and increase dramatically 
post treatment. About thirty distinct bacterial species were found colonising BU wounds with 
gram-negative rods dominating.  
We previously established that BU wounds could be infected by bacterial pathogens contrary 
to formerly held beliefs that they were sterile as a result of the presence of mycolactone [14]. 
However, it has recently been demonstrated that mycolactone is inactive against the bacterial 
species Streptococcus pneumoniae, Neisseria meningitidis, Escherichia coli as well as the 
yeast Saccharomyces cerevisae and amoeba Dictyostelium discoideum [18]. The results 
obtained from this study confirms our previous finding and findings from others [19-20] on 
secondary infection of BU wounds.  
A decrease in bacterial load during treatment compared to pre and post treatment was 
observed. This appears to be due to administration of the broad spectrum antibiotics within 
that time period. A study by Gardener [21] also reported decreased bacterial loads in study 
subjects who were on systemic antibiotics during the time of study, compared to those not on 
antibiotics. This result was also in good agreement with observed clinical signs, such as fewer 
lesions presenting with slough, necrosis and high wound exudate production. 
The bacterial species isolated from the BU wounds are representative of the spectrum of 
bacterial species usually isolated from chronic wounds [22]. Colonisation of most wounds by 
Gram negative bacteria indicates that they were at an advanced stage of bacterial 
colonisation, since early colonising bacteria in chronic wounds are mainly Gram positive 
organisms, notably Staphylococci and Beta-haemolytic Streptococci, which are replaced by 
Gram negative organisms as the wound microbiota becomes more complex [23]. Many BU 
patients report late to the formal health centers for treatment [24]. The period between the 
time of ulceration and the time of first presentation thus provides contaminating bacteria with 
adequate time to multiply and establish a complex microbiota accounting for the high number 
of Gram negatives isolated from the lesions.  
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P. aeruginosa was dominant at all time points. This organism is detected in wounds at its 
later natural history when a complex microbial flora is being formed [25] and is also 
frequently cited as a source of wound healing delay and wound infection [9, 26-27]. Two 
anaerobes were isolated from the lesions of two patients’ pre and during treatment. The 
presence of anaerobic bacteria indicates that the wounds are at a stage of irreversible adhesive 
colonization, as anaerobes are only known to colonise lesions after a hypoxic state has been 
created due to increased multiplication of the wound microflora [23]. Bacteria at this stage 
also develop inherent resistance to antibiotics which could impact on wound healing [23]. 
Previous work we did at the study health center has shown high levels of antibiotic resistance 
among bacteria isolated from lesions of hospitalized BU patients, including MRSA and MDR 
P. aeruginosa [14, 28]. Most of the isolated bacteria are known nosocomial pathogens and 
since BU treatment is associated with long hospital stays [29], BU patients are at high  risk 
for the acquisition of these pathogens in the health centers.  
A potential limitation of this study is that it did not formally assess the impact of the bacterial 
burden on wound healing outcome. However, various studies have shown that an increased 
bacterial load negatively impacts wound healing and the presence of bacteria in wounds even 
in the absence of obvious clinical signs can inhibit the normal wound healing process. 
Therefore BU wound management guidelines should consider the bacterial load and entail 
strategies for decreasing bacterial load at all time points during the course of the infection. 
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Figures 
 
Figure 1: Bacterial loads at different time points  
Bacterial loads obtained at different stages of treatment classified as clean, contaminated and 
infeccted. Blue coloured: loads obtained pre-treatment, red coloured: loads obtained during 
treatment, green coloured: loads obtained post treatment. 
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Figure 2: Bacterial loads of individual patients  
Bacterial loads of 17 patients at all three stages showing the evolution of the bacterial burden. 
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Tables 
Table 1- Clinical presentations of wounds  
Description / Presentations Week 0 
 
Week 2 
 
Week 4 
 
Week 8 
 
Post treatment  
 
Number of patients  assessed  21 4 19 19 15 
Tissue type on wound bed       
Granulation tissue  11 3 15 14 15 
Slough  14 2 16 12 15 
Necrotic tissue  2 1 3 1 4 
Epithelialisation  2 1 3 5 3 
Undermining  13 2 5 6 5 
Wound exudates  and type       
Low  None None 4 8 None 
High  16 1 3 5 12 
Medium  3 2 10 3 3 
Serous  10 1 14 10 7 
Serosanguineous 3 1 1 1 3 
sanguineous None None None None None 
Purulent (green/brown) 4 1 2 4 7 
malodor 16 1 7 5 9 
Surrounding skin       
Macerated  None None 3 2 5 
Oedematous  11 1 4 5 7 
Erythema None None None None None 
Indurated  5 1 5 2 3 
Dry and scaling  3 1 5 2 5 
Healthy /intact  1 1 6 7 2 
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Table 2: Bacterial species isolated 
Time Point Bacteria isolated Number isolated n (%) 
Pre-treatment Pseudomonas aeruginosa 4 (14.3) 
 Staphylococcus aureus 3 (10.7) 
 Chryseomonas lutoela 4 (14.3) 
 Proteus mirabilis 2 (7.1) 
 Enterobacter cloacae 2 (7.1) 
 Aeromonas sobria 1 (3.6) 
 Escherichia coli 1 (3.6) 
 Flavibacterium oryzihabitans 1 (3.6) 
 Micrococcus luteus 1 (3.6) 
 Acinetobacter baumanii 1 (3.6) 
 Enterococcus faecalis 5 (17.8) 
 Morganella morganii 1 (3.6) 
 Enterobacter sakazakii 1 (3.6) 
 Clostridium sporogenes 1 (3.6) 
 Total bacterial isolates 28 (100) 
During treatment Pseudomonas aeruginosa 12 (41.4) 
 Proteus mirabilis 4 (13.8) 
 Chryseomonas luteola 2 (6.9) 
 Coagulase Negative Staphylococcus 2 (6.9) 
 Enterobacter cloacae 1 (9.1) 
 Pseudomonas fluorescence 1 (3.4) 
 Citrobacter diversus 1(3.4) 
 Serratia marcescens 1 (3.4) 
 Enterobacter sp 1 (3.4) 
 Enterococcus faecalis 1 (3.4) 
 Providencia stuartii 1 (3.4) 
 Streptococcus anginosus_milleri_group 1 (3.4) 
 Clostridium perfringens 1 (3.4) 
 Total bacterial isolates 29 (100) 
Post treatment Pseudomonas aeruginosa 16 (28.1) 
 Enterobacter cloacae 6  (10.5) 
 Staphylococcus aureus 5 (8.8) 
 Pseudomonas fluorescence 4 (7.0) 
 Proteus mirabilis 5 (8.8) 
 Chryseomonas luteola 3 (5.3) 
 Aeromonas sobria 2 (3.5) 
 Enterobacter sakazakii 2 (3.5) 
 Leclercia adecarboxylata 2 (3.5) 
 Citrobacter fruendii 1 (1.8) 
 Flavimonas oryzihabitans 1 (1.8) 
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 Tatumella ptyseos 1 (1.8) 
 Klebsiella pneumoniae 1 (1.8) 
 Enterobacter sp 1 (1.8) 
 Coagulase Negative Staphylococcus 1 (1.8) 
 Staphylococcus epidermidis 1 (1.8) 
 Alcaligenes faecalis 1 (1.8) 
 Serratia marcescens 1 (1.8) 
 Aeromonas salmonicida 1 (1.8) 
 Enterococcus faecalis 1 (1.8) 
 Providencia rettgeri 1 (1.8) 
 Total bacterial isolates 57 (100) 
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Supplementary Material 
S1 Table: Bacteria isolated from individual patients at different time points  
Patient 
ID 
Time of sample collection Sample 
type 
 Organism (s) isolated 
PS001 week 0 swab Enterobacter cloacae, Morganella morganii 
 week 4 swab Pseudomonas aeruginosa, Providencia stuartii 
 week 8 swab Enterobacter sakazakii, Enterococcus faecalis 
 9 weeks post  SR8 tissue Pseudomonas fluorescence, Pseudomonas aeruginosa, Alcaligens faecalis, Enterobacter cloacae 
PS002 week 0 swab Flavibacterium oryzihabitans, Enterococcus faecalis 
 week 4 swab Pseudomonas aeruginosa, Clostridium perfringens 
 week 8 swab Chryseomonas luteola 
 4 weeks post  SR8 tissue Chryseomonas luteola, Proteus mirabilis 
 59 weeks post  SR8 swab Enterobacter cloacae 
 75 weeks post  SR8 swab Pseudomonas aeruginosa, Tatumella ptyseos, Enterobacter cloacae, Pseudomonas fluorescence 
PS003 week 0 swab Pseudomonas aeruginosa, Clostridium sporogenes 
 week 4 swab Pseudomonas aeruginosa, Serratia marcescens 
 week 8 swab Aeromonas sobria, Serratia marcescens 
PS005A week 0 swab Enterobacter sakazakii, Enterococcus faecalis 
 week 4 swab Proteus mirabilis 
 week 8 swab Pseudomonas aeruginosa, Providencia rettgeri 
PS005B week 0 swab Proteus mirabilis 
 week 4 swab Pseudomonas aeruginosa, Proteus mirabilis 
 week 8 swab Pseudomonas aeruginosa 
PS006 week 0 swab E. coli 
 week 4 swab Chryseomonas luteola 
 week 8 swab Aeromonas sobria, Proteus mirabilis, Leclercia adecarboxylata 
 11 weeks post  SR8 tissue Enterobacter sakazakii, Leclercia adecarboxylata 
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PS010 week 0 swab Pseudomonas aeruginosa, Enterococcus faecalis 
 week 4 swab Enterobacter sp, Enterococcus faecalis 
 week 8 swab Proteus mirabilis, Chryseomonas luteola 
 53 weeks post  SR12 swab Flavimonas oryzihabitans 
PS012 week 0 swab Micrococcus luteus 
 week 4 swab Enterobacter cloacae 
 week 8 swab Pseudomonas aeruginosa 
PS014 week 0 swab Chryseomonas luteola, Enterococcus faecalis 
 week 4 swab Pseudomonas fluorescence, Streptococcus anginosus_milleri_group 
 week 8 swab Pseudomonas fluorescence, Enterobacter cloacae, Staphylococcus epidermidis 
    27 weeks post  SR8, SGF  swab Gram positive rods 
 60 weeks post  SR8 swab Pseudomonas aeruginosa 
PS015 week 0 swab Pseudomonas aeruginosa, Enterococcus faecalis 
 week 4 swab Pseudomonas aeruginosa 
 week 8 swab Pseudomonas aeruginosa, Proteus mirabilis 
 29 weeks post  SR8, SGF  swab Pseudomonas fluorescence 
PS016 week 0 swab Staphylococcus aureus, Acinetobacter baumanii, Enterobacter cloacae 
 week 4 swab Pseudomonas aeruginosa 
 week 8 swab Pseudomonas aeruginosa 
 18 weeks post  SR8 tissue No growth 
 4 weeks post  SR8 tissue Pseudomonas aeruginosa 
PS017A week 0 swab Chryseomonas luteola 
 post  SR8 swab Staphylococcus aureus 
 post  SR8 swab Enterobacter cloacae 
PS017B week 0 swab Chryseomonas luteola 
 post  SR8 swab Staph aureus 
 post  SR8 swab Aeromonas salmonicida 
PS019 week 0 swab Yeast  
 week 4 swab Yeast  
 week 8 swab Gram negative rods (unidentified) 
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PS020 week 0 swab Chryseomonas luteola 
 week 4 swab Chryseomonas luteola 
 week 8 swab Gram negative rods (unidentified) 
PS021 week 0 swab Gram negative rods (unidentified) 
 week 2 swab Pseudomonas aeruginosa 
 week 4 swab Proteus mirabilis 
 week 8 swab Gram positive rods 
 post  SR8 lesion B tissue Enterobacter cloacae 
 post  SR8 lesion A swab Pseudomonas aeruginosa 
 post  SR8 lesion B swab Pseudomonas aeruginosa 
 post  SR8 lesion C swab Gram positive rods 
 post  SR8 lesion A swab Staph aureus 
 post  SR8 lesion B swab Enterobacter sp 
 post  SR8 lesion C swab Staph aureus 
 post  SR8 lesion D swab Staph aureus 
PS023 week 0 swab No growth 
 week 6 swab Coagulase negative Staphylococci 
PS024 week 0 swab Staphylococcus aureus 
 week 4 sswab Citrobacter diversus 
 week 8 swab Pseudomonas aeruginosa  
 post  SR8 tissue Citrobacter fruendii 
 post  SR8 swab Pseudomonas aeruginosa 
 post  SR8 swab Pseudomonas aeruginosa 
PS025 week 0 swab Aeromonas sobria 
 week 2 swab Gram positive rods 
 week 4 swab Gram positive rods 
 week 8 swab Coagulase negative Staphylococci 
PS026 week 0 swab Proteus mirabilis 
 week 2 swab Pseudomonas aeruginosa 
 week 4 swab Proteus mirabilis, Coagulase Negative Staphylococcus 
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 week 8 swab Proteus mirabilis 
 post  SR8 tissue Klebsiella pneumoniae 
PS027 week 0 swab Pseudomonas aeruginosa 
 week 2 swab Pseudomonas aeruginosa 
 week 4 swab Pseudomonas aeruginosa 
 week 8 tissue Pseudomonas aeruginosa 
  post  SR8 swab Pseudomonas aeruginosa 
PS028 week 4 swab Pseudomonas aeruginosa 
 week 6 swab Pseudomonas aeruginosa 
 week 8 swab Gram positive rods 
PS029 week 0 swab Staphylococcus aureus 
 week 4 swab No growth 
 
SGF: skin graft failure   
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Chapter 3 
 
 
Challenges Associated with Management of Buruli Ulcer/Human 
Immunodeficiency Virus Co-infection in a Treatment Center in Ghana: A 
Case Series Study 
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Abstract 
The synergy between Mycobacterium tuberculosis infection and human immunodeficiency 
virus (HIV)/ acquired immunodeficiency syndrome is well established but not so in Buruli 
ulcer (BU). We screened confirmed BU cases for HIV infection and followed seven 
BU/HIV-coinfected patients. Management of BU/HIV was based on the World Health 
Organization guidelines and patient condition. The HIV positivity among BU patients 
(8.2%; 11/134) was higher compared with that of general patients attending the facility 
(4.8%; 718/14,863; P = 0.07) and that of pregnant women alone (2.5%; 279/11,125; P = 
0.001). All seven BU/HIV-coinfected cases enrolled in the study presented with very large 
(category III) lesions with four having multiple lesions compared with 54.5% of category 
III lesions among HIV-negative BU patients. During the recommended BU treatment with 
streptomycin and rifampicin (SR) all patients developed immune infiltrates including CD4 
T cells in their lesions. However, one patient who received antiretroviral therapy (ART) 1 
week after beginning SR treatment developed four additional lesions during antibiotic 
treatment, while two out of the four who did not receive ART died. Further evidence is 
required to ascertain the most appropriate time to commence ART in relation to SR 
treatment to minimize paradoxical reactions. 
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Introduction 
Buruli ulcer (BU), a disease caused by Mycobacterium ulcerans, leads mainly to the destruction 
of skin tissues [1]. The disease is rarely fatal, but delayed treatment often results in contracture 
deformities because of the massive skin destruction by the cytotoxic macrolide, mycolactone 
[2,3]. The disease presents in two main active clinical forms: non-ulcerative (papule, nodule, 
plaque, and edema) and ulcerative. Severe forms include osteomyelitis and disseminated (or 
multifocal) lesions [1,4]. BU lesions are categorized based on World Health Organization (WHO) 
classification into category I, which consist of lesions with a size of < 5 cm at the widest 
diameter; category II, which consist of lesions with a size between 5 and 15 cm at the widest 
diameter; and category III, which consist of lesions with a size > 15 cm at the widest diameter, 
lesions at critical sites and multiple lesions [1]. The WHO recommended first-line treatment of 
BU is daily injection with streptomycin (SR) and oral rifampicin for 8 weeks, and if necessary, 
surgery either to improve healing and/or to correct deformities [1,5,6]. The efficacy of this 
treatment regimen has been confirmed in several studies [7-9]. Active lesions present with large 
focal clusters of extracellular acid-fast bacilli (AFB) and only minor leukocyte infiltration 
[10,11]. Antimicrobial therapy leads to massive leukocyte infiltration, which culminates in the 
development of ectopic lymphoid structures in the lesions [12]. Some studies have reported 
paradoxical reactions in BU patients, which is defined as an increase in lesion size of > 100% 
after initial improvement, and/or the appearance of a new lesion(s) following or during 
antimycobacterial treatment [13,14]. Currently, it is not clear whether immune reconstitution 
inflammatory syndrome (IRIS)–like mechanisms, secondary infections [15], or other mechanisms 
are primarily responsible for impaired wound healing and deterioration of lesions during and after 
SR treatment in some of the BU patients. A retrospective study conducted in Cameroon revealed 
that human immunodeficiency virus (HIV) infection may affect the clinical presentation and 
severity of BU disease with a reported increased incidence of multiple, larger, and ulcerated BU 
lesions [16-18]. Data available on the absorption of antituberculosis medications in tuberculosis 
(TB)/HIV coinfection compared with HIV-negative patients showed conflicting results [19,20]. 
Therefore, whether antimycobacterial combination treatment is less efficacious in persons with 
HIV infection is unknown and needs to be systematically studied. 
The associations between HIV infection and some other infectious diseases are clearly defined, 
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but that between BU and HIV is not fully understood [21]. It is well known that HIV infection is 
fueling the global TB epidemic and the convergence of the TB and the HIV epidemics pose new 
public health challenges [22]. The interaction between HIV and TB in coinfected persons is 
bidirectional and synergistic; on one hand, HIV infection predisposes to the development of 
active TB, on the other hand the course of HIV-related immunodeficiency is worsened by active 
TB infection [22,23]. Although it is clearly known that HIV/acquired immunodeficiency 
syndrome (AIDS), which leads to reduced CD4 helper T-cell activity, is a risk factor for TB, 
immune protection mechanisms in BU disease are not fully understood [24]. However, like in 
other mycobacterial diseases, adaptive immune responses championed by CD4
+
 activation of 
macrophages are presumably also crucial for protection against BU. Although large clusters of 
toxin-producing M. ulcerans bacteria are found in established BU lesions, there are indications 
that multiplication of the pathogen in phagocytes plays a role in the early steps of the infection 
[25,26]. Furthermore, BU disease leads to reduced interferon (IFN)-g release [27]. 
Management of HIV/AIDS over the years has seen progressive improvement in drug therapy and 
clearer guidelines, which has dramatically decreased mortality and incidence of AIDS-defining 
opportunistic infections [28,29]. Despite this breakthrough in management, there is still the 
challenge of a paradoxical IRIS in HIV patients on antiretroviral therapy (ART), which is a 
phenomenon that has been defined to be a new type B or C AIDS-defining condition or 
emergence of a range of mucocutaneous or autoimmune conditions diagnosed within 180 days of 
starting ART with a corresponding CD4 response [30]. In the presence of a treated or ongoing 
opportunistic infection such as TB, such paradoxical IRIS could occur in which case it would be 
defined as 1) a new, worsening or recurrent sign or symptom consistent with an exaggerated or 
atypical inflammatory reaction to the previously diagnosed opportunistic infection, 2) the 
exclusion of medication toxicity or other disease processes as the cause of the abnormal event, 
and 3) a supportive evidence be it by some specialized imaging or histopathology [31]. The 
combined effect of the IRIS associated with HIV patients on ART [30] and the paradoxical 
reaction experienced in BU patients on antimicrobial treatment [13,14] could possibly pose a 
challenge to the management of BU/HIV coinfection. 
Anemia is common among sub-Saharan Africans with BU [32]. Susceptibility to BU is 
associated with polymorphism in the gene for the iron transporter protein NRAMP1 [33]. Models 
exist to explain iron deficiency anemia in mycobacterial diseases such as BU. Notable among 
them suggests sequestration of Fe
2+
 from the body into phagosomes and the lack of NRAMP1 to 
 
 
86 
 
export the iron back, as the possible cause of the anemia [34], which could be worsened with an 
HIV coinfection depending on the clinical stage and state of immunity [35,36]. 
This study compares the prevalence of HIV infection among confirmed BU patients at a district 
hospital in Ghana with the general population of patients in that same facility and also describes 
BU/HIV coinfection cases highlighting the challenges associated with the mana gement of 
BU/HIV coinfection. 
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Materials and Methods 
 
Ethical statement  
Ethical clearance for the study was obtained from the institutional review board of the Noguchi 
Memorial Institute for Medical Research (NMIMR) (Federal-wide Assurance number 
FWA00001824). All study participants were well informed of the study objectives and written 
informed consent was obtained either from the patient or from the guardian of the patient. 
Sampling and laboratory confirmation for both M. ulcerans and HIV infection followed the 
national approved procedure. All confirmed cases were referred for appropriate treatment of BU 
and HIV/AIDS. 
 
Study participants  
The participants involved in the study were passively recruited from the Ga West Municipal 
Hospital in Amasaman, Ghana, from October 2009 to March 2013; one clinician at the health 
facility who made the final clinical diagnostic decision reviewed all patients in this study. A 
participant was included in this study if he/she met the WHO clinical definition for the different 
BU lesions and was positive for at least IS2404 polymerase chain reaction (PCR) as previously 
described [37]. Basic demographic data and clinical history of cases were recorded by adapting 
the BU01 form of the WHO. Lesions were categorized according to the WHO classification as 
previously described [1]. In addition lesions were classified either as ulcer, edema, nodule, or 
papule as well as single or multiple lesions [2]. Patients were screened for HIV infection by 
collecting blood samples after counseling and consent has been sought. Two 
immunochromatographic (lateral flow) strip–based rapid test kits, OraQuick 
(OraSure,Bethlehem, PA) and/or First Response HIV 1-2.0 Card Test (PMC Medical Pvt. Ltd., 
Daman, India), were used for initial screening, and samples that tested positive were confirmed 
by the Inno-Lia HIV I/II immunoblot assay (Immunogenetics, Gent, Belgium) [38].
  
 
BU confirmation 
Swabs were collected from the undermined edges of ulcerative lesions and fine needle aspirates 
were collected from cases with non-ulcerative lesions for bacteriological confirmation of BU 
disease [39,40]. All samples were analyzed by IS2404 quantitative PCR, microscopy and culture. 
For those patients presenting with multiple lesions, samples were collected from each lesion. For 
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patients who underwent surgery, tissue biopsies were taken for further microbiological analyses 
at NMIMR and histopathology at Swiss Tropical and Public Health Institute. 
 
 
 
Treatment and monitoring  
The patients were treated with daily SR (15 mg/kg/day intramuscular injection) and rifampicin 
(10 mg/kg/day orally) according to the WHO protocol for duration of 8 weeks [8]. Patients were 
questioned about side effects from the antibiotic treatment at each biweekly clinical assessment 
and asked to report any problems to the health center between periodic reviews. Surgical 
debridement was done 4 weeks after antibiotic treatment of BU for some of the lesions. Biopsy 
samples from the wound edges were sent for culture and histopathology. Any septic wound 
diagnosed clinically was confirmed by culture and sensitivity testing using swab samples and was 
treated accordingly. Biweekly wound assessment was done involving wound measurement and 
photography using a wound imaging, measurement, and documentation device, ARANZ Medical 
Silhouette Mobile
™
 (ARANZ Medical, Christchurch, New Zealand). Standard moist wound 
management practices were conducted, which involved saline dressing and covering of the floor 
of the ulcers with Vaseline gauze [41]. Frequency of dressing change was individualized 
according to the characteristics of the ulcer. Following initial wound excision after antibiotic 
treatment, surgical debridement and skin grafting subsequently done was tailored to the need of 
each patient and on the discretion of the attending surgeon. New lesions occurring during the 
course of therapy or follow-up period were closely examined and analyzed by culture and in 
certain cases by histopathology [13,14]. 
 
Laboratory and radiological investigations  
Baseline complete blood count, liver function test, blood urea electrolytes and creatinine, 
erythrocyte sedimentation rate, fasting blood sugar and sickling test with/without Hb 
electrophoresis as indicated were done for all patients. Unless clinically indicated earlier for a 
patient, complete blood count, liver function test, and blood urea electrolytes and creatinine tests 
were routinely repeated 8 weeks to ascertain any renal or hepatic toxicity and to assess the 
hemoglobin levels. Baseline CD4 count was done and repeated at 6-month intervals for only two 
patients until the wound was completely healed and patient discharged. X-rays of the limbs with 
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the ulcers were done for all patients as part of baseline investigations to rule out osteomyelitis 
associated with BU/HIV coinfection. TB was ruled out in all the patients clinically and by means 
of normal chest X-rays. Computerized tomography scan of the head was done for one patient 
who developed some neurological deficits during wound management to rule out any space 
occupying lesions most especially cerebral toxoplasmosis. 
 
Histopathology 
Histopathological analysis was done for all surgical debridement and excisions. Surgically 
excised tissue samples were immediately fixed in 10% neutral-buffered formalin for 24 hours at 
room temperature to maintain tissue structures. Afterward samples were directly transferred to 
70% ethanol for storage and transport. Tissue specimens were subsequently dehydrated, 
embedded into paraffin, and cut into 5 mm sections. After deparaffinization and rehydration, 
sections were stained with Ziehl–Neelsen (ZN)/methylene blue, hematoxylin or by 
immunohistochemistry according to WHO standard protocols [42]. The following antibodies 
were used for T-cell staining (CD3, Dako; CD4, cell marque; CD8, Serotec) and B-cell staining 
(CD20, Dako). Tissue sections were analyzed with a Leica DM2500 Microscope (Wetzlar, 
Germany). Pictures were either taken with a Leica DFC 420C camera or with an Aperio 
ScanScope XT. 
 
Data analysis 
All data were entered into Microsoft Excel package and verified before exporting into the 
statistical package Stata (Release 12; Stata Corporation, College Station, TX) that was used to 
perform all the statistical analyses. The c
2
 tests at 95% confidence (CI) level was used to compare 
HIV prevalence among BU patients and HIV in the general hospital attendants and also among 
pregnant women screened at the same health facility. 
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Results 
 
Study participants and prevalence of HIV/BU coinfection 
All PCR-confirmed BU patients (67 males and females each) were screened for HIV at the Ga 
West Municipal Hospital. Their age range was between 3 and 86 years with a mean age of 33.8 
years (standard deviation [SD]: 21.6); 36 (26.8%) were ≤ 15 years. Eleven (8.2%) of the cases (5 
females and 6 males) were HIV positive. During the period, 14,863 individuals were tested for 
HIV infection in the same facility and the positivity rate was 4.8% (718/14,863) though lower 
was not significant, P = 0.070. On the other hand prevalence was significantly lower (P value = 
0.001) among pregnant women using the preventing mother to child transmission (PMTCT) 
facility (2.5%; 279/11,125). The age range of the HIV-positive BU cases was between 12 and 65 
years with a mean age of 37.1 years (SD: 13.1). Only one of the 11 HIV-positive BU cases was a 
child (aged 12), the remaining 10, were between 29 and 65 years of age. Seven out of the 11 
HIV/BU coinfected cases were followed during treatment and Table 1 shows the baseline 
characteristics of these seven study participants. The other four patients were lost to follow-up. 
All the seven patients went through some form of traditional or herbal treatment of the ulcers 
with duration of ulcers before antibiotic therapy ranging from 4 to 24 months. Four of them were 
males and three were females. The ages were from 12–46 years with a mean age of 33.1 years 
(SD: 11.7 years). All seven patients presented with category III lesions with six presenting with 
lower limb lesions and one presenting with an upper limb lesion. In comparison, 67/123 (54.47%) 
HIV-negative BU patients presented with category III lesions. One of the BU/HIV coinfected 
patients presented with an ulcer and a plaque not yet ulcerated at presentation, whereas the others 
had ulcerated forms only at presentation. Four had multiple lesions at presentation whereas three 
had single lesions. M. ulcerans infection of all seven patients was reconfirmed by IS2404 PCR. 
In addition, 6/7 were reconfirmed by microscopic detection of AFBs after ZN staining and 3/7 
were confirmed by positive M. ulcerans culture. 
The mean hemoglobin level (Table 2) at baseline was 8.7 g/dL (SD: 2.5). One of the patients had 
a normal hemoglobin level at presentation but worsening anemia with new lesions formed. 
Median CD4 counts at baseline (Table 2) were 318 cells/mm
3
 (interquartile range [IQR]: 265–
750 cells/mm
3
). Two patients who were at WHO clinical stage 2 of HIV infection at baseline had 
6 monthly CD4 count repeated until study end point. Of these two patients, one started ART 1 
week after beginning of SR treatment and the other started ART 1 week after completing SR 
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treatment. The CD4 counts (Table 2) measured after 6 months dropped to 185 cells/mm
3
 from a 
baseline of 298 cells/mm
3
 (for patient starting ART 1 week after SR started), which then 
improved to 586 cells/mm
3
 at 1 year, whereas the second patient showed a steady rise in the CD4 
count from baseline. 
 
 
Duration of SR treatment 
The duration of SR treatment was 8 weeks according to WHO protocol. However, three patients 
had treatment extended to 12 weeks upon the discretion of the clinician, whereas one patient had 
SR changed after 26 days to rifampicin–amikacin for an additional 30 days because of suspected 
adverse reaction to SR. One patient (case 5) died after 40 days on SR treatment. Time of starting 
ART in relation to SR treatment. Of the three patients (cases 1, 2, and 3) who took ART during 
wound management, one (case 2) commenced 1 week after starting SR, another (case 3) started 1 
week after completing SR, and the other (case 1) started 13 weeks after completing SR. The type 
of ART combination given is as shown in Table 3. Two (cases 4 and 5) of the remaining four 
patients died and the other two (cases 6 and 7) were referred to ART centers away from the 
center of the study after wounds had healed with no recurrence after 6 months of follow-up, 
because no ART center was established at the district hospital at the time of their management. 
Figure 1 shows immune infiltrates observed in one patient (case 2) who developed four new 
lesions with excessive exudates at different sites of the same limb. One at the anteromedial aspect 
of the proximal third of the right limb, the other on the right lateral aspect of the thigh, and the 
other two developed on the medial aspect of the knee and the dorsum of the right foot. The onset 
of the infiltration started about 2 weeks after starting the SR treatment. The other lesions 
developed following the administration of additional SR treatment after completion of the 8 
weeks’ standard regimen. The new lesions were managed by saline dressing and required no 
further antibiotic treatment. 
 
Wound healing rate  
We designated a wound healed when complete (100%) epithelialization of the ulcer had 
occurred. The study adopted an endpoint to healing at 52 weeks at which point all ulcers that 
were not 100% epithelialized were censored or classified as failing to heal [43]. The healing rate 
at the study endpoint was 42.9% (3/7) with a median time to healing of 37 weeks (IQR: 36–37) 
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(Table 3). Two patients (cases 4 and 5) died within the study period and two (cases 2 and 3) had 
still not healed completely 56 and 64 weeks after start of treatment, respectively. The three 
patients (cases 1, 6, and 7) that healed had excision and skin grafting done. One of the nonhealing 
wounds (case 3) had the graft breaking down leading to a recurrent ulcer after 40 weeks of 
complete epithelialization and discharge from the hospital. M. ulcerans culture of tissue samples 
was negative ruling out relapse and the reopening was probably due to poor scar care. 
 
Development of immune infiltrates 
For histopathological analysis, tissue samples were collected after completion of at least the 
standard 8 weeks of SR treatment. All samples still presented with BU typical histopathological 
features, such as epidermal hyperplasia, fat cell ghosts, and some remaining tissue necrosis 
(Figure 2A, B, and E). In addition, all samples showed immune infiltration, blood vessel and 
granuloma formation (Figure 2A, C, and D), as is commonly observed in antibiotic-treated 
lesions of HIV-negative BU patients.
12
 Mixed infiltrates containing large numbers of CD3 
positive T cells were found mainly in the dermis and subcutaneous tissue layer. Granulomas and 
clusters of CD20 positive B cells were embedded in the mixed unstructured infiltrates. 
Granulomas were mainly formed by macrophages, giant cells, T cells, and B cells (Figure 2F–I). 
In all lesions the infiltration contained CD4 positive T cells, even when CD4 blood counts (Table 
2) were low. However, in 4/6 patients analyzed, CD8
+
 T cells outnumbered CD4
+
 cells. Larger 
numbers of N-elastase-positive neutrophils were only observed in association with secondary 
bacterial infections. AFBs were detected in only 2/6 analyzed tissue samples as scattered beaded 
bacteria. 
 
 
 
 
  
 
 
93 
 
Discussion 
Little is known about the impact of HIV infection on susceptibility to M. ulcerans infection and 
BU treatment outcomes such as cure, recurrence, long-term disability, and the incidence of 
paradoxical reactions secondary to antibiotic treatment. In a study conducted in 426 BU patients 
and 613 controls in southern Benin [44], a significantly higher HIV prevalence was observed 
among BU patients than in controls (2.6% versus 0.3%; P = 0.003). Although in this study, the 
HIV prevalence among BU patients (8.2%) was higher than that (4.8%) among general patients 
attending the same health facility, this difference was not statistically significant (P value = 
0.070). In contrast, a significant difference (P value = 0.001) was found with the HIV prevalence 
of 2.5% among pregnant women attending the same health facility during the same period. The 
cases that were followed had varying disease presentation, responses to treatment as well as 
treatment outcomes. All seven BU/HIV coinfected cases included in the study presented with 
category III lesions as compared with 54.47% of category III lesions in HIV-negative BU cases. 
Severity of BU disease did not necessarily reflect the level of underlying immune suppression 
especially when using CD4 as the marker, as a case with CD4 counts below 300 had no 
multifocal disease, while another case with CD4 counts above 500 developed multiple lesions. 
One of the BU/HIV coinfected patients developed chronic osteomyelitis (case 4). This patient 
was severely immunosuppressed, as evidenced by a CD4 count of 37 and clinical stage 4 HIV 
disease. Since osteomyelitis is also occurring in HIV-negative patients, further studies are 
required to establish whether a severe immune suppressed state increases the risk for developing 
osteomyelitis. Although CD4 blood counts were reduced in the six patients analyzed by 
histopathology (unfortunately no tissue sample became available from the patient with the very 
low CD4 blood count of 37), substantial numbers of CD4 positive T cells were found in mixed 
infiltrates and granulomas emerging in the treated BU lesions. However, CD8 T cells 
outnumbered CD4 T cells in 4/6 patients (Figure 2H and I). 
The HIV coinfected BU cases presented here showed mild to moderate anemia at admission but 
severe anemia concomitant with new lesions in one patient (case 2). Anemia has been found to be 
present at varying degrees in HIV patients, correlating with the clinical stage and state of 
immunity of the patient [35,36]. However within the cases followed, we found severe anemia as 
defined by the CDC even though the CD4 count of the patient was above 500. Literature also 
supports that some mycobacteria such as M. tuberculosis and M. avium complex can cause 
peripheral blood cytopenia in HIV patients but no such documentation with M. ulcerans is 
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currently available [45]. Persistent anemia resulting from a BU/HIV coinfection could account 
for the delayed healing of wounds (median time to wound healing being 37 weeks) of the cases 
presented here.  
One of the BU-HIV coinfected cases (case 2) developed new lesions 2 weeks after starting SR 
treatment, coinciding with 1 week after starting ART. Whether this occurrence was a result of the 
relative early onset of the ART with SR treatment is unclear. The appropriate time to start ART 
in HIV patients with opportunistic infection has always been a dilemma to clinicians since ART 
can trigger severe IRIS-like reactions when it is commenced early. On the other hand, delaying 
treatment could similarly lead to worsening of the disease condition and prognoses. With 
TB/HIV coinfection, it is recommended that ART should be started 2 weeks into antimicrobial 
treatment
 
[46]; however, based on a large randomized controlled trial it is recommended to delay 
ART till 5 weeks into antimicrobial treatment when managing HIV/ Cryptococcus coinfection 
[47]. Hence, the optimal time to starting ART may depend on the specific coinfection and known 
interactions of some ART with antimicrobial agents. Studies have shown that taking ART 
containing nevirapine alongside SR treatment leads to a decreased Cmax and Cmin of nevirapine 
due to interaction with rifampicin [48-50]. This notwithstanding, early onset of ART and co-
trimoxazole prophylaxis is highly recommended by WHO preliminary guidelines for 
management of HIV/BU coinfection [51] to build up immunity and to fight opportunistic 
infections associated with HIV as these could worsen the prognosis of the condition. Here 4/7 
BU/HIV coinfected patients did not start with ART treatment within the study period because of 
unavailability of an ART center within or close to the study center. Since HIV testing has become 
a standard element in BU management, access to an ART center should be secured as a part of 
BU care. The 2/7 study participants who died within the study period as a result of worsening 
disease were not started on ART. Possibly, such mortality could have been averted by early onset 
of ART. 
The duration of SR treatment of 3/7 of the HIV/BU coinfected cases studied here was extended 
based on the judgment of the responsible clinicians to 12 weeks, since deterioration of the lesions 
suggested M. ulcerans ongoing disease activity after completion of the standard 8 weeks of 
treatment. However, no laboratory confirmation for the presence of viable M. ulcerans bacteria 
before the extension of the antibiotic treatment was available. 
 
  
 
 
95 
 
Conclusion 
Despite the limitations of the small sample size, the difficulties in assessing the immunological 
statuses of some participants, as well as ascertaining the viral loads of the patients, results of this 
study indicate that HIV coinfection could predispose BU patients to the development of more 
severe clinical forms (large and multiple lesions) and delayed wound healing. Although early 
onset of ART in BU/HIV coinfection is recommended, systematic studies are required to develop 
detailed guidelines for the management of BU/HIV coinfected patients as there are for TB and 
Cryptococcus/HIV coinfections. Further studies would be required to determine the cumulative 
effect of the IRIS and paradoxical reactions in BU/HIV coinfected patients on ART and SR 
treatments. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Emergence of new lesions during streptomycin (SR) treatment in one of the enrolled 
coinfected patients (case 2).  
(A) Features of the first lesion before the start of SR treatment, (B) appearance of a new lesion after 2 
weeks of antibiotic treatment, (C) appearance of a third lesion after 4 weeks of SR treatment, (D) 
appearance of a fourth lesion after 6 weeks of SR treatment, and (E) increase in wound sizes after surgical 
excision and appearance of a fifth lesion after start of the SR treatment. 
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Figure 2. Emergence of immune infiltrates in the Buruli ulcer (BU) lesion during SR treatment in a 
representative patient (case 7).  
Histological sections were stained either with hematoxylin–eosin (A–E), or with antibodies against CD20 
(F), CD3 (G), CD8 (H), or CD4 (I) (counterstain hematoxylin). (A) cross section through a BU lesion 
presenting with epidermal hyperplasia, an intact dermis, healthy fat cells as well as fat cell ghosts, a layer 
of numerous well-defined granulomas, and a necrotic area. Fat cell ghosts (B), granulomas (C), giant cells 
(D), and necrosis (E) are shown at higher magnification. Immunohistochemical analysis of the granulomas 
showed the presence of B-cell clusters (F) as well as the presence of large numbers of CD3, CD4, and 
CD8 positive T cells (G, H, and I). 
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Tables 
 
Table 1: Demographics, clinical features and diagnostic data of study participants with BU and HIV 
coinfection 
Patients parameters  Values  
Total no.          7 
Sex(no. of  males/females  4/3 
Median(range) age  yr. 33.7(12-46) 
No.(%) with indicated site of lesion  
      Upper limb   
      Lower limb  
 
 
1(14.2) 
6(85.7) 
No. (%) with indicated clinical form of lesion 
      Ulcer   
     Plaque/ulcer 
 
 
6(85.7) 
1(14.2) 
No. (%) with indicated category of lesion  
       III 
 
 
 
7(100) 
 No.(%) with indicated number of lesion 
             Single  
            Multiple  
 
 
3(42.8) 
4(57.1) 
No. with indicated laboratory confirmation results 
       M. ulcerans culture (+/-) 
       PCR for IS2404 (+/-) 
 
 
3/4 
7 
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Table 2: CD4 counts and Hb level monitoring of the seven enrolled patients at 8-weeks intervals 
 
 
 
BU case         WK0        WK 8     WK16 WK24  WK 32 WK 40 WK48 
CD4 HB CD4 HB CD4 HB CD4 HB CD4 HB CD4 HB CD4 HB 
1 318 8.8g/dl - 8.2 g/dl - 10.5 g/dl - - - - - - - - 
2 298 11.4g/dl - 7.9g/dl - 7.0g/dl 185 8.2g/dl - 8.2g/d
l 
- 9.9g/dl 558 11g/dl 
3 265 7g/dl - 11.8g/dl - 10.2g/dl 394 8.0g/dl - 7.2g/d
l 
- 9.2g/dl 455 8.7g/dl 
4 37 9.5g/dl - 8.2g/dl -       - - - - - - - - - 
5 791 5.0g/dl - 6.4g/dl - 6.2g/dl - 8.2g/dl - - - - - - 
     6  730      
12.g/dl 
      -     
11.8g/dl 
      -     
12.1g/dl 
      -       -       -       -       -       -       -       - 
7 751 7.1g/dl - 10.7g/dl - 9.6g/dl - - - - - - - - 
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Table 3: Laboratory confirmation, HIV clinical stage, and treatment characteristics of the seven patients 
enrolled 
 
 
 
 
 
BU Case BU 
confirmation 
Retro serotype/HIV  
clinical stage 
SR 
 treatment 
HIV treatment Treatment  
outcome 
Time to complete  
wound healing 
1 PCR HIV 1, Stage 2 SR8 Tenofovir,  
lamivudine,  
efavirenz + co-
trimoxazole 
Woun healed with  
skin grafting 
37 weeks 
2 PCR, ZN HIV 1, Stage 2 SR12 Tenofovir,  
lamivudine,  
nevirapine + co-
trimoxazole 
Still dressing wound at 64  
weeks of treatment 
Failed to heal 
3 PCR, ZN HIV 1, Stage 2 SR12 Tenofovir,  
lamivudine,  
efavirenz + co-
trimoxazole 
Wound re-opened after 40 
 weeks of discharge. Still  
dressing wound at 52 weeks 
Re-opened  
leg ulcer 
4 PCR, ZN HIV 1, Stage 4 SR8 Co-trimoxazole Patient died of deterioration 
 of disease 
Censored 
5 PCR, ZN HIV 1, Stage 4 SR8 Co-trimoxazole Patient died of sever 
Staphylococcus aureus septicemia 
and anemia 26 weeks after 
completion of treatment 
Censored 
6 PCR, ZN HIV 1, Stage 2 SR8 Co-trimoxazole Wound healed after  
skin grafting 
37 weeks 
7 PCR, ZN HIV 1, Stage 2 SR12 Co-trimoxazole Wound healed after 
 skin grafting 
36 weeks 
BU = Buruli ulcer; HIV = human immunodeficiency virus; PCR = polymerase chain reaction; SR = 
streptomycin/rifampicin; ZN = Ziehl–Neelsen. 
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Abstract 
We have previously shown that secondary infection of Buruli ulcer (BU) wounds were 
frequently caused by Staphylococcus aureus. Such complications may lead to significant 
healing delays. To gain understanding into possible routes of secondary infection, we 
characterised S. aureus isolates from patient lesions and surrounding environments across two 
Ghanaian health centres. One hundred and one S. aureus isolates were isolated from wounds 
(n=93, 92.1%) and the hospital environment (n=8, 7.9%) by microbiological culture and 
characterised by the spa gene, mecA and the Pantone Valentine Leukocidin (PVL) toxin 
followed by spa sequencing and  whole genome sequencing (WGS) of a subset of 49 isolates. 
Susceptibility testing of the isolates to commonly prescribed antibiotics was performed. Spa 
typing and sequencing of the spa gene from 91 isolates identified 29 different spa types with 
t355 (ST152), t186 (ST88), and t346 dominating.  While many distinct strains were isolated 
from both health centers, genotype clustering was also identified within centers. These 
clusters were confirmed by phylogenomic analysis. Twenty-four (22.8%) isolates were 
identified as methicillin-resistant S. aureus (MRSA) and lukFS genes encoding PVL were 
identified in 67 (63.8%) of the isolates. Phenotype screening showed widespread resistance to 
tetracycline, erythromycin, rifampicin, amikacin and streptomycin. Genomics confirmed the 
widespread presence of antibiotic resistance genes to ß-lactams, chloramphenicol, 
trimethoprim, quinolone, streptomycin and tetracycline. Our findings indicate that the health-
care environment likely contributes to the superinfection of BU wounds and calls for 
improved training in wound management and infection control techniques.  
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Introduction 
Microbial contamination and colonization of wounds is common to all wounds healing by 
secondary intention and has been proposed as a precondition to the formation of granulation 
tissue and stimulation of wound healing [1]. Wound microflora is usually polymicrobial [2] 
comprising organisms such as staphylococci, enterococci, streptococci, facultative Gram-
negative bacteria and anaerobic bacteria [3]. When wound colonization is not managed 
properly and host defences fail to control the multiplication of microorganisms, localized 
wound infection occurs, which can progress to severe and deep-seated infections. Infection of 
a wound may lead to delayed healing, an increase in treatment costs and increased trauma to 
the affected patients [3] . 
Wounds can be infected through three main sources; the surrounding skin, endogenous 
sources such as the nasal mucosa, gastrointestinal tract and genitourinary tract and the wider 
environment. Within a health care facility, the sources of contamination and subsequent 
infection of a wound may include health care workers (HCW), patients and the inanimate 
environment. Direct contact of a patient with an infected HCW during general care or medical 
treatment can result in the transmission of microorganisms. Indirectly, an infected patient  or 
HCW could touch and contaminate an object, instrument or surface and subsequent contact 
between the item and a second patient is likely to contaminate the patient leading to infection.  
Staphylococcus aureus is a notorious opportunistic nosocomial pathogen, and one of the main 
organisms involved in infection of chronic wounds [4]. It may be carried asymptomatically by 
a carrier and transferred from patient to patient. It is estimated that about 25% of the normal 
population may be carriers, with higher carriage rates around 50% in insulin dependent 
diabetics, intravenous drug users and dialysis patients [5].  
In a previous study, we identified infection of Buruli ulcer (BU) wounds by bacterial 
pathogens as a possible cause of wound healing delay among study participants [6]. Several 
bacterial species were isolated with S. aureus and Pseudomonas aeruginosa dominating. 
Despite the finding that majority of the organisms identified were nosocomial pathogens, the 
possible routes of infection of the lesions were not examined in this study. In seeking to have 
a better understanding of the possible routes of infection of the lesions, we initiated the 
current study to characterize S. aureus isolated from different sources in two health facilities 
in Ghana treating BU. 
  
 
 
107 
 
Materials and Methods 
Study sites, participants and sample collection 
The study was carried out at the two main BU treatment centers in the Ga West and Ga South 
districts of the Greater Accra Region of Ghana, designated facility A and B respectively. The 
study involved the analysis of S. aureus isolates from wounds of microbiologically confirmed 
BU (BU) and non-BU (NBU) patients (initially suspected BU cases that were not confirmed 
by any of the three confirmation methods (Ziehl-Neelson microscopy, IS2404 PCR and 
culture) who received treatment either as in-patients on admission or out-patients at one of the 
two health centers from October 2010 to February 2014. Lesions of patients were swabbed 
and the samples analyzed at the Bacteriology Department of the Noguchi Memorial Institute 
for Medical Research. A total of 173 samples were collected from 162 patients and S. aureus 
was isolated from 88 samples originating from 76 patients, 61 of whom were BU and 15 NBU 
patients. Of the 61 BU patients, 56 were outpatients and five were inpatients at the time of 
sampling, while all the NBU patients were outpatients. The five inpatients had been on 
admission for four weeks or more and therefore isolates from these patients could be 
classified as potentially hospital acquired. To elucidate the sources of infection, between 
August 2013 and February 2014 hands of health care workers, dressing rooms and wards of 
the health centers, surfaces of dressing tables, door handles, instruments and equipment as 
well as dressing solutions and materials were sampled for microbiological analysis. Swab 
samples were also taken from the palms of nurses and their gloved hands in between dressing 
of patients and the lesions of the patients they dressed before and after dressing. Swab 
samples were transported in phosphate buffered saline at 4
0
C to the Noguchi Memorial 
Institute for Medical Research.  Eighty-six samples were collected and analyzed and S. aureus 
was isolated from 13 of them (see web only appendix, Figure A1). 
 
Microbiological methods  
The samples were processed and inoculated on Blood and Mannitol salt agars and incubated 
for 18-24 hours at 37
0
C after which they were examined. Identification of Staphylococcus 
species was by colony and microscopic morphology, catalase reaction and the coagulase 
biochemical test (BD). The Staphylase Kit, BD BBL
TM
 Staphyloslide Latex Test (Becton, 
Dickinson and Company) was used to differentiate the catalase positive Gram positive 
bacteria, S. aureus from other Staphylococcus species.  
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Antibiogram of isolated bacteria 
Antibiotic susceptibility testing was determined by the Kirby-Bauer disc diffusion method 
according to CLSI guidelines [7]. Susceptibility was determined for the antibiotics; amikacin 
(30μg), sulphamethoxazole-trimethoprim (23.75µg/1.25μg), ampicillin (10μg), tetracycline 
(30μg), gentamicin (10μg), erythromycin (15μg), cefuroxime (30μg), ceftriaxone (30μg), 
chloramphenicol (30μg), cefoxitin (30μg), rifampicin (5μg), streptomycin (10μg), 
vancomycin (30μg), clindamycin (2μg) and cefotaxime (30μg). Cartridges of antibiotics were 
obtained from Oxoid and Beckton Dickinson. S. aureus ATCC 25923 was used as reference 
strain.  
 
Genotyping 
Traditional Molecular typing 
Crude DNA extracts were prepared by boiling and used as template in the PCR reaction. 
Genetic relatedness of the isolates was determined through amplification of the polymorphic 
X region of the protein A (spa) gene using the primer pairs spa-1113F and spa-1514R (see 
web only appendix, Table A1) [8] and DNA from S. aureus ATCC
®
 25923 as positive 
control.  A total of 95 isolates out of the 101 were typed using these primers. A number of 
suspected S. aureus strains could not be typed by these primers and were further typed using 
another set of primers spaT3-F and spa-1517R (see web only appendix, Table A1). These 
primers were previously described to detect S. aureus strains which may have rearrangements 
in the IgG-binding region of the gene where the forward primer is located, making them 
untypeable by the original spa primers [9]. Sequencing of the spa gene from positive isolates 
was outsourced to Macrogen (Netherlands, Europe) and sequences analyzed and assigned to 
spa types using DNAGear [10]. The relationship between strains was investigated using the 
Staden package [11]  and a maximum likelihood phylogenetic tree produced in Mega 5.05 
(www.megasoft.net) and visualised in FigTree v1.4.2. 
(http://tree.bio.ed.ac.uk/software/figtree/). 
 Genes for mecA and PVL were sought using the primers mecA P4, mecA P7 and pvl-F, pvl-R 
(see web only appendix, Table A1) [12-13] . A mecA and PVL positive isolate S. aureus 282-
101 from the Statens Serum Institute (SSI, Denmark) kindly provided by Dr Beverly Egyir, 
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was used as positive control. Agr types were determined using the primers pan agr F, agr 1-R, 
agr 2-R, agr 3-R and agr 4-R (see web only appendix, Table A1) [14]. PCR reactions 
contained 12.5 µl HotStarTaq Mastermix (Qiagen), 5 µl nuclease free water, 2 µl of each 
primer and 3.5 µl of DNA.  Results of mecA, agr and PVL typing were analyzed using 
Microsoft Excel.  
 
Whole genome sequencing and analysis 
 From the 101 isolates, a subset of 70 isolates were selected for WGS made up of 31 MRSA 
isolates and 39 other MSSA isolates spanning the clusters observed from the phylogenetic tree 
obtained from sequencing of the spa gene. Genomic DNA was extracted with the Qiagen 
DNeasy Blood and tissue kit (Qiagen) according to the manufacturer’s instruction and 
sequenced using the Illumina MiSeq platform (2x 250bp sequencing by synthesis chemistry 
using DNA libraries prepared using Nextera XT (Illumina, San Diego, California, USA). 
Resulting sequence reads were processed using a custom bioinformatics analysis pipeline 
Nullarbor (nullarbor.pl 0.6, https://github.com/tseemann/nullabor) to de novo assemble and 
also align read data against the Sa_aus0325 reference genome (S. Giulieri et al., unpublished). 
Nullarbor uses a BLAST-based method to screen contigs from de novo assemblies for the 
presence of antibiotic resistance genes. Pairwise alignments of core genome SNPs were used 
with FastTree [15] to infer maximum likelihood phylogenetic trees using the general time 
reversible model of nucleotide substitution. Resulting trees were visualized in FigTree v1.4.2. 
The topologies of rooted phylogenetic trees obtained from both spa typing and WGS using 
Staphylococcus simiae CCM7213 as an outgroup were compared by tanglegram in 
Dendroscope (v3.4.4) [16]. 
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Results 
Bacterial isolates 
One hundred and one (101) S. aureus isolates were identified from the sources sampled. 
Eighty-eight isolates were recovered from 76 patients; 72 (81.6%) were from 61 BU patients 
and 15 from NBU wounds. One isolate each was identified from 66 patients and multiple 
isolates from the other 10 patients. Five patients had two isolates from a single lesion 
collected at one time point, one patient had two isolates from two lesions, three isolates were 
identified from a patient with three lesions (patient A, one from each), two patients had two 
isolates sampled at two different time points during the course of treatment and one patient 
with three isolates sampled thrice at different time points during the course of treatment.  
S. aureus was isolated from 13 (15.1%) of the samples collected during sampling of HCWs 
and the patients they attended to as well as the environment and equipment in the health 
facilities.. The isolates were made up of five from patient lesions, six from equipment 
(forceps) and one each from the hand of a healthcare worker and a table used for dressing 
wounds. All these isolates were from Facility B. In total, 53 isolates were from Facility A 
while 48 isolates were from Facility B. 
 
Population structure of S. aureus and epidemiological association 
Spa typing identified 29 different spa types including 15 (14.9%) singles.  The three dominant 
spa types (t355, t186 and t346) were found in seven (6.93%) isolates each (see web only 
appendix, Table A2). Thirty-five isolates could not be assigned a spa type. Phylogenetic 
analysis identified ten different clusters, where a cluster was defined as a group of two or 
more isolates found on the same branch of the tree (Clusters A-H, Figure 1), which consisted 
of health center specific clusters, and common clusters. Clusters A, C, D, H and J were made 
up of strains from both health centers (Figure 1), clusters B, G, and I made up of mainly 
strains from Facility A while clusters E and F were made up mainly of strains from Facility B 
(Figure 1). Within cluster F were isolates cultured from samples taken on the same day from 
the hand of a health care worker and patients dressed consecutively by this worker, isolates 
from samples taken on a different day from one equipment (forceps) after it had been used on 
four patients consecutively and two isolates recovered from a patient at two different time 
points (weeks 2 and 8) during treatment (Figure 1). This finding led us to conclude that 
 
 
111 
 
transmission events were ongoing within this health center. Cluster G was made up mainly of 
MRSA isolates (Figure 1) while cluster I was made up of isolates from three different lesions 
of one patient which had the same spa type (t2500) (Figure 1), suggesting that the three 
lesions were infected from a common source, possibly from the patients’ microbiota.   
 
Detection of mecA and PVL genes and Agr type  
PCR screening for the mecA gene identified 31 isolates as MRSA. The genotypes of 24 of 
these isolates correlated with their antibiogram results; however mecA was also detected in 
seven isolates showing susceptible phenotypes. Twenty-one of these were from BU patients 
while eight were from NBU patients and two from the environment.  Four of the MRSA were 
isolated from in-patients.  The PVL gene was detected in 66 isolates; 51 from BU patients, 12 
from NBU patients and three from the environment. Both mecA and PVL genes were detected 
in 20 isolates made up of 14 from BU patients, five from NBU patients and one from the 
environment. Nineteen (18.8%) isolates belonged to agr type 1, 23 (22.8% ) isolates to agr 
type 2, 30 (29.7%) isolates to agr type 3, three (2.9%) isolates to agr type 4, and four  (3.9%) 
isolates showed bands for both agr types 2 and 3, while 22 (21.8%) isolates were non typable 
and possibly agr defective mutants. 
Antibiogram of isolates 
Over 70% of the isolates were susceptible to amikacin (89, 88%) and gentamicin (89, 88%). 
Resistance rates above 50% were recorded against the antibiotics ampicillin (89, 88%), 
tetracycline (57, 56.4%) and chloramphenicol (67, 66%). Lower resistance rates of 25%, 26% 
and 37% were also recorded against the cephalosporins; ceftriaxone, cefotaxime and 
cefuroxime, respectively while 26% of the isolates showed reduced susceptibility to 
vancomycin (Table 1). Comparing the antibiograms of MRSA and MSSA isolates, a 
significant proportion of MRSA isolates were resistant to the antibiotics cefotaxime, 
tetracycline, ceftriaxone and cefoxitin (p < 0.05) (Table 2). Resistance to chloramphenicol and 
ampicillin was equally high among MRSA and MSSA.   
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Whole Genome Sequencing Analysis  
During the course of this project we had the opportunity to investigate some of the isolates 
further by WGS. From an initial 70 isolates subjected to WGS, 21 were of low read-coverage 
and excluded from analysis. We first inferred multilocus sequence typing data (MLST) from 
the WGS data. The 49 isolates belonged to 12 different sequence types (ST) with ST15 (13 
isolates) and ST88 (11 isolates) dominating. The remainder belonged to ST 1(1 isolate), ST 5 
(6 isolates), ST 6 (1 isolate), ST 72 (2 isolates), ST 121 (2 isolates), ST 152 (3 isolates), 
ST395 (1 isolate), ST 707 (1 isolate), ST 2434 (1 isolate) and ST 3248 (3 isolates)( see web 
only appendix, supplementary data B1). Four isolates represented new STs. The 11 ST88 
isolates were all MRSA and will be described elsewhere (Kpeli et al, manuscript in 
preparation).  
Read-mapping of the 49 genomes against the Sa_aus0325 reference sequence produced a 
2.2Mbp core genome with 100,361 single nucleotide polymorphisms (SNPs). A maximum 
likelihood phylogeny was inferred from pairwise comparisons of these SNPs (Figure 2). 
Among the 13 ST15 isolates, 10 were isolated from one health center, including from the 
hand of a health care worker, patients and equipment, corresponding with results from spa 
typing and giving support to the conclusion that transmission events were ongoing within this 
health center. The three isolates from patient A were of the same ST type (ST 3248) and 
between them had SNP differences of 29 bp, 51 bp and 34 bp (see web only appendix, 
supplementary data B2) also corresponding with the spa typing results discussed above. This 
small number of SNPs differences points to the isolates spreading from a common source.  
We then inferred the resistome of each isolate from the WGS data (see methods). Antibiotic 
resistance genes coding for resistance to ß-lactams (blaZ), chloramphenicol (cat and 
catpC221), trimethoprim (dfrG), methicillin (mecA), quinolone (norA), streptomycin (str) and 
tetracycline (tetK, tetL and tetM), were identified in 48 (98%), one (2%), 22 (45%), 13 
(25.5%), 13 (25.5%), 49 (100%), 12 (24.5%), eight (16.3%), 12 (24.5%) and 12 (24.5%) of 
the 49 isolates, respectively (see web only appendix, supplementary data B1). We further 
investigated the rpoB gene of rifampicin resistant strains and identified two known amino acid 
substitutions H481N and I527M implicated in rifampicin resistance in seven and one isolate 
respectively(see web only appendix, supplementary data B1). Other mutations were also 
found within the rifampin resistance-determining (Rif) region of the rifampicin resistant 
isolates but further studies will need to be done to ascertain if these mutations contribute to 
rifampicin resistance.  
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Analysis of the topologies of the phylogenies produced by spa typing and WGS shows lots of 
agreement but also some differences (Figure 3). Clustering of MRSA, isolates from patient A, 
and isolates from facility B from a HCW, patients dressed by this worker and an equipment 
were both predicted by the two methods. However, though spa typing predicted the clustering 
of isolate SA_NOG-W15 which is an MRSA with other MRSA isolates, this cluster was not 
confirmed by WGS which predicted it to cluster with isolate SA_NOG-W28 an MSSA.  
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Discussion 
 
This study confirmed healthcare associated infection (HAI) as a source of wound infection 
within our study health centers. Our analysis shows that spa typing is useful for predicting 
transmission patterns in resource limited settings but that there is also a need for access to 
low-cost microbial genomics in developing countries. Genome analysis rapidly revealed 
widespread antibiotic resistance among the isolates and clearly identified likely transmission 
clusters. 
In previous work [6], we found that wound infection may be a source of healing delay. The 
findings from our current study implicate the health care environment (including health care 
personnel) as possible sources of S.aureus infection. From our cluster analysis using spa 
typing, we inferred three modes of wound infection; two health facility related sources 
through a HCW and the inanimate environment (Figure 1), and the third source through self 
infection (Figure 1). This result corresponds with that of previous studies which have 
implicated HCW, patients and the inanimate environment in the transmission and subsequent 
acquisition of S. aureus in health care settings [17]. HAIs are known to negatively impact 
health care delivery around the world. Effective infection prevention and control (IPC) 
practices especially compliance with hand hygiene recommendations will lead to significant 
reduction in the rate of HAIs. Ghana has a policy document to aid the training of HCW in IPC 
(www.tbghana.gov.gh). However, a monitoring survey in selected health facilities within the 
Greater Accra region showed that the compliance level of HCW to these guidelines is low 
(Ghana Health Service 2011, Infection Prevention and Control. A survey in Greater Accra. 
unpublished) with rates below the 70% recommended by the World Health Organization 
(apps.searo.who.int>PDS_DOCS). Adherence to strict policies supported by periodic training 
and monitoring of HCWs are required to ensure compliance with existing IPC guidelines and 
to decrease the frequency of HAIs.  
With regard to the patient-specific clusters, Yeboah-Manu and colleagues [6] reported that 
some patients recycle bandages used in wound dressing due to inadequate financial support 
during their treatment period, and this could result in the transfer of pathogens from one 
lesion to another. Additionally, wound management in Ghana is influenced to a high degree 
by local traditional beliefs and practices. Beliefs revolving around the category of people 
deemed qualified to manage wounds affect the behaviour of patients. A recent study from our 
team (Koka et al manuscript in preparation) reports that in many communities, pregnant 
women and nursing mothers are seen as unqualified to manage wounds and in cases where 
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HCWs fall into this category, patients resort to the redressing of their wounds after the HCW 
has dressed them. This could also lead to the transfer of pathogenic organisms into the lesions 
as patients do not observe proper aseptic procedures during wound redressing. Thus, there is a 
need to counsel patients to adhere to the biomedical wound care and management practices to 
reduce or avoid self infection of their lesions. 
This study was limited by not performing a thorough investigation of other body sites of the 
patients where S. aureus is known to exist as a normal flora. An exhaustive investigation 
should have included culture of samples from other areas of the patients such as the skin, hand 
and anterior nares of the nasal cavity to compare between strains from these sites and the 
wounds. The study may also have been affected by the Hawthorne effect at Facility A and this 
could account for no S. aureus isolates from sampling the environment and HCWs at this 
facility.  
Two methods were employed to arrive at our conclusion of HAIs; the single gene locus DNA 
sequence-based marker spa typing and WGS. As revealed from our analysis, phylogenies 
from both methods predicted similar clusters. While WGS reveals variability across the whole 
genome and is able to discriminate down to single nucleotide differences, spa typing looks at 
genetic variability at a single locus between 200-600 bp in length. Spa typing is less 
expensive and demanding in terms of infrastructure and expertise and has a shorter turnaround 
time compared to WGS. Our results show that the level of discrimination of spa typing is 
adequate to guide infection control and also supports its use in epidemiological studies. 
However, the lack of congruence between the two methods is likely indicating that spa typing 
lacks resolution to be able to differentiate between highly genetically related isolates. This 
partial sequencing technique also cannot reveal the finer genetic details that accumulate 
during the evolution of bacterial populations. Therefore, although spa typing is useful for the 
prediction of transmission events in resource limited settings, where access to the newer, more 
expensive and more advanced WGS technologies is limited, we should be looking for ways to 
implement low cost microbial genomics in these countries because the rich data obtained from 
pathogen genomes can be used to make well-informed decisions to control the spread of 
disease. 
Another important finding from this study is the high genetic diversity and PVL-positivity 
among the isolates. This agrees with existing knowledge on the genetic diversity and PVL 
prevalence among African S. aureus isolates [18-20]. It also supports the assertion that Africa 
is a PVL endemic continent with high prevalence of PVL being a distinguishing trait of 
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African S. aureus isolates [19] compared with Asia, Europe and the USA [21]. Additionally, 
we identified t355 as one of the most prevalent spa types. This correlates with studies in 
Ghana and other African countries which identified this spa type as one of the most 
widespread, hence suggesting it to be widely established and distributed in Africa [18, 22-23].   
Clinical S. aureus isolates are known to be agr positive [24] and this is also evidenced from 
our results with 79 (78.2%) isolates having this locus. However 22 (21.8%) isolates were 
defective for agr function. Previous research suggests that agr defective mutants can interact 
with agr positive variants during clinical infection [24]. These agr defective mutants play an 
important role in persistent infection by forming thicker biofilms as compared to agr positive 
isolates [25]. This phenomenon might be playing a role in delayed wound healing, which we 
observed among patients within our study health centers [6]. 
Antibiotic resistance rates from both phenotypic and resistome investigations confirms the 
increasing prevalence of drug resistance in Ghana [26]. Thirty-one isolates (30.7%) were 
confirmed as MRSA. This data is consistent with the recognized fact that Africa has an 
intermediate prevalence of MRSA, usually between 25-50% [27]. Out of the thirty-one 
isolates, seven showed susceptible phenotypes though the mecA gene was detected in 
molecular analysis. Phenotypically susceptible mecA positive clones have been reported by 
various research groups [28-29]. The MRSA phenotype is regulated by two genes mecI-
mecR1. The induction of MRSA expression by this system is however very slow and may 
render some isolates with the mecA gene phenotypically susceptible.   The existence of such 
strains represents a hidden reservoir for transmission of the methicillin resistance gene in any 
environment. In many resource limited settings, clinicians mostly rely on the results of culture 
and drug susceptibility testing to guide treatment of patients and most laboratories are also not 
equipped for molecular testing of organisms. As these clones can only be detected through 
molecular analysis, they will be reported as susceptible organisms which will lead to 
treatment failure.  
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Conclusion 
Our findings indicate that health-care associated transmission contributes to wound infection 
and calls for periodic training in IPC practices to prevent the occurrence of epidemics of 
nosocomial MRSA.  
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Figure1: Spa phylogeny showing clusters and relationships between isolates:  
Maximum likelihood phylogeny of spa gene. The tree was rooted in the midpoint. Numbers in 
nodes indicate support values in the form of proportions of bootstrap pseudoreplicates. 
Branches with support values higher than 55% are collapsed. A-J = the clusters identified.  
The green colored strains are from Health center A, and the blue ones Health center B. The 
yellow coloured circles represent MRSA and the violet circles show isolates from a HCW, 
patients and equipment in health center B. 
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Figure2:  Whole genome phylogeny of sequenced isolates 
Maximum likelihood phlogeny of WGS isolates. The tree was rooted in the midpoint. 
Numbers in nodes indicate support values in the form of proportions of bootstrap 
pseudoreplicates. Branches with support values higher than 55% are collapsed.  Green colored 
strains are from Health center A and the blue ones Health center B. The red coloured circles 
represent isolates from patient A, yellow coloured circles represent MRSA and the violet 
circles show isolates from a HCW, patients and equipment in health center B. 
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Figure 3: Tanglegram of spa and whole genome phylogenies 
Tanglegram of spa (a) and whole genome sequencing (b) phylogenies produced in 
dendroscope. Topologies show some agreement between phylogenies but an overall lack of 
congruence.  
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Tables 
Table 1: Antibiogram of isolates 
 
Antibiotics 
Antibiogram 
Sensitive n(%) Intermediate n(%) Resistant n(%) 
Amikacin 89 (88)  7 (7)  5 (5) 
Cefotaxime 56 (55) 19 (19) 26 (26) 
Gentamicin 89 (88) 4 (4) 8 (8) 
Tetracycline 39 (38.6) 5 (5) 57 (56.4) 
Chloramphenicol 26 (26) 8 (8) 67 (66) 
Ceftriaxone 60 (59) 16 (16) 25 (25) 
Cotrimoxazole 65 (64.3) 4 (4) 32 (31.6) 
Cefuroxime 64 (63) 0 37 (37) 
Ampicillin 8 (8) 4 (4) 89 (88) 
Clindamycin 52 (51.4) 18 (18) 31 (30.6) 
Cefoxitin 66 (65) 5 (5) 30 (30) 
Erythromycin 41 (41) 37 (36) 23 (23) 
Rifampicin 46 (45.5) 9 (9) 46 (45.5) 
Streptomycin 66 (65.3) 9 (9) 26 (25.7) 
Vancomycin 75 (74)  26 (26) 
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Table 2: Comparison of antibiotic resistance between MRSA and MSSA 
 
Antibiotics  Resistance rates p-value 
MRSA, N=31 n(%) MSSA, N=70 n(%) 
Amikacin 3 (9.6) 2 (2.8 ) 0.167 
Cefotaxime 17 (54.8 ) 9 (12.9 ) 0.000 
Gentamicin 3 (9.6 ) 5 (7.1 ) 0.698 
Tetracycline 24 (77.4 ) 33 (47.1 ) 0.005 
Chloramphenicol 24 ( 77.4) 43 (61.4 ) 0.170 
Ceftriaxone 17 (54.8 ) 8 (11.4 ) 0.000 
Cotrimoxazole 10 (32.3 ) 22 (31.4 ) 1.000 
Cefuroxime 9 (29.0 ) 28 (40.0 ) 0.372 
Ampicillin 29 (93.5) 60 (85.7 ) 0.335 
Clindamycin 6 (19.4 ) 25 (35.7 ) 0.110 
Cefoxitin 19 (61.3 ) 11 (15.7 ) 0.000 
Erythromycin 8 (25.8 ) 15 (21.4 ) 0.617 
Rifampicin 11 (35.5 ) 35 (50.0 ) 0.200 
Streptomycin 5 (16.1 ) 21 (30.0 ) 0.217 
Vancomycin 11 (35.5 ) 15 (21.4 ) 0.147 
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Figure A1: Flowchart of study design 
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Table A1: Primer sequences 
 
Primer Name Primer Sequence  5′--3′ 
spa-1113F TAAAGACGATCCTTCGGTGAGC 
spa-1514R  CAGCAGTAGTGCCGTTTGCTT 
spaT3-F  CAACGCAATGGTTTCATCCA 
spa-1517R  GCTTTTGCAATGTCATTTACTG 
mecA P4  TCCAGATTACAACTTCACCAGG 
mecA P7 CCACTTCATATCTTGTAACG 
pvl-F  GCTGGACAAAACTTCTTGGAATAT 
pvl-R GATAGGACACCAATAAATTCTGGATTG 
pan agr F  ATGCACATGGTGCACATGC 
agr 1-R  GTCACAAGTACTATAAGCTGCGAT 
agr 2-R  GTATTACTAATTGAAAAGTGCCATAGC 
agr 3-R  CTGTTGAAAAAGTCAACTAAAAGCTC 
agr 4-R  CGATAATGCCGTAATACCCG 
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Table A2: Spa types of isolated Staphylococcus aureus strains 
 
Spa type Frequency 
t161 1 
t 210 1 
t 460 1 
t 002 1 
t 008 1 
t 085 1 
t 1123 1 
t 127 2 
t 1458 1 
t 186 7 
t 208 1 
t 2235 1 
t 2304 3 
t 2422 2 
t 2500 3 
t 2649 1 
t 311 5 
t 314 2 
t 335 2 
t 346 7 
t 355 7 
t 448 2 
t 537 1 
t 591 1 
t 769 3 
t 786 3 
t 803 1 
t 939 3 
t 948 1 
unknown  35 
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Supplementary Data B1 
 
Antibiotic resistance genes identified 
Isolate ID ST blaZ cat cat(pC221) dfrG mecA norA str tet(K) tet(L) tet(M) rpoB mutation 
Sa_NOG-W01 88 √ . . . √ √ . . √ √ . 
Sa_NOG-W02 88 √ . √ . √ √ . . √ √ H481N 
Sa_NOG-W04 88 √ . . . √ √ . . √ √ . 
Sa_NOG-W05 - √ . √ √ √ √ . . √ √ H481N 
Sa_NOG-W06 88 √ . . . √ √ . . √ √ . 
Sa_NOG-W07 88 √ . √ . √ √ . . √ √ H481N 
Sa_NOG-W10 88 √ . . . √ √ . . √ √ . 
Sa_NOG-W11 88 √ . . √ √ √ . . √ √ H481N 
Sa_NOG-W13 88 √ . √ √ √ √ . . √ √ . 
Sa_NOG-W14 88 √ . √ . √ √ . . √ √ H481N 
Sa_NOG-W15 72 √ . √ . √ √ . √ . . . 
Sa_NOG-W17 1 √ . . √ . √ . . . . . 
Sa_NOG-W23 15 √ . √ . . √ √ . . . . 
Sa_NOG-W24 88 √ . . . √ √ . . √ √ . 
Sa_NOG-W25 88 √ . √ √ √ √ . . √ √ . 
Sa_NOG-W28 72 √ . . . . √ . . . . . 
Sa_NOG-W32 6 √ . . . . √ . . . . . 
Sa_NOG-W33 5 √ . . . . √ . . . . . 
Sa_NOG-W34 121 √ . . √ . √ . . . . . 
Sa_NOG-W35 5 √ . . . . √ . . . . H481N 
Sa_NOG-W36 5 √ . . . . √ . . . . H481N 
Sa_NOG-W37 - √ . . √ . √ . . . . . 
Sa_NOG-W41 2434 √ √ . √ . √ . . . . . 
Sa_NOG-W43 - √ . . √ . √ . . . . . 
Sa_NOG-W45 152 √ . . . . √ . . . . I527T 
Sa_NOG-W47 152 . . . . . √ . . . . . 
Sa_NOG-W48 152 √ . √ . . √ . . . . . 
Sa_NOG-W49 15 √ . √ √ . √ . √ . . . 
Sa_NOG-W50 15 √ . √ . . √ √ . . . . 
Sa_NOG-W51 15 √ . √ . . √ √ . . . . 
Sa_NOG-W52 15 √ . √ . . √ √ . . . . 
Sa_NOG-W53 - √ . √ . . √ √ . . . . 
Sa_NOG-W54 15 √ . √ . . √ √ . . . . 
Sa_NOG-W55 15 √ . √ . . √ √ . . . . 
Sa_NOG-W56 15 √ . √ . . √ √ . . . . 
Sa_NOG-W58 15 √ . √ . . √ √ . . . . 
Sa_NOG-W60 15 √ . √ . . √ √ . . . . 
Sa_NOG-W61 15 √ . √ . . √ √ . . . . 
Sa_NOG-W63 15 √ . . √ . √ . √ . . . 
Sa_NOG-W64 5 √ . . √ . √ . . . . . 
Sa_NOG-W66 3248 √ . . . . √ . √ . . . 
Sa_NOG-W67 3248 √ . . . . √ . √ . . . 
Sa_NOG-W68 3248 √ . . . . √ . √ . . . 
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Sa_NOG-W69 707 √ . . . . √ . . . . . 
Sa_NOG-W70 395 √ . √ . . √ . √ . . . 
Sa_NOG-W71 5 √ . . . . √ . . . . . 
Sa_NOG-W72 5 √ . . . . √ . . . . . 
Sa_NOG-W73 121 √ . . √ . √ . √ . . . 
Sa_NOG-W74 15 √ . √ . . √ √ . . . . 
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Supplementary Data B2 
ID Reference 
Sa_NO
G-W01 
Sa_NO
G-W02 
Sa_NO
G-W04 
Sa_NO
G-W05 
Sa_NOG-
W06 
Sa_NOG-
W07 
Sa_NOG-
W10 
Sa_NOG-
W11 
Sa_NOG-
W13 
Sa_NOG-
W14 
Sa_NOG-
W15 
Sa_NOG-
W17 
Sa_NOG-
W23 
Sa_NOG-
W24 
Sa_NO
G-W25 
Sa_NOG
-W28 
Reference 0 382 395 395 379 382 374 382 375 380 361 13166 13358 13740 378 386 13149 
Sa_NOG-W01 382 0 111 107 95 94 90 0 91 96 77 13153 13343 13726 90 102 13135 
Sa_NOG-W02 395 111 0 124 108 111 103 111 90 95 90 13168 13357 13739 107 101 13150 
Sa_NOG-W04 395 107 124 0 108 49 103 107 104 109 90 13165 13360 13737 49 115 13148 
Sa_NOG-W05 379 95 108 108 0 95 87 95 88 93 74 13152 13344 13725 91 99 13134 
Sa_NOG-W06 382 94 111 49 95 0 90 94 91 96 77 13153 13347 13724 24 102 13135 
Sa_NOG-W07 374 90 103 103 87 90 0 90 83 88 49 13145 13338 13720 86 94 13127 
Sa_NOG-W10 382 0 111 107 95 94 90 0 91 96 77 13153 13343 13726 90 102 13135 
Sa_NOG-W11 375 91 90 104 88 91 83 91 0 47 70 13146 13339 13719 87 53 13128 
Sa_NOG-W13 380 96 95 109 93 96 88 96 47 0 75 13151 13344 13722 92 58 13133 
Sa_NOG-W14 361 77 90 90 74 77 49 77 70 75 0 13134 13326 13707 73 81 13116 
Sa_NOG-W15 13166 13153 13168 13165 13152 13153 13145 13153 13146 13151 13134 0 12505 12858 13149 13157 165 
Sa_NOG-W17 13358 13343 13357 13360 13344 13347 13338 13343 13339 13344 13326 12505 0 12114 13343 13350 12516 
Sa_NOG-W23 13740 13726 13739 13737 13725 13724 13720 13726 13719 13722 13707 12858 12114 0 13722 13730 12849 
Sa_NOG-W24 378 90 107 49 91 24 86 90 87 92 73 13149 13343 13722 0 98 13131 
Sa_NOG-W25 386 102 101 115 99 102 94 102 53 58 81 13157 13350 13730 98 0 13139 
Sa_NOG-W28 13149 13135 13150 13148 13134 13135 13127 13135 13128 13133 13116 165 12516 12849 13131 13139 0 
Sa_NOG-W32 13438 13418 13431 13432 13416 13419 13411 13418 13410 13415 13398 12350 12647 12971 13415 13419 12334 
Sa_NOG-W33 13914 13902 13918 13919 13904 13907 13899 13902 13899 13904 13886 13674 14207 13769 13903 13910 13684 
Sa_NOG-W34 29191 29177 29196 29195 29179 29183 29174 29177 29172 29180 29162 28926 28858 29369 29179 29186 28921 
Sa_NOG-W35 13936 13924 13940 13941 13926 13929 13921 13924 13921 13926 13908 13703 14223 13782 13925 13932 13707 
Sa_NOG-W36 13942 13930 13946 13947 13932 13935 13927 13930 13927 13932 13914 13709 14231 13792 13931 13938 13709 
Sa_NOG-W37 13723 13709 13722 13724 13708 13711 13703 13709 13702 13707 13690 12866 12107 237 13707 13713 12855 
Sa_NOG-W41 13741 13727 13740 13742 13726 13729 13721 13727 13720 13725 13708 12881 12121 267 13725 13731 12874 
Sa_NOG-W43 13997 13982 13996 13998 13982 13985 13975 13982 13976 13981 13963 12870 13300 13550 13981 13987 12850 
Sa_NOG-W45 42551 42533 42551 42550 42536 42538 42532 42533 42531 42538 42518 42455 42465 42667 42534 42541 42435 
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Sa_NOG-W47 42577 42559 42577 42576 42562 42564 42558 42559 42557 42564 42544 42506 42490 42696 42560 42567 42486 
Sa_NOG-W48 42565 42549 42567 42566 42552 42554 42548 42549 42547 42554 42534 42476 42501 42688 42550 42557 42456 
Sa_NOG-W49 13754 13740 13753 13755 13739 13742 13734 13740 13733 13738 13721 12872 12124 232 13738 13744 12863 
Sa_NOG-W50 13755 13741 13754 13752 13740 13739 13735 13741 13734 13737 13722 12873 12125 39 13737 13745 12858 
Sa_NOG-W51 13755 13741 13754 13752 13740 13739 13735 13741 13734 13737 13722 12863 12129 43 13737 13745 12858 
Sa_NOG-W52 13736 13722 13735 13733 13721 13720 13716 13722 13715 13718 13703 12876 12134 70 13718 13726 12865 
Sa_NOG-W53 13744 13730 13743 13741 13729 13728 13724 13730 13723 13726 13711 12865 12112 50 13726 13734 12854 
Sa_NOG-W54 13754 13740 13753 13751 13739 13738 13734 13740 13733 13736 13721 12867 12116 52 13736 13744 12856 
Sa_NOG-W55 13769 13755 13768 13766 13754 13753 13749 13755 13748 13751 13736 12873 12123 43 13751 13759 12862 
Sa_NOG-W56 13756 13742 13755 13753 13741 13740 13736 13742 13735 13738 13723 12870 12118 40 13738 13746 12861 
Sa_NOG-W58 13752 13738 13751 13749 13737 13736 13732 13738 13731 13734 13719 12864 12116 32 13734 13742 12857 
Sa_NOG-W60 13750 13736 13749 13747 13735 13734 13730 13736 13729 13732 13717 12863 12120 44 13732 13740 12856 
Sa_NOG-W61 13749 13735 13748 13746 13734 13733 13729 13735 13728 13731 13716 12864 12115 41 13731 13739 12857 
Sa_NOG-W63 13751 13737 13750 13752 13736 13739 13731 13737 13730 13735 13718 12874 12124 235 13735 13741 12867 
Sa_NOG-W64 13936 13924 13940 13941 13926 13929 13921 13924 13921 13926 13908 13688 14215 13781 13925 13932 13694 
Sa_NOG-W66 13365 13354 13368 13371 13355 13358 13349 13354 13350 13355 13337 12527 340 12156 13354 13361 12537 
Sa_NOG-W67 13370 13355 13369 13372 13356 13359 13350 13355 13351 13356 13338 12528 335 12151 13355 13362 12535 
Sa_NOG-W68 13354 13339 13353 13356 13340 13343 13334 13339 13335 13340 13322 12530 339 12135 13339 13346 12521 
Sa_NOG-W69 29775 29756 29773 29769 29754 29758 29752 29756 29752 29758 29740 29632 29554 30079 29756 29764 29627 
Sa_NOG-W70 43058 43039 43056 43057 43037 43044 43036 43039 43034 43040 43024 42713 42751 43174 43040 43045 42731 
Sa_NOG-W71 13945 13933 13949 13950 13935 13938 13930 13933 13930 13935 13917 13702 14229 13788 13934 13941 13706 
Sa_NOG-W72 13911 13897 13913 13914 13899 13902 13894 13897 13894 13899 13881 13668 14196 13749 13898 13905 13675 
Sa_NOG-W73 29101 29087 29106 29105 29089 29093 29084 29087 29082 29090 29072 28868 28790 29315 29089 29096 28857 
Sa_NOG-W74 13742 13728 13741 13739 13727 13726 13722 13728 13721 13724 13709 12868 12122 54 13724 13732 12859 
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Supplementary Data B2 cont’ 
ID 
Sa_NOG-
W32 
Sa_NOG-
W33 
Sa_NOG-
W34 
Sa_NOG-
W35 
Sa_NOG-
W36 
Sa_NOG-
W37 
Sa_NOG-
W41 
Sa_NOG-
W43 
Sa_NOG-
W45 
Sa_NOG-
W47 
Sa_NOG-
W48 
Sa_NOG-
W49 
Sa_NOG-
W50 
Sa_NOG-
W51 
Sa_NOG-
W52 
Sa_NOG-
W53 
Sa_NOG-
W54 
Reference 13438 13914 29191 13936 13942 13723 13741 13997 42551 42577 42565 13754 13755 13755 13736 13744 13754 
Sa_NOG-W01 13418 13902 29177 13924 13930 13709 13727 13982 42533 42559 42549 13740 13741 13741 13722 13730 13740 
Sa_NOG-W02 13431 13918 29196 13940 13946 13722 13740 13996 42551 42577 42567 13753 13754 13754 13735 13743 13753 
Sa_NOG-W04 13432 13919 29195 13941 13947 13724 13742 13998 42550 42576 42566 13755 13752 13752 13733 13741 13751 
Sa_NOG-W05 13416 13904 29179 13926 13932 13708 13726 13982 42536 42562 42552 13739 13740 13740 13721 13729 13739 
Sa_NOG-W06 13419 13907 29183 13929 13935 13711 13729 13985 42538 42564 42554 13742 13739 13739 13720 13728 13738 
Sa_NOG-W07 13411 13899 29174 13921 13927 13703 13721 13975 42532 42558 42548 13734 13735 13735 13716 13724 13734 
Sa_NOG-W10 13418 13902 29177 13924 13930 13709 13727 13982 42533 42559 42549 13740 13741 13741 13722 13730 13740 
Sa_NOG-W11 13410 13899 29172 13921 13927 13702 13720 13976 42531 42557 42547 13733 13734 13734 13715 13723 13733 
Sa_NOG-W13 13415 13904 29180 13926 13932 13707 13725 13981 42538 42564 42554 13738 13737 13737 13718 13726 13736 
Sa_NOG-W14 13398 13886 29162 13908 13914 13690 13708 13963 42518 42544 42534 13721 13722 13722 13703 13711 13721 
Sa_NOG-W15 12350 13674 28926 13703 13709 12866 12881 12870 42455 42506 42476 12872 12873 12863 12876 12865 12867 
Sa_NOG-W17 12647 14207 28858 14223 14231 12107 12121 13300 42465 42490 42501 12124 12125 12129 12134 12112 12116 
Sa_NOG-W23 12971 13769 29369 13782 13792 237 267 13550 42667 42696 42688 232 39 43 70 50 52 
Sa_NOG-W24 13415 13903 29179 13925 13931 13707 13725 13981 42534 42560 42550 13738 13737 13737 13718 13726 13736 
Sa_NOG-W25 13419 13910 29186 13932 13938 13713 13731 13987 42541 42567 42557 13744 13745 13745 13726 13734 13744 
Sa_NOG-W28 12334 13684 28921 13707 13709 12855 12874 12850 42435 42486 42456 12863 12858 12858 12865 12854 12856 
Sa_NOG-W32 0 13689 28949 13707 13713 12962 12995 13076 42403 42436 42443 12977 12983 12983 13002 12974 12978 
Sa_NOG-W33 13689 0 29222 422 434 13761 13783 14343 42442 42462 42467 13766 13772 13766 13777 13757 13771 
Sa_NOG-W34 28949 29222 0 29253 29248 29369 29393 29165 38693 38710 38718 29368 29386 29382 29384 29375 29381 
Sa_NOG-W35 13707 422 29253 0 42 13775 13796 14380 42478 42494 42501 13776 13785 13781 13790 13770 13786 
Sa_NOG-W36 13713 434 29248 42 0 13787 13806 14376 42475 42491 42498 13786 13797 13791 13800 13780 13796 
Sa_NOG-W37 12962 13761 29369 13775 13787 0 269 13555 42663 42692 42684 93 228 232 247 225 227 
Sa_NOG-W41 12995 13783 29393 13796 13806 269 0 13575 42693 42722 42714 258 266 264 293 259 255 
Sa_NOG-W43 13076 14343 29165 14380 14376 13555 13575 0 42616 42655 42657 13566 13567 13571 13561 13552 13565 
Sa_NOG-W45 42403 42442 38693 42478 42475 42663 42693 42616 0 276 304 42676 42683 42677 42687 42672 42675 
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Sa_NOG-W47 42436 42462 38710 42494 42491 42692 42722 42655 276 0 214 42707 42714 42708 42708 42701 42706 
Sa_NOG-W48 42443 42467 38718 42501 42498 42684 42714 42657 304 214 0 42697 42704 42698 42708 42693 42696 
Sa_NOG-W49 12977 13766 29368 13776 13786 93 258 13566 42676 42707 42697 0 221 221 246 222 220 
Sa_NOG-W50 12983 13772 29386 13785 13797 228 266 13567 42683 42714 42704 221 0 26 53 35 35 
Sa_NOG-W51 12983 13766 29382 13781 13791 232 264 13571 42677 42708 42698 221 26 0 53 37 39 
Sa_NOG-W52 13002 13777 29384 13790 13800 247 293 13561 42687 42708 42708 246 53 53 0 58 62 
Sa_NOG-W53 12974 13757 29375 13770 13780 225 259 13552 42672 42701 42693 222 35 37 58 0 28 
Sa_NOG-W54 12978 13771 29381 13786 13796 227 255 13565 42675 42706 42696 220 35 39 62 28 0 
Sa_NOG-W55 12985 13780 29388 13793 13803 228 264 13567 42683 42712 42704 223 24 28 51 31 27 
Sa_NOG-W56 12984 13775 29377 13788 13798 221 257 13558 42676 42705 42697 220 29 25 46 30 36 
Sa_NOG-W58 12980 13765 29383 13778 13788 227 259 13560 42672 42701 42693 216 25 25 56 32 34 
Sa_NOG-W60 12980 13763 29373 13778 13788 221 257 13556 42666 42697 42687 214 35 35 56 30 30 
Sa_NOG-W61 12977 13764 29370 13777 13787 216 244 13553 42669 42698 42690 207 30 28 53 21 25 
Sa_NOG-W63 12979 13766 29373 13780 13790 100 259 13567 42669 42700 42690 87 222 218 251 223 221 
Sa_NOG-W64 13705 283 29237 440 446 13773 13795 14359 42446 42468 42471 13784 13782 13780 13793 13771 13785 
Sa_NOG-W66 12669 14230 28865 14247 14249 12145 12156 13328 42481 42510 42517 12161 12163 12167 12181 12148 12152 
Sa_NOG-W67 12657 14231 28861 14248 14242 12140 12149 13321 42478 42507 42516 12156 12160 12164 12176 12143 12149 
Sa_NOG-W68 12646 14241 28863 14258 14258 12128 12133 13305 42458 42487 42494 12140 12148 12148 12164 12131 12135 
Sa_NOG-W69 29728 30002 14952 30031 30025 30082 30108 29867 39511 39522 39533 30089 30096 30090 30096 30085 30085 
Sa_NOG-W70 42845 42715 39358 42732 42733 43169 43197 42560 51743 51763 51772 43177 43185 43185 43188 43176 43174 
Sa_NOG-W71 13715 434 29255 193 195 13779 13805 14364 42474 42492 42497 13790 13789 13787 13800 13778 13792 
Sa_NOG-W72 13684 37 29220 439 453 13741 13763 14330 42436 42456 42461 13754 13750 13750 13761 13739 13753 
Sa_NOG-W73 28876 29162 254 29192 29188 29313 29336 29086 38653 38672 38696 29312 29332 29326 29328 29319 29325 
Sa_NOG-W74 12982 13773 29377 13788 13798 241 279 13564 42674 42705 42693 226 43 39 64 50 50 
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Supplementary Data B2 cont’ 
ID 
Sa_NOG-
W55 
Sa_NOG-
W56 
Sa_NOG-
W58 
Sa_NOG-
W60 
Sa_NOG-
W61 
Sa_NOG-
W63 
Sa_NOG-
W64 
Sa_NOG-
W66 
Sa_NOG-
W67 
Sa_NOG-
W68 
Sa_NOG-
W69 
Sa_NOG-
W70 
Sa_NOG-
W71 
Sa_NOG-
W72 
Sa_NOG-
W73 
Sa_NOG-
W74 
Reference 13769 13756 13752 13750 13749 13751 13936 13365 13370 13354 29775 43058 13945 13911 29101 13742 
Sa_NOG-W01 13755 13742 13738 13736 13735 13737 13924 13354 13355 13339 29756 43039 13933 13897 29087 13728 
Sa_NOG-W02 13768 13755 13751 13749 13748 13750 13940 13368 13369 13353 29773 43056 13949 13913 29106 13741 
Sa_NOG-W04 13766 13753 13749 13747 13746 13752 13941 13371 13372 13356 29769 43057 13950 13914 29105 13739 
Sa_NOG-W05 13754 13741 13737 13735 13734 13736 13926 13355 13356 13340 29754 43037 13935 13899 29089 13727 
Sa_NOG-W06 13753 13740 13736 13734 13733 13739 13929 13358 13359 13343 29758 43044 13938 13902 29093 13726 
Sa_NOG-W07 13749 13736 13732 13730 13729 13731 13921 13349 13350 13334 29752 43036 13930 13894 29084 13722 
Sa_NOG-W10 13755 13742 13738 13736 13735 13737 13924 13354 13355 13339 29756 43039 13933 13897 29087 13728 
Sa_NOG-W11 13748 13735 13731 13729 13728 13730 13921 13350 13351 13335 29752 43034 13930 13894 29082 13721 
Sa_NOG-W13 13751 13738 13734 13732 13731 13735 13926 13355 13356 13340 29758 43040 13935 13899 29090 13724 
Sa_NOG-W14 13736 13723 13719 13717 13716 13718 13908 13337 13338 13322 29740 43024 13917 13881 29072 13709 
Sa_NOG-W15 12873 12870 12864 12863 12864 12874 13688 12527 12528 12530 29632 42713 13702 13668 28868 12868 
Sa_NOG-W17 12123 12118 12116 12120 12115 12124 14215 340 335 339 29554 42751 14229 14196 28790 12122 
Sa_NOG-W23 43 40 32 44 41 235 13781 12156 12151 12135 30079 43174 13788 13749 29315 54 
Sa_NOG-W24 13751 13738 13734 13732 13731 13735 13925 13354 13355 13339 29756 43040 13934 13898 29089 13724 
Sa_NOG-W25 13759 13746 13742 13740 13739 13741 13932 13361 13362 13346 29764 43045 13941 13905 29096 13732 
Sa_NOG-W28 12862 12861 12857 12856 12857 12867 13694 12537 12535 12521 29627 42731 13706 13675 28857 12859 
Sa_NOG-W32 12985 12984 12980 12980 12977 12979 13705 12669 12657 12646 29728 42845 13715 13684 28876 12982 
Sa_NOG-W33 13780 13775 13765 13763 13764 13766 283 14230 14231 14241 30002 42715 434 37 29162 13773 
Sa_NOG-W34 29388 29377 29383 29373 29370 29373 29237 28865 28861 28863 14952 39358 29255 29220 254 29377 
Sa_NOG-W35 13793 13788 13778 13778 13777 13780 440 14247 14248 14258 30031 42732 193 439 29192 13788 
Sa_NOG-W36 13803 13798 13788 13788 13787 13790 446 14249 14242 14258 30025 42733 195 453 29188 13798 
Sa_NOG-W37 228 221 227 221 216 100 13773 12145 12140 12128 30082 43169 13779 13741 29313 241 
Sa_NOG-W41 264 257 259 257 244 259 13795 12156 12149 12133 30108 43197 13805 13763 29336 279 
Sa_NOG-W43 13567 13558 13560 13556 13553 13567 14359 13328 13321 13305 29867 42560 14364 14330 29086 13564 
Sa_NOG-W45 42683 42676 42672 42666 42669 42669 42446 42481 42478 42458 39511 51743 42474 42436 38653 42674 
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Sa_NOG-W47 42712 42705 42701 42697 42698 42700 42468 42510 42507 42487 39522 51763 42492 42456 38672 42705 
Sa_NOG-W48 42704 42697 42693 42687 42690 42690 42471 42517 42516 42494 39533 51772 42497 42461 38696 42693 
Sa_NOG-W49 223 220 216 214 207 87 13784 12161 12156 12140 30089 43177 13790 13754 29312 226 
Sa_NOG-W50 24 29 25 35 30 222 13782 12163 12160 12148 30096 43185 13789 13750 29332 43 
Sa_NOG-W51 28 25 25 35 28 218 13780 12167 12164 12148 30090 43185 13787 13750 29326 39 
Sa_NOG-W52 51 46 56 56 53 251 13793 12181 12176 12164 30096 43188 13800 13761 29328 64 
Sa_NOG-W53 31 30 32 30 21 223 13771 12148 12143 12131 30085 43176 13778 13739 29319 50 
Sa_NOG-W54 27 36 34 30 25 221 13785 12152 12149 12135 30085 43174 13792 13753 29325 50 
Sa_NOG-W55 0 23 29 33 24 222 13792 12165 12160 12146 30096 43189 13799 13760 29332 41 
Sa_NOG-W56 23 0 26 34 19 219 13789 12160 12153 12141 30087 43182 13796 13757 29321 32 
Sa_NOG-W58 29 26 0 28 25 217 13779 12156 12151 12135 30091 43188 13786 13749 29327 36 
Sa_NOG-W60 33 34 28 0 17 211 13775 12159 12154 12138 30081 43173 13782 13743 29317 42 
Sa_NOG-W61 24 19 25 17 0 208 13776 12153 12146 12130 30078 43173 13783 13744 29314 39 
Sa_NOG-W63 222 219 217 211 208 0 13784 12159 12156 12140 30089 43180 13790 13754 29317 225 
Sa_NOG-W64 13792 13789 13779 13775 13776 13784 0 14234 14233 14249 30012 42716 430 292 29175 13789 
Sa_NOG-W66 12165 12160 12156 12159 12153 12159 14234 0 29 51 29563 42762 14248 14221 28798 12162 
Sa_NOG-W67 12160 12153 12151 12154 12146 12156 14233 29 0 34 29560 42763 14247 14220 28796 12157 
Sa_NOG-W68 12146 12141 12135 12138 12130 12140 14249 51 34 0 29559 42765 14263 14230 28788 12141 
Sa_NOG-W69 30096 30087 30091 30081 30078 30089 30012 29563 29560 29559 0 39809 30027 29990 14974 30087 
Sa_NOG-W70 43189 43182 43188 43173 43173 43180 42716 42762 42763 42765 39809 0 42744 42698 39346 43170 
Sa_NOG-W71 13799 13796 13786 13782 13783 13790 430 14248 14247 14263 30027 42744 0 437 29190 13796 
Sa_NOG-W72 13760 13757 13749 13743 13744 13754 292 14221 14220 14230 29990 42698 437 0 29154 13759 
Sa_NOG-W73 29332 29321 29327 29317 29314 29317 29175 28798 28796 28788 14974 39346 29190 29154 0 29313 
Sa_NOG-W74 41 32 36 42 39 225 13789 12162 12157 12141 30087 43170 13796 13759 29313 0 
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Abstract 
Background. The emergence and evolution of community-acquired methicillin resistant 
Staphylococcus aureus (CA-MRSA) strains in Africa is poorly understood. However, one 
particular MRSA lineage called ST88, appears to be rapidly establishing itself as an 
``African´´ CA-MRSA clone. In this study, we employed whole genome sequencing to 
provide more information on the genetic background of ST88 CA-MRSA isolates from 
Ghana and to describe in detail ST88 CA-MRSA isolates in comparison with other MRSA 
lineages worldwide.  
Methods. We first established a complete ST88 reference genome (AUS0325) using PacBio 
SMRT sequencing. We then used comparative genomics to assess relatedness among 17 
ST88 CA-MRSA isolates recovered from patients attending Buruli ulcer treatment centers in 
Ghana, three non-African ST88s and 15 other MRSA lineages.  
Results. We show that Ghanaian ST88 forms a discrete MRSA lineage (harbouring SCCmec-
IV [2B]). Gene content analysis identified five distinct genomic regions enriched among 
ST88 isolates compared with the other S. aureus lineages. The Ghanaian ST88 isolates had 
only 658 core genome SNPs and there was no correlation between phylogeny and geography, 
suggesting the recent spread of this clone. The lineage was also resistant to multiple classes 
of antibiotics including ß-lactams, tetracycline and chloramphenicol.  
Discussion. This study reveals that S. aureus ST88-IV is a recently emerging and rapidly 
spreading CA-MRSA clone in Ghana. The study highlights the capacity of small snapshot 
genomic studies to provide actionable public health information in resource limited settings. 
To our knowledge this is the first genomic assessment of the ST88 CA-MRSA clone.  
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Introduction 
Since the 1990s, community acquired methicillin-resistant Staphylococcus aureus (CA-
MRSA) infections have been increasing worldwide [1-2]. CA-MRSA clones are known to be 
more virulent than hospital-acquired MRSA, with infections linked to significant mortality 
and morbidity [3-8]. First reported in Australia and the United States, CA-MRSA occurrence 
has been increasing, with epidemics due to clones such as ST8 USA300 in the United States 
[9], ST93 and ST1 in Australia [10], ST80 in Europe [11], ST59 in China and Taiwan [12], 
ST772 in India [13-16] and ST72 in South Korea [17]. Other identified CA-MRSA clones 
belong to ST30 (South West Pacific clone) [18], ST45 (Berlin clone) [19], ST1 (USA400) 
[16] and ST78 (Western Australian MRSA-2) [18]. In Africa, the distribution of MRSA 
clones in general is not well understood [20]. A recent review on MRSA in Africa with data 
from 15 of the 54 countries identified community clones of ST8-IV [2B] (USA300) and 
ST88-IV [2B] “West Australia MRSA-2 clone” in both community and health care associated 
infections in seven countries and a “Brazilian/Hungarian clone” ST239-III [3A] in hospital 
acquired infections in nine countries [20]. The European ST80-IV [2B] clone was limited to 
Algeria, Egypt and Tunisia while clonal types ST22-IV [2B], ST36-II [2A], and ST612-IV 
[2B] have only been reported so far in South Africa [20]. Among the two CA-MRSA clones, 
the ST8IV [2B]  clone is an internationally disseminated clone recognized in every continent 
except Antarctica [21]. The ST88-IV [2B]  CA-MRSA clone however is predominant in Sub-
Saharan Africa (West, Central and East Africa) with reported rates of 24.2-83.3% of all 
MRSA isolates [22]. Studies from Angola [23], Cameroon [24], Gabon [25-26], Ghana [27-
29], Madagascar [24], Niger [24], Nigeria [30-32] and Senegal [24] have identified it as a 
major circulating clone within both hospital and community settings. It was also detected in 
children from West Africa who underwent surgery in Switzerland but had been hospitalized 
in their home countries prior to surgical treatment [33]. Globally, this clone has been 
identified in China [34] and Japan [35] in lower proportion (5.3-12.5%) than in Africa and  
sporadically in Belgium [36], Portugal [37] and Sweden [38].  
Control of MRSA infections is assisted by a thorough knowledge of the epidemiology and 
dissemination of specific clones. To this end we employed whole genome sequencing and 
comparative genomics to describe in detail ST88 CA-MRSA isolates in comparison to other 
MRSA lineages worldwide.  
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Materials & Methods 
Bacterial isolates and antibiogram analysis  
The 17 ST88 S. aureus isolates analyzed from Ghana are listed in Table 1 and comprised five 
strains isolated in the Akwapim South District (Eastern Region) of Ghana with previously 
published genome data (GenBank accession numbers LFNJ00000000, LFNI00000000, 
LFNH00000000, LFMH00000000, LFMG00000000) [29] and 12 isolates recovered from 
wounds of 11 patients attending Buruli ulcer (BU) treatment centers in the Ga-South and Ga-
West municipalities (Greater Accra Region) of Ghana with two isolates from one patient; one 
a PVL positive isolate and the other PVL negative. Patients were outpatients, nine of whom 
had laboratory confirmed BU. Initial isolate identification was made using colony and 
microscopic morphology, catalase and coagulase biochemical reactions and a Staphylase kit 
BD BBL
TM
 Staphyloslide Latex Test (Becton, Dickinson and Company) for further 
confirmation. Antibiograms were determined using the Kirby Bauer disc diffusion method 
according to CLSI guidelines [39] and PCR targeting the mecA gene [40] for identification of 
MRSA. Ethical clearance was obtained from the institutional review board of the Noguchi 
Memorial Institute for Medical Research (NMIMR) (Federal-wide Assurance number 
FWA00001824). All study participants were well informed of the study objectives and 
written informed consent was obtained either from the patient or from the guardian of the 
patient. 
 
DNA Extraction, Whole Genome Sequencing and Analysis 
Genomic DNA was extracted from isolates using the Qiagen DNeasy kit and protocol 
(Qiagen, Hilden, Germany). DNA libraries were prepared using Nextera XT (Illumina, San 
Diego, California, USA) and whole genome sequencing was performed using the Illumina 
MiSeq with 2 x 300 bp chemistry. Small Molecular Real Time sequencing was performed on 
the RS-II (Pacific Biosciences) using P6-C4 chemistry, and reference genome assembly was 
performed as described [41]. 
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Read mapping, variant calling and phylogenomic analysis 
The sequence reads were processed using Nullarbor (nullarbor.pl 0.6, 
https://github.com/tseemann/nullarbor), a recently developed bioinformatics pipeline for 
public health microbial genomics as described previously [42]. S. aureus ST88 raw sequence 
reads with accession numbers  ERS1354589-600 have been deposited in the European 
Nucleotide Archive (ENA), Project  PRJEB15428 (url - 
http://www.ebi.ac.uk/ena/data/view/PRJEB15428.   Ortholog clustering was performed using 
Roary [43] and was visualized with Fripan (http://drpowell.github.io/FriPan/). Recombination 
within the core genome was inferred using ClonalFrameML v1.7 [44] with the whole genome 
alignment generated by Nullarbor. Using FastTree v2.1.8 [45], a ML tree was generated and 
used as a guide tree for ClonalFrameML. Positions in the reference genome that were not 
present in at least one genome (non-core) were omitted from the analysis using the 
“ignore_incomplete_sites true” option and providing ClonalFrameML with a list of all non-
core positions. Maximum likelihood trees were constructed using a recombination free SNP 
alignment using FastTree. Bootstrap support was derived from comparisons between the 
original tree against 1000 trees that were built upon pseudo-alignments (sampled from the 
original alignment with replacement). 
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Results and Discussion 
ST88 complete reference genome 
A prerequisite for high-resolution comparative genomics by read-mapping is a high-quality, 
complete reference genome, closely related to the bacterial population under investigation 
[42]. There were no fully-assembled ST88 S. aureus genomes publicly available, so to 
address this issue, we selected the methicillin-susceptible, penicillin-resistant ST88 S. aureus 
isolate AUS0325. This clinical isolate was obtained in 2013 from a patient in Melbourne, 
Australia who had a persistent infection of a prosthetic joint, and was part of a separate, 
unpublished study. The  AUS0325 genome comprised a 2,771,577 bp circular chromosome 
with 32.9% GC content. There were no plasmids; the beta-lactamase operon (bla) was carried 
by the Tn552 transposon and integrated into the chromosome. The overall chromosome 
architecture of AUS0325 was  like representative S. aureus genomes from other community-
associated lineages (ST1, ST8 and ST93) but with five distinct regions of difference, 
discussed in more detail below (Fig. 1A). We took advantage of the PacBio data to define the 
Sa_aus0325 methylome. Motif analysis and inspection of the AUS0325 annotation identified 
two active type I restriction modification hsdMS loci. Protein alignment of the two hsdS 
alleles with previously characterised hsdS proteins allowed the attribution of target 
recognition sequences to either allele [46] (Table 2). The first hsdS recognized a motif not 
previously described, while the second hsdS contained an identical sequence to the target 
recognition domain-2 of CC30-2 and ST93-2, which recognises TCG (Table 2). 
 
ST88 population structure 
To understand the genomic diversity and evolutionary origin of the ST88 isolates, a core 
genome phylogeny was inferred by mapping reads from the 17 ST88 isolates (Table 1, Fig. 
1B), two published ST88 MRSA genomes from Lebanon and USA and 15 other 
geographically and genetically distinct S. aureus clones to AUS0325 (Table 3, Fig. 1B). To 
assess the clonal ancestry, SNPs within inferred regions of recombination (71,862 clonal 
SNPs; 26,570 recombinogenic SNPs) (Fig. S1) were removed and a maximum likelihood 
phylogenomic tree was established using the clonal core SNP alignment (71,862 SNPs). All 
20 ST88 genomes formed a discrete, closely related lineage, defined by only 1,759 core 
genome SNPs, compared with 71,862 SNPs among all 35 S. aureus genomes (Fig. 1B, Fig. 
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2A). The global tree was rooted using Bacillus_subtilis_B4068 (GenBank ID: 
JXHK00000000) [47] as an outgroup and this phylogeny indicated ST88 shares a most recent 
common ancestor (MRCA) with ST72 (Fig. 1A). 
Five distinct genomic regions were identified by ortholog comparisons, enriched among the 
ST88 genomes compared to the 15 other diverse S. aureus genomes. These regions included 
νSAα (GI-3, Fig. 1) that harboured 10 staphylococcal superantigen-like (ssl) genes, of which 
four were uniquely present in the ST88 isolates. Upregulation of SSLs has been reported in 
some CA-MRSA strains and may be involved in neutrophil and complement activation [48-
49]. GI-3 also harboured the first of the two functional type I restriction modification hsdMS 
loci (see above, Table 2). GI-1 and GI-4 may be mobile integrative elements of unknown 
function with the presence of putative integrases and four and 12 CDS respectively, all 
encoding hypothetical proteins. GI-1 also harbours elements of a putative restriction 
modification system (Fig. 1, Table S1). GI-2 contains 13 CDS,  most of unknown function 
although three CDS may encode membrane proteins (Fig. 1, Table S1). GI-5 had 14 CDS, 
that included the second of the type I restriction modification hsdMS loci and seven CDS 
encoding putative proteases (Table 2, Table S1). 
 
Evolution and molecular epidemiology of ST88 in Ghana 
To assess the evolutionary relationships among the ST88 genomes, a phylogenomic tree 
comprised exclusively of ST88 genomes was established using clonal, core SNPs (1,759 
clonal SNPs; 207 recombinogenic SNPs) (Fig. S2, Fig. 2A). The tree was rooted using an 
ST93 genome (Sa_JKD6159) as an outgroup. The phylogeny and the restricted genomic 
diversity (658 core SNPs) suggests that the spread of ST88 MRSA in Ghana is a recent 
phenomenon, with isolates from the United States, Australia and Lebanon ancestral to the 
spread of these isolates in Ghana. Five specific clusters of CDS were also found to be  
exclusively present with the African ST88 genomes (Fig. 2C). These CDS were different to 
the five genomic regions identified in all ST88 relative to other S. aureus clones (Fig. 1B)  
suggesting that they were horizontally acquired by an ST88 MRCA that has since spread in 
Ghana, (although a significantly larger sampling effort would be required to confirm this 
hypothesis). These regions harbour CDS suggestive of plasmid, phage and other mobile DNA 
elements (Table S2). We conducted a phylogeographic analysis to formally assess the 
relationship between the Ghanaian ST88 phylogeny and the specific geographic origin of the 
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isolates, based on patient villages. However, there was no correlation between geography and 
phylogeny, suggesting again that the spread of ST88 in Ghana has been recent and rapid (Fig. 
3). 
 
Phenotypic and genotypic antibiotic resistance 
All 17 Ghanaian ST88 isolates harboured a SCCmec-IV [2B] cassette, and displayed 
phenotypic resistance to -lactams, tetracycline, and chloramphenicol (Table 1). Isolates 
were variably resistant to erythromycin, clindamycin, trimethoprim, amikacin and 
streptomycin (Table 1). There was agreement between phenotypic and inferred genotypic 
resistance (Fig. 1B). For the four genes (blaZ, mecA, tetL, tetM) detected in all 12 ST88 
isolates from the Greater Accra Region, resistance correlated with phenotypic resistance to all 
-lactams and tetracyclines. Six isolates showed phenotypic and genotypic resistance to 
chloramphenicol (Table 1, Fig. 1B). Five of these isolates were from the same health center, 
however the time of isolation and the geographic origins of the patients were different, 
suggesting that these isolates are spread across the region and were not acquired from a 
common source.  
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Conclusions 
The analysis presented here suggests that S. aureus ST88-IV is an emerging CA-MRSA clone 
in Ghana. This has the potential to become a serious public health threat, with implications 
for the treatment of S. aureus infections in Ghana, where there is no developed surveillance 
infrastructure to monitor antibiotic resistance. The abuse and misuse of antibiotics by health 
care givers and patients in Ghana is extensive [50]. The development of resistance is 
furthermore encouraged by the widespread availability of higher classes of antibiotics to 
lower level health centers from regional medical stores, in addition to the unrestricted sale of 
these medicines to over-the-counter medicine sellers by pharmaceutical wholesalers- even 
though existing laws are supposed to limit the scope of these facilities to handle such 
medicines. Also implicated and widely documented are the prescribing practices of 
clinicians; with over-reliance on presumptive treatment and haphazardly prescribing 
antibiotics without recourse to due laboratory investigation. CA-MRSA has undergone rapid 
evolution and expansion worldwide. Because of its epidemic potential and limited treatment 
options, vigilance and antibiotic stewardship programmes need to be put in place to prevent 
further spread.  
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Data Summary 
 
1. Strain data protocol has been deposited in Figshare; DOI: 
10.6084/m9.figshare.3863475  (url - https://figshare.com/articles/Table_S1/3863475) 
2. S. aureus ST88 raw sequence reads have been deposited in ENA, Project  
PRJEB15428 (url - http://www.ebi.ac.uk/ena/data/view/ PRJEB15428 )  
3. AUS0325 Chromosome Assembly has been deposited in ENA, LT615218 (url -  
http://www.ebi.ac.uk/ena/data/view/LT615218) 
4. AUS0325 PacBio raw sequence reads have been deposited in ENA, ERS1354601 (url 
-http://www.ebi.ac.uk/ena/data/view/ERS1354601) 
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Figures 
 
 
Figure. 1: Comparative genomic analysis of S. aureus ST88. (a) DNA-DNA comparisons 
visualized using the Artemis Comparison Tool of three CA-MRSA representative chromosomes and 
S. aureus COL against the complete chromosome of ST88 isolate AUS0325. (b) Core genome 
phylogeny and accessory genome elements identified among ST88 isolates. The phylogeny was based 
on an alignment of 71,862 non-recombinogenic core genome SNPs (indels excluded) and inferred 
using FastTree. Nodes with greater than 70% bootstrap support (1000 replicates) are labelled with red 
dots. Antibiotic resistance genes were identified using Abricate 
(https://github.com/tseemann/abricate) and genomic islands (GIs) enriched among ST88 isolates were 
identified by ortholog comparisons using Roary and visualized using FriPan. CDS present in specific 
GI are listed in Table S1. 
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Figure. 2: High resolution ST88 phylogeny and accessory genome analysis. (a). Phylogeny 
inferred by read-mapping and variant identification among only ST88 genomes. Tree was produced 
using FastTree based on a pairwise alignment of 1,759 non-recombinogenic core genome SNPs 
among the 20 ST88 genomes. All major nodes in the tree (red circles) had greater than 70% bootstrap 
support (1000 replicates). (b) Accessory gene content variation among the 20 ST88 genomes as 
assessed by ortholog comparisons using Roary. (c) Distinct genomic islands (GI) identified in 
Ghanaian isolates. 
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Figure 3: Relationship between phylogeny of Ghanaian ST88 and their geographic origin. (a) 
Phylogeographic alignment of phylogeny against isolate origin geography performed with GenGIS 
software and (b) Monte-Carlo analysis following 1000 permutations of tree tips and geography of 
originating villages. The arrangement derived from the data was not significantly different to that 
which is expected by chance alone (p value >0.05), indicating a lack of geographical structure among 
the ST88 genomes. 
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Tables 
Table 1: S. aureus ST88 isolates tested in this study 
Isolate ID 
Origin 
(Ghana) 
Phenotypic 
resistance* 
Genotype 
(spa, agr, PVL) 
Reference 
Sa_NOG-W02 Greater Accra 
Region 
cld, tet, amp, ery, fox, 
ctx, chl, cro 
t939, agr-3, PVL + This study 
Sa_NOG-W25 Greater Accra 
Region 
gen, amk, cld,  str, amp, 
tet, sxt, cfx, ctx, chl, cro 
t448, agr-3, PVL - This study 
Sa_NOG-W11 Greater Accra 
Region 
str, amk, gen, sxt, cfx, 
cld, fox, ctx, tet, chl, 
cro, amp, ery 
t186, agr-3, PVL + This study 
Sa_NOG-W13 Greater Accra 
Region 
gen, str,  amk, ctx, tet, 
chl, cro, sxt, cfx, amp, 
cld, fox 
07-12-12-118-13-13, 
agr-3, PVL + 
This study 
Sa_NOG-W01 Greater Accra 
Region 
amk, cfx, tet, ctx, chl, 
cro, fox 
t186, agr-3, PVL +  This study 
Sa_NOG-W10 Greater Accra 
Region 
sxt, ery, gen, str, amk, 
cld, amp, cfx, tet, fox, 
ctx, chl, cro 
t186, agr-3, PVL - This study 
Sa_NOG-W07 Greater Accra 
Region 
gen, str, amp, tet, sxt, 
cfx, chl, cro, ctx, fox,  
cld, ery,  
t448, agr-3, PVL - This study 
Sa_NOG-W14 Greater Accra 
Region 
gen, ery, sxt, amk, cld, 
str, tet, amp, cfx, ctx, 
chl, cro, fox,  
t2649, agr-3, PVL + This study 
Sa_NOG-W04 Greater Accra 
Region 
sxt, ery, gen, str, amk, 
amp, cfx, tet, fox, ctx, 
chl, cro 
07-12-21-17-13-13-
34-34-33-34-34, agr-3, 
PVL - 
This study 
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Sa_NOG-W06 Greater Accra 
Region 
sxt, gen, amk, cld, amp, 
tet, cfx, fox, chl, cro 
t786, agr-3, PVL - This study 
Sa_NOG-W24 Greater Accra 
Region 
gen, sxt , amk, str, amp,  
tet, cfx, ctx, chl, cro, 
fox,  
t786, agr-3, PVL + This study 
Sa_NOG-W05 Greater Accra 
Region 
ery, amk, str, amp, cfx, 
tet, sxt, cld,  
t186, agr-3, PVL - This study 
BU_G0701_t5 Eastern Region fox, ben, oxa, tet, chl t786, agr-3, PVL - (Amissah et al., 
2015b) 
BU_G0201_t8 Eastern Region fox, ben, oxa, tet, chl t786, agr-3, PVL - (Amissah et al., 
2015b) 
BU_G0202_t2 Eastern Region fox, ben, oxa, tet, chl t786, agr-3, PVL - (Amissah et al., 
2015b) 
BU_G1905_t3 Eastern Region fox, ben, oxa, tet, chl t786, agr-3, PVL - (Amissah et al., 
2015b) 
BU_W13_11 Eastern Region fox, ben, oxa, tet, chl t186, agr-3, PVL - (Amissah et al., 
2015b) 
Notes: *oxacillin=oxa, cefoxitin=fox, tetracycline=tet, chloramphenicol=chl, cefuroxime=cfx, 
erythromycin=ery, clindamycin=cld, sulphamethxazole-trimethoprim=sxt, amikacin=amk, streptomycin=str, 
ampicillin=amp, cefotaxime=ctx, ceftriaxone=cro, gentamicin=gen, benzylpenicillin=ben, spa=Staphylococcus 
aureus Protein A, agr=Accesory Gene regulator, PVL=Pantone Valentine Leukocidin toxin 
 
 
 
 
 
 
 
156 
 
Table 2: Sa_aus0325 methylome analysis 
HsdS 
(nucleotide position) 
TRD1 N TRD2 
397,724 -> 399,280  ACC 5 RTGT 
1,849,852 <- 1,851,408  GAG 6 TCG 
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Table 3: Comparator Reference Genomes 
Sequence 
type 
Region/Country of 
origin 
MSSA/MRSA Reference Strain Assembly/Accesssion 
number 
ST8 USA/Canada CA-MRSA Staphylococcus aureus subsp. aureus USA 300 FPR 3757 NC_007793.1 
ST 1 USA/Canada CA-MRSA Staphylococcus aureus subsp. aureus MW2 NC_003923.1 
ST 80 Europe CA-MRSA Staphylococcus aureus 11819-97 NC_017351.1 
ST45 Europe/ USA/Canada CA-MRSA Staphylococcus aureus subsp. aureus 300-169 GCA_000534855.1 
ST 30 Europe/ Australia/Asia CA-MRSA Staphylococcus aureus subsp. aureus_S2397 GCA_000577595.1 
ST 72 Asia CA-MRSA Staphylococcus aureus MRSA_CVM43477 GCA_000830555.1 
ST 59 Asia CA-MRSA Staphylococcus aureus subsp. aureus  M013 NC_016928.1 
ST93 Australia CA-MRSA Staphylococcus aureus subsp. aureus JKD 6159 NC_017338.1 
ST 250 England HA-MRSA Staphylococcus aureus subsp. aureus COL NC_002951.2 
ST254 Japan MSSA Staphylococcus aureus subsp. aureus Newman NC_009641.1 
ST1 United Kingdom MSSA Staphylococcus aureus subsp. aureus MSSA476 NC_002953.3 
ST5 Ireland MSSA Staphylococcus aureus subsp. aureus ED98 NC_013450.1 
ST5 Japan MRSA Staphylococcus aureus subsp. aureus N315 NC_002745.2 
ST 239 Australia MRSA Staphylococcus aureus subsp. aureus JKD 6008 NC_017341.1 
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ST772 India MRSA Staphylococcus aureus subsp. aureus_ST772-MRSA GC_000516935.1 
ST 88 Lebanon MRSA HST-105 GCA_000564895.1 
ST 88 United States MSSA Staphylococcus aureus subsp aureus_21343 GCA_000245595.2 
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Supplementary Materials 
 
Figure. S1: Recombination analysis among the 20 ST88 and 15 non-ST88 genomes. Light grey and 
black blocks denote recombination regions detected in ancestral nodes and the sampled genomes, 
respectively. In total there were 98,432 core SNPs, 26,570 of which were located within inferred 
regions of recombination.    
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Figure. S2: Recombination analysis among the 20 ST88 genomes. Light grey and black blocks denote 
recombination regions detected in ancestral nodes and the sampled genomes, respectively. In total 
there were 1,966 core SNPs, 207 of which were located within inferred regions of recombination. 
161 
 
Table S1: Genomic regions enriched in S. aureus MRSA ST88 
Feature Gene Annotation No. 
isolates 
No. sequences Avg sequences 
per isolate 
Genome 
Fragment 
Order 
within 
Fragment 
Accessory 
Fragment 
Accessory Order with 
Fragment 
Min 
group 
size nuc 
Max 
group 
size nuc 
Avg group 
size nuc 
ST88_GI-1 group_572 hypothetical protein 16 16 1 1 4209 1 1497 737 1730 1667 
ST88_GI-1 group_2165 putative restriction enzyme 20 20 1 1 4206 1 1494 1904 1904 1904 
ST88_GI-1 group_399 hypothetical protein 20 20 1 1 4205 1 1493 290 917 808 
ST88_GI-1 group_2873 hypothetical protein 1 1 1 1 4863 1 129 284 284 284 
ST88_GI-1 group_1298 hypothetical protein 20 20 1 1 4864 1 1492 182 182 182 
ST88_GI-1 group_403 Integrase core domain 
protein 
23 23 1 1 4865 1 1490 422 806 451 
ST88_GI-1 yjaB putative N-acetyltransferase 
YjaB 
20 20 1 1 4860 1 1488 458 458 458 
ST88_GI-2 group_2187 hypothetical protein 20 20 1 1 4534 2 17 491 491 491 
ST88_GI-2 group_1491 hypothetical protein 29 29 1 1 4535 2 30 413 683 673 
ST88_GI-2 group_1492 hypothetical protein 29 29 1 1 4531 2 32 611 611 611 
ST88_GI-2 group_939 hypothetical protein 24 24 1 1 4528 2 42 500 500 500 
ST88_GI-2 group_1493 hypothetical protein 20 20 1 1 4521 2 6 269 482 471 
ST88_GI-2 group_940 hypothetical protein 24 24 1 1 4522 2 50 491 491 491 
ST88_GI-2 group_2188 hypothetical protein 27 27 1 1 4520 2 65 683 683 683 
ST88_GI-2 group_419 hypothetical protein 24 24 1 1 4517 2 70 272 491 472 
ST88_GI-2 group_941 hypothetical membrane 
protein 
24 24 1 1 4515 2 71 302 473 330 
ST88_GI-2 group_942 hypothetical protein 25 25 1 1 4513 2 72 374 374 374 
ST88_GI-2 group_943 putative membrane protein 25 25 1 1 4512 2 73 389 389 389 
ST88_GI-2 group_597 putative membrane protein 25 25 1 1 4511 2 81 392 392 392 
ST88_GI-2 group_2189 hypothetical protein 20 20 1 1 4508 2 80 500 500 500 
ST88_GI-3 group_960 sodium/dicarboxylare 
symporter 
20 20 1 1 602 233 1 209 209 209 
ST88_GI-3 group_610 hypothetical protein 35 35 1 1 603   944 956 955 
ST88_GI-3 group_4341 hypothetical protein 35 35 1 1 604   662 662 662 
ST88_GI-3 yflT putative heat induced stress 
protein 
35 35 1 1 605   407 440 408 
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ST88_GI-3 xprT putative xanthine 
phosphoribosyltransferase 
35 35 1 1 606   578 578 578 
ST88_GI-3 pbuX NCS2 family 
nucleobase:cation 
symporter-2 
35 35 1 1 607   1211 1268 1264 
ST88_GI-3 guaB putative inosine-5'-
monophosphate 
dehydrogenase 
35 35 1 1 608   1466 1466 1466 
ST88_GI-3 guaA bifunctional GMP 
synthase/glutamine 
amidotransferase protein 
35 35 1 1 614   1541 1541 1541 
ST88_GI-3 group_2197 abortive infection 
bacteriophage resistance 
protein 
26 26 1 1 528 1 989 1106 1106 1106 
ST88_GI-3 group_2198 hypothetical protein 26 26 1 1 527 1 990 392 392 392 
ST88_GI-3 group_961 hypothetical protein 24 24 1 1 525 1 991 221 479 253 
ST88_GI-3 group_1509 hypothetical protein 22 22 1 1 514 1 992 185 584 547 
ST88_GI-3 group_612 hypothetical protein 33 33 1 1 650 1 993 152 152 152 
ST88_GI-3 group_613 hypothetical protein 33 33 1 1 656 1 978 359 359 359 
ST88_GI-3 group_614 cobalt (Co2 ) ABC 
superfamily ATP binding 
cassette transporter, 
membrane protein 
34 34 1 1 660 1 976 845 845 845 
ST88_GI-3 set6 superantigen-like protein 20 20 1 1 661 1 963 413 680 666 
ST88_GI-3 set7 superantigen-like protein 32 32 1 1 666 1 957 695 695 695 
ST88_GI-3 set8 superantigen-like protein 28 28 1 1 669 1 954 1058 1070 1068 
ST88_GI-3 group_2199 superantigen-like protein 19 19 1 1 667 1 890 992 992 992 
ST88_GI-3 set10 superantigen-like protein 5 20 20 1 1 678 1 906 704 704 704 
ST88_GI-3 group_2201 superantigen-like protein 20 20 1 1 679 1 907 698 698 698 
ST88_GI-3 set11 superantigen-like protein 7 20 20 1 1 680 1 908 695 695 695 
ST88_GI-3 set12 superantigen-like protein 31 31 1 1 692 1 949 698 698 698 
ST88_GI-3 set13 superantigen-like protein, 
exotoxin 13 
33 33 1 1 697 1 946 311 698 686 
ST88_GI-3 set14 superantigen-like protein, 
exotoxin 14 
32 32 1 1 698 1 940 683 683 683 
ST88_GI-3 hsdM_1 Type I restriction-
modification system 
methyltransferase subunit 
26 26 1 1 716 1 939 1556 1556 1556 
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ST88_GI-3 hsdS_1 restriction endonuclease S 
subunit 
20 20 1 1 701 1 923 1187 1187 1187 
ST88_GI-3 set15 superantigen-like protein 20 20 1 1 700 1 922 692 692 692 
ST88_GI-3 group_2205 hypothetical protein 20 20 1 1 699 1 921 1502 1502 1502 
ST88_GI-3 group_4807 hypothetical protein 35 35 1 1 724   308 308 308 
ST88_GI-3 lpl3 staphylococcal tandem 
lipoprotein 
20 20 1 1 725 5 10 809 809 809 
ST88_GI-3 lpl8 tandem lipoprotein 20 20 1 1 726 5 11 752 776 771 
ST88_GI-3 lpl2 staphylococcal tandem 
lipoprotein 
21 21 1 1 727 5 63 815 815 815 
ST88_GI-3 group_2207 putative membrane protein 20 20 1 1 728 5 64 1322 1322 1322 
ST88_GI-3 group_2208 hypothetical protein 20 20 1 1 729 5 65 323 323 323 
ST88_GI-3 group_2209 hypothetical protein 20 20 1 1 730 5 1 296 296 296 
ST88_GI-4 group_2126 hypothetical protein 20 20 1 1 2877 1 1144 152 152 152 
ST88_GI-4 group_2127 hypothetical protein 20 20 1 1 2876 1 1143 242 242 242 
ST88_GI-4 group_2128 Integrase core domain 
protein 
20 20 1 1 2875 1 1142 491 491 491 
ST88_GI-4 group_2129 hypothetical protein 20 20 1 1 2874 1 1141 647 647 647 
ST88_GI-4 group_2130 hypothetical protein 20 20 1 1 2873 1 1140 407 407 407 
ST88_GI-4 group_373 hypothetical protein 19 19 1 1 2872 1 1139 251 764 723 
ST88_GI-4 group_374 hypothetical protein 2 2 1 1 2871 1 1138 191 380 285 
ST88_GI-4 group_2131 hypothetical protein 20 20 1 1 388 1 1137 392 392 392 
ST88_GI-4 group_851 hypothetical protein 20 20 1 1 389 1 1136 512 512 512 
ST88_GI-4 group_2132 hypothetical protein 20 20 1 1 390 1 1135 608 608 608 
ST88_GI-4 group_2133 hypothetical protein 27 27 1 1 1200 1 1134 323 323 323 
ST88_GI-4 group_2134 hypothetical protein 20 20 1 1 387 1 1133 248 248 248 
ST88_GI-5 hsdS_2 restriction endonuclease S 
subunit 
20 20 1 1 4869 1 138 1235 1238 1235 
ST88_GI-5 hsdM_2 Type I restriction-
modification system 
methyltransferase subunit 
21 21 1 1 4868 1 188 1556 1556 1556 
ST88_GI-5 group_1075 glutamyl endopeptidase 30 30 1 1 3330 1 183 224 719 694 
ST88_GI-5 group_1723 glutamyl endopeptidase 27 27 1 1 3329 1 182 719 719 719 
ST88_GI-5 group_1722 glutamyl endopeptidase 21 21 1 1 3328 1 141 716 716 716 
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ST88_GI-5 group_1721 glutamyl endopeptidase 21 21 1 1 3326 1 143 719 719 719 
ST88_GI-5 group_1720 glutamyl endopeptidase 21 21 1 1 2633 1 144 722 722 722 
ST88_GI-5 splB glutamyl endopeptidase 30 30 1 1 3323 1 180 164 722 703 
ST88_GI-5 group_688 glutamyl endopeptidase 30 30 1 1 3322 1 179 329 716 695 
ST88_GI-5 group_2297 hypothetical protein 20 20 1 1 3317 1 175 581 581 581 
ST88_GI-5 group_1074 hypothetical protein 29 29 1 1 3315 1 177 218 698 317 
ST88_GI-5 group_2296 hypothetical protein 24 24 1 1 3314 1 176 473 473 473 
ST88_GI-5 group_1073 hypothetical protein 25 25 1 1 3293 1 165 791 791 791 
ST88_GI-5 group_2295 hypothetical protein 20 20 1 1 3292 1 161 221 221 221 
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Table S1 cont’ 
 ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 NON-ST88 
Feature COUNTER aureus_11819-
97 
aureus_300-
169 
aureus_COL aureus_ED98 aureus_JKD6009 aureus_JKD6159 aureus_M013 aureus_MSSA476 aureus_MW2 aureus_N315 aureus_S2397 
ST88_GI-1 _2560_ * * * * * * * * * * * 
ST88_GI-1 _2465_ * * * * * * * * * * * 
ST88_GI-1 _2488_ * * * * * * * * * * * 
ST88_GI-1 _4262_ * * * * * * * * * * * 
ST88_GI-1 _2443_ * * * * * * * * * * * 
ST88_GI-1 _2384_ * * * aureus_ED98_01750 * * * * * aureus_N315_01678 aureus_S2397_00184 
ST88_GI-1 _2466_ * * * * * * * * * * * 
ST88_GI-2 _2467_ * * * * * * * * * * * 
ST88_GI-2 _2205_ aureus_11819-
97_00278 
* aureus_COL_00266 aureus_ED98_00256 * * * aureus_MSSA476_00265 aureus_MW2_00268 aureus_N315_00285 * 
ST88_GI-2 _2206_ aureus_11819-
97_00279 
* aureus_COL_00267 aureus_ED98_00257 * * * aureus_MSSA476_00266 aureus_MW2_00269 aureus_N315_00286 * 
ST88_GI-2 _2360_ * * aureus_COL_00269 * * * * * * * * 
ST88_GI-2 _2447_ * * * * * * * * * * * 
ST88_GI-2 _2361_ aureus_11819-
97_00282 
* aureus_COL_00273 * * * * * * * * 
ST88_GI-2 _2265_ aureus_11819-
97_00283 
aureus_300-
169_02192 
aureus_COL_00274 * * aureus_JKD6159_00277 * * * * * 
ST88_GI-2 _2358_ * aureus_300-
169_02201 
* * aureus_JKD6009_00450 * * * * * aureus_S2397_01480 
ST88_GI-2 _2362_ * aureus_300-
169_02195 
* * aureus_JKD6009_00444 * aureus_M013_00273 * * * aureus_S2397_02248 
ST88_GI-2 _2349_ * aureus_300-
169_02196 
* * aureus_JKD6009_00445 * aureus_M013_00274 * * * aureus_S2397_02247 
ST88_GI-2 _2350_ * aureus_300-
169_02197 
* * aureus_JKD6009_00446 * aureus_M013_00275 * * * aureus_S2397_02246 
ST88_GI-2 _2342_ * aureus_300-
169_02198 
* * aureus_JKD6009_00447 * aureus_M013_00276 * * * aureus_S2397_02245 
ST88_GI-2 _2468_ * * * * * * * * * * * 
ST88_GI-3 _2491_ * * * * * * * * * * * 
ST88_GI-3 _1724_ aureus_11819-
97_00365 
aureus_300-
169_02282 
aureus_COL_00432 aureus_ED98_00343 aureus_JKD6009_01296 aureus_JKD6159_00359 aureus_M013_00359 aureus_MSSA476_00353 aureus_MW2_00356 aureus_N315_00374 aureus_S2397_01807 
ST88_GI-3 _614_ aureus_11819-
97_00366 
aureus_300-
169_02283 
aureus_COL_00433 aureus_ED98_00344 aureus_JKD6009_01297 aureus_JKD6159_00360 aureus_M013_00360 aureus_MSSA476_00354 aureus_MW2_00357 aureus_N315_00375 aureus_S2397_01808 
ST88_GI-3 _1725_ aureus_11819-
97_00367 
aureus_300-
169_02284 
aureus_COL_00434 aureus_ED98_00345 aureus_JKD6009_01298 aureus_JKD6159_00361 aureus_M013_00361 aureus_MSSA476_00355 aureus_MW2_00358 aureus_N315_00376 aureus_S2397_01809 
ST88_GI-3 _1493_ aureus_11819-
97_00368 
aureus_300-
169_02285 
aureus_COL_00435 aureus_ED98_00346 aureus_JKD6009_01299 aureus_JKD6159_00362 aureus_M013_00362 aureus_MSSA476_00356 aureus_MW2_00359 aureus_N315_00377 aureus_S2397_01810 
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ST88_GI-3 _224_ aureus_11819-
97_00369 
aureus_300-
169_02286 
aureus_COL_00436 aureus_ED98_00347 aureus_JKD6009_01300 aureus_JKD6159_00363 aureus_M013_00363 aureus_MSSA476_00357 aureus_MW2_00360 aureus_N315_00378 aureus_S2397_01811 
ST88_GI-3 _1066_ aureus_11819-
97_00370 
aureus_300-
169_02287 
aureus_COL_00437 aureus_ED98_00348 aureus_JKD6009_01301 aureus_JKD6159_00364 aureus_M013_00364 aureus_MSSA476_00358 aureus_MW2_00361 aureus_N315_00379 aureus_S2397_01812 
ST88_GI-3 _941_ aureus_11819-
97_00371 
aureus_300-
169_02288 
aureus_COL_00438 aureus_ED98_00349 aureus_JKD6009_01302 aureus_JKD6159_00365 aureus_M013_00365 aureus_MSSA476_00359 aureus_MW2_00362 aureus_N315_00380 aureus_S2397_01813 
ST88_GI-3 _2305_ aureus_11819-
97_00372 
* * * * * aureus_M013_00366 aureus_MSSA476_00360 aureus_MW2_00363 * * 
ST88_GI-3 _2306_ aureus_11819-
97_00373 
* * * * * aureus_M013_00367 aureus_MSSA476_00361 aureus_MW2_00364 * * 
ST88_GI-3 _2363_ aureus_11819-
97_00374 
* * * * * * aureus_MSSA476_00362 aureus_MW2_00365 * * 
ST88_GI-3 _2395_ * * * * * * * * * * * 
ST88_GI-3 _2072_ aureus_11819-
97_00381 
* aureus_COL_00442 aureus_ED98_00353 aureus_JKD6009_01334 aureus_JKD6159_00370 aureus_M013_00372 aureus_MSSA476_00368 aureus_MW2_00371 aureus_N315_00384 * 
ST88_GI-3 _2073_ aureus_11819-
97_00385 
aureus_300-
169_02302 
aureus_COL_00443 aureus_ED98_00354 aureus_JKD6009_01335 * aureus_M013_00376 aureus_MSSA476_00372 aureus_MW2_00375 aureus_N315_00385 aureus_S2397_02120 
ST88_GI-3 _1993_ aureus_11819-
97_00386 
aureus_300-
169_02303 
aureus_COL_00444 aureus_ED98_00355 aureus_JKD6009_01336 * aureus_M013_00377 aureus_MSSA476_00373 aureus_MW2_00376 aureus_N315_00386 aureus_S2397_02119 
ST88_GI-3 _2449_ * * * * * * * * * * * 
ST88_GI-3 _2137_ aureus_11819-
97_00388 
* aureus_COL_00446 aureus_ED98_00357 aureus_JKD6009_01338 * aureus_M013_00380 aureus_MSSA476_00375 aureus_MW2_00378 aureus_N315_00388 * 
ST88_GI-3 _2244_ aureus_11819-
97_00389 
* aureus_COL_00447 aureus_ED98_00358 * * * aureus_MSSA476_00376 aureus_MW2_00379 aureus_N315_00389 * 
ST88_GI-3 _2498_ * * * * * * * * * * * 
ST88_GI-3 _2470_ * * * * * * * * * * * 
ST88_GI-3 _2471_ * * * * * * * * * * * 
ST88_GI-3 _2472_ * * * * * * * * * * * 
ST88_GI-3 _2143_ aureus_11819-
97_00393 
* * aureus_ED98_00362 aureus_JKD6009_00989 * aureus_M013_00385 aureus_MSSA476_00381 aureus_MW2_00384 aureus_N315_00393 * 
ST88_GI-3 _2056_ aureus_11819-
97_00394 
* aureus_COL_00449 aureus_ED98_00363 aureus_JKD6009_00990 aureus_JKD6159_00385 aureus_M013_00386 aureus_MSSA476_00382 aureus_MW2_00385 aureus_N315_00394 * 
ST88_GI-3 _2138_ aureus_11819-
97_00395 
* aureus_COL_00450 aureus_ED98_00364 aureus_JKD6009_00991 * aureus_M013_00387 aureus_MSSA476_00383 aureus_MW2_00386 aureus_N315_00395 * 
ST88_GI-3 _2319_ aureus_11819-
97_00396 
aureus_300-
169_02312 
aureus_COL_00451 aureus_ED98_00365 aureus_JKD6009_00992 * aureus_M013_00388 aureus_MSSA476_00384 aureus_MW2_00387 aureus_N315_00396 * 
ST88_GI-3 _2473_ * * * * * * * * * * * 
ST88_GI-3 _2474_ * * * * * * * * * * * 
ST88_GI-3 _2475_ * * * * * * * * * * * 
ST88_GI-3 _1082_ aureus_11819-
97_00400 
aureus_300-
169_02316 
aureus_COL_00455 aureus_ED98_00369 aureus_JKD6009_00996 aureus_JKD6159_00391 aureus_M013_00392 aureus_MSSA476_00388 aureus_MW2_00391 aureus_N315_00400 aureus_S2397_00998 
ST88_GI-3 _2476_ * * * * * * * * * * * 
ST88_GI-3 _2450_ * * * * * * * * * * * 
ST88_GI-3 _2420_ * * * * * * aureus_M013_00403 * * * * 
ST88_GI-3 _2477_ * * * * * * * * * * * 
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ST88_GI-3 _2478_ * * * * * * * * * * * 
ST88_GI-3 _2479_ * * * * * * * * * * * 
ST88_GI-4 _2455_ * * * * * * * * * * * 
ST88_GI-4 _2456_ * * * * * * * * * * * 
ST88_GI-4 _2457_ * * * * * * * * * * * 
ST88_GI-4 _2458_ * * * * * * * * * * * 
ST88_GI-4 _2459_ * * * * * * * * * * * 
ST88_GI-4 _2500_ * * * * * * * * * * * 
ST88_GI-4 _3712_ * * * * * * * * * * * 
ST88_GI-4 _2460_ * * * * * * * * * * * 
ST88_GI-4 _2490_ * * * * * * * * * * * 
ST88_GI-4 _2461_ * * * * * * * * * * * 
ST88_GI-4 _2264_ aureus_11819-
97_00824 
* aureus_COL_00817 aureus_ED98_00729 aureus_JKD6009_00481 * * * * aureus_N315_00762 * 
ST88_GI-4 _2462_ * * * * * * * * * * * 
ST88_GI-5 _2486_ * * * * * * * * * * * 
ST88_GI-5 _2439_ aureus_11819-
97_01791 
* aureus_COL_01778 aureus_ED98_01754 * * * aureus_MSSA476_01723 aureus_MW2_01744 aureus_N315_01682 * 
ST88_GI-5 _2171_ aureus_11819-
97_01792 
* aureus_COL_01779 aureus_ED98_01755 * * * aureus_MSSA476_01724 aureus_MW2_01745 aureus_N315_01683 aureus_S2397_01407 
ST88_GI-5 _2260_ aureus_11819-
97_01793 
* aureus_COL_01781 aureus_ED98_01756 * * * * * aureus_N315_01684 * 
ST88_GI-5 _2426_ * * * * * * * * * * aureus_S2397_01405 
ST88_GI-5 _2425_ * * * * * aureus_JKD6159_01752 * * * * * 
ST88_GI-5 _2424_ * * * * * aureus_JKD6159_01753 * * * * * 
ST88_GI-5 _2180_ aureus_11819-
97_01796 
* aureus_COL_01783 aureus_ED98_01758 * * * aureus_MSSA476_01726 aureus_MW2_01747 aureus_N315_01686 aureus_S2397_01402 
ST88_GI-5 _2197_ aureus_11819-
97_01797 
* aureus_COL_01784 aureus_ED98_01759 * aureus_JKD6159_01754 * aureus_MSSA476_01727 aureus_MW2_01748 aureus_N315_01687 * 
ST88_GI-5 _2483_ * * * * * * * * * * * 
ST88_GI-5 _2203_ aureus_11819-
97_01799 
* aureus_COL_01786 aureus_ED98_01761 * * * aureus_MSSA476_01729 aureus_MW2_01750 aureus_N315_01689 * 
ST88_GI-5 _2357_ * * * aureus_ED98_01762 * * * * * aureus_N315_01690 * 
ST88_GI-5 _2325_ * * * aureus_ED98_01763 * aureus_JKD6159_01758 * * * aureus_N315_01691 * 
ST88_GI-5 _2482_ * * * * * * * * * * * 
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Table S1 cont’ 
 NON-ST88 NON-ST88 NON-ST88 NON-ST88 ST88 ST88 ST88 ST88 ST88 
Feature aureus_str._Newman MRSA_CVM43477 ST772-
MRSA-V 
USA300_FPR3757 aureus_21343 BU_G0201_t8 BU_G0202_t2 BU_G0701_t5 BU_G1905_t3 
ST88_GI-1 * * * * aureus_21343_02477 BU_G0201_t8_01011 BU_G0202_t2_00597 BU_G0701_t5_00943 BU_G1905_t3_00972 
ST88_GI-1 * * * * aureus_21343_02478 BU_G0201_t8_01012 BU_G0202_t2_00596 BU_G0701_t5_00942 BU_G1905_t3_00971 
ST88_GI-1 * * * * aureus_21343_02479 BU_G0201_t8_01013 BU_G0202_t2_00595 BU_G0701_t5_00941 BU_G1905_t3_00970 
ST88_GI-1 * * * * * * * * * 
ST88_GI-1 * * * * aureus_21343_02480 BU_G0201_t8_01014 BU_G0202_t2_00594 BU_G0701_t5_00940 BU_G1905_t3_00969 
ST88_GI-1 * * * * aureus_21343_02481 BU_G0201_t8_01015 BU_G0202_t2_00593 BU_G0701_t5_00939 BU_G1905_t3_00968 
ST88_GI-1 * * * * aureus_21343_02482 BU_G0201_t8_01016 BU_G0202_t2_00592 BU_G0701_t5_00938 BU_G1905_t3_00967 
ST88_GI-2 * * * * aureus_21343_00775 BU_G0201_t8_01403 BU_G0202_t2_00940 BU_G0701_t5_01548 BU_G1905_t3_01577 
ST88_GI-2 aureus_str._Newman_00237 MRSA_CVM43477_00130 * USA300_FPR3757_00292 aureus_21343_00774 BU_G0201_t8_01404 BU_G0202_t2_00941 BU_G0701_t5_01549 BU_G1905_t3_01578 
ST88_GI-2 aureus_str._Newman_00238 MRSA_CVM43477_00129 * USA300_FPR3757_00293 aureus_21343_00773 BU_G0201_t8_01405 BU_G0202_t2_00942 BU_G0701_t5_01550 BU_G1905_t3_01579 
ST88_GI-2 aureus_str._Newman_00240 MRSA_CVM43477_00128 * USA300_FPR3757_00295 aureus_21343_00772 BU_G0201_t8_01406 BU_G0202_t2_00943 BU_G0701_t5_01551 BU_G1905_t3_01580 
ST88_GI-2 * * * * aureus_21343_00771 BU_G0201_t8_01407 BU_G0202_t2_00944 BU_G0701_t5_01552 BU_G1905_t3_01581 
ST88_GI-2 aureus_str._Newman_00244 * * USA300_FPR3757_00299 aureus_21343_00770 BU_G0201_t8_01408 BU_G0202_t2_00945 BU_G0701_t5_01553 BU_G1905_t3_01582 
ST88_GI-2 aureus_str._Newman_00245 MRSA_CVM43477_02294 * USA300_FPR3757_00300 aureus_21343_00769 BU_G0201_t8_01409 BU_G0202_t2_00946 BU_G0701_t5_01554 BU_G1905_t3_01583 
ST88_GI-2 * MRSA_CVM43477_02285 * * aureus_21343_00768 BU_G0201_t8_01410 BU_G0202_t2_00947 BU_G0701_t5_01555 BU_G1905_t3_01584 
ST88_GI-2 * * * * aureus_21343_00766 BU_G0201_t8_01412 BU_G0202_t2_00949 BU_G0701_t5_01557 BU_G1905_t3_01586 
ST88_GI-2 * MRSA_CVM43477_02289 * * aureus_21343_00765 BU_G0201_t8_01413 BU_G0202_t2_00950 BU_G0701_t5_01558 BU_G1905_t3_01587 
ST88_GI-2 * MRSA_CVM43477_02288 * * aureus_21343_00764 BU_G0201_t8_01414 BU_G0202_t2_00951 BU_G0701_t5_01559 BU_G1905_t3_01588 
ST88_GI-2 * MRSA_CVM43477_02287 * * aureus_21343_00763 BU_G0201_t8_01415 BU_G0202_t2_00952 BU_G0701_t5_01560 BU_G1905_t3_01589 
ST88_GI-2 * * * * aureus_21343_00762 BU_G0201_t8_01416 BU_G0202_t2_00953 BU_G0701_t5_01561 BU_G1905_t3_01590 
ST88_GI-3 * * * * aureus_21343_02563 BU_G0201_t8_01502 BU_G0202_t2_01039 BU_G0701_t5_01647 BU_G1905_t3_01676 
ST88_GI-3 aureus_str._Newman_00401 MRSA_CVM43477_00245 ST772-MRSA-
V_00357 
USA300_FPR3757_00385 aureus_21343_02562 BU_G0201_t8_01503 BU_G0202_t2_01040 BU_G0701_t5_01648 BU_G1905_t3_01677 
ST88_GI-3 aureus_str._Newman_00402 MRSA_CVM43477_00244 ST772-MRSA-
V_00358 
USA300_FPR3757_00386 aureus_21343_02561 BU_G0201_t8_01504 BU_G0202_t2_01041 BU_G0701_t5_01649 BU_G1905_t3_01678 
ST88_GI-3 aureus_str._Newman_00403 MRSA_CVM43477_00243 ST772-MRSA-
V_00359 
USA300_FPR3757_00387 aureus_21343_02560 BU_G0201_t8_01505 BU_G0202_t2_01042 BU_G0701_t5_01650 BU_G1905_t3_01679 
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ST88_GI-3 aureus_str._Newman_00404 MRSA_CVM43477_00242 ST772-MRSA-
V_00360 
USA300_FPR3757_00388 aureus_21343_02559 BU_G0201_t8_01506 BU_G0202_t2_01043 BU_G0701_t5_01651 BU_G1905_t3_01680 
ST88_GI-3 aureus_str._Newman_00405 MRSA_CVM43477_00241 ST772-MRSA-
V_00361 
USA300_FPR3757_00389 aureus_21343_02558 BU_G0201_t8_01507 BU_G0202_t2_01044 BU_G0701_t5_01652 BU_G1905_t3_01681 
ST88_GI-3 aureus_str._Newman_00406 MRSA_CVM43477_00240 ST772-MRSA-
V_00362 
USA300_FPR3757_00390 aureus_21343_02557 BU_G0201_t8_01508 BU_G0202_t2_01045 BU_G0701_t5_01653 BU_G1905_t3_01682 
ST88_GI-3 aureus_str._Newman_00407 MRSA_CVM43477_00239 ST772-MRSA-
V_00363 
USA300_FPR3757_00391 aureus_21343_02556 BU_G0201_t8_01509 BU_G0202_t2_01046 BU_G0701_t5_01654 BU_G1905_t3_01683 
ST88_GI-3 * MRSA_CVM43477_00238 ST772-MRSA-
V_00364 
* aureus_21343_02555 BU_G0201_t8_01510 BU_G0202_t2_01047 BU_G0701_t5_01655 BU_G1905_t3_01684 
ST88_GI-3 * MRSA_CVM43477_00237 ST772-MRSA-
V_00365 
* aureus_21343_02554 BU_G0201_t8_01511 BU_G0202_t2_01048 BU_G0701_t5_01656 BU_G1905_t3_01685 
ST88_GI-3 * * ST772-MRSA-
V_00366 
* aureus_21343_02553 BU_G0201_t8_01512 BU_G0202_t2_01049 BU_G0701_t5_01657 BU_G1905_t3_01686 
ST88_GI-3 * MRSA_CVM43477_00230 ST772-MRSA-
V_00372 
* aureus_21343_02552 BU_G0201_t8_01513 BU_G0202_t2_01050 BU_G0701_t5_01658 BU_G1905_t3_01687 
ST88_GI-3 aureus_str._Newman_00411 MRSA_CVM43477_00229 ST772-MRSA-
V_00373 
USA300_FPR3757_00395 aureus_21343_02551 BU_G0201_t8_01514 BU_G0202_t2_01051 BU_G0701_t5_01659 BU_G1905_t3_01688 
ST88_GI-3 aureus_str._Newman_00412 * ST772-MRSA-
V_00374 
USA300_FPR3757_00396 aureus_21343_02550 BU_G0201_t8_01515 BU_G0202_t2_01052 BU_G0701_t5_01660 BU_G1905_t3_01689 
ST88_GI-3 aureus_str._Newman_00413 MRSA_CVM43477_01399 ST772-MRSA-
V_00375 
USA300_FPR3757_00397 aureus_21343_02549 BU_G0201_t8_01516 BU_G0202_t2_01053 BU_G0701_t5_01661 BU_G1905_t3_01690 
ST88_GI-3 * * * * aureus_21343_02548 BU_G0201_t8_01517 BU_G0202_t2_01054 BU_G0701_t5_01662 BU_G1905_t3_01691 
ST88_GI-3 aureus_str._Newman_00415 MRSA_CVM43477_01397 ST772-MRSA-
V_00377 
USA300_FPR3757_00399 aureus_21343_02547 BU_G0201_t8_01518 BU_G0202_t2_01055 BU_G0701_t5_01663 BU_G1905_t3_01692 
ST88_GI-3 aureus_str._Newman_00416 * * USA300_FPR3757_00400 aureus_21343_02546 BU_G0201_t8_01519 BU_G0202_t2_01056 BU_G0701_t5_01664 BU_G1905_t3_01693 
ST88_GI-3 * * * * aureus_21343_02545 BU_G0201_t8_01520 BU_G0202_t2_01057 BU_G0701_t5_01665 * 
ST88_GI-3 * * * * aureus_21343_02544 BU_G0201_t8_01521 BU_G0202_t2_01058 BU_G0701_t5_01666 BU_G1905_t3_01695 
ST88_GI-3 * * * * aureus_21343_02543 BU_G0201_t8_01522 BU_G0202_t2_01059 BU_G0701_t5_01667 BU_G1905_t3_01696 
ST88_GI-3 * * * * aureus_21343_02542 BU_G0201_t8_01523 BU_G0202_t2_01060 BU_G0701_t5_01668 BU_G1905_t3_01697 
ST88_GI-3 aureus_str._Newman_00421 MRSA_CVM43477_01392 ST772-MRSA-
V_00382 
USA300_FPR3757_00405 aureus_21343_02541 BU_G0201_t8_01524 BU_G0202_t2_01061 BU_G0701_t5_01669 BU_G1905_t3_01698 
ST88_GI-3 aureus_str._Newman_00422 MRSA_CVM43477_01391 ST772-MRSA-
V_00383 
USA300_FPR3757_00406 aureus_21343_02540 BU_G0201_t8_01525 BU_G0202_t2_01062 BU_G0701_t5_01670 BU_G1905_t3_01699 
ST88_GI-3 aureus_str._Newman_00423 MRSA_CVM43477_01390 ST772-MRSA-
V_00384 
USA300_FPR3757_00407 aureus_21343_02539 BU_G0201_t8_01526 BU_G0202_t2_01063 BU_G0701_t5_01671 BU_G1905_t3_01700 
ST88_GI-3 aureus_str._Newman_00424 MRSA_CVM43477_01389 ST772-MRSA-
V_00385 
USA300_FPR3757_00408 aureus_21343_02538 BU_G0201_t8_01527 BU_G0202_t2_01064 BU_G0701_t5_01672 * 
ST88_GI-3 * * * * aureus_21343_02537 BU_G0201_t8_01528 BU_G0202_t2_01065 BU_G0701_t5_01673 BU_G1905_t3_02504 
ST88_GI-3 * * * * aureus_21343_02536 BU_G0201_t8_01529 BU_G0202_t2_01066 BU_G0701_t5_01674 BU_G1905_t3_02503 
ST88_GI-3 * * * * aureus_21343_02535 BU_G0201_t8_01530 BU_G0202_t2_01067 BU_G0701_t5_01675 BU_G1905_t3_02502 
ST88_GI-3 aureus_str._Newman_00428 MRSA_CVM43477_01385 ST772-MRSA-
V_00389 
USA300_FPR3757_00412 aureus_21343_02534 BU_G0201_t8_01531 BU_G0202_t2_01068 BU_G0701_t5_01676 BU_G1905_t3_02501 
ST88_GI-3 * * * * aureus_21343_02533 BU_G0201_t8_01532 BU_G0202_t2_01069 BU_G0701_t5_01677 BU_G1905_t3_02500 
ST88_GI-3 * * * * aureus_21343_02532 BU_G0201_t8_01533 BU_G0202_t2_01070 BU_G0701_t5_01678 BU_G1905_t3_02499 
ST88_GI-3 * * * * aureus_21343_02531 BU_G0201_t8_01534 BU_G0202_t2_01071 BU_G0701_t5_01679 BU_G1905_t3_02498 
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ST88_GI-3 * * * * aureus_21343_02530 BU_G0201_t8_01535 BU_G0202_t2_01072 BU_G0701_t5_01680 BU_G1905_t3_02497 
ST88_GI-3 * * * * aureus_21343_02529 BU_G0201_t8_01536 BU_G0202_t2_01073 BU_G0701_t5_01681 BU_G1905_t3_02496 
ST88_GI-3 * * * * aureus_21343_02528 BU_G0201_t8_01537 BU_G0202_t2_01074 BU_G0701_t5_01682 BU_G1905_t3_02495 
ST88_GI-4 * * * * aureus_21343_00931 BU_G0201_t8_00649 BU_G0202_t2_00275 BU_G0701_t5_00276 BU_G1905_t3_00273 
ST88_GI-4 * * * * aureus_21343_00930 BU_G0201_t8_00650 BU_G0202_t2_00274 BU_G0701_t5_00275 BU_G1905_t3_00274 
ST88_GI-4 * * * * aureus_21343_00929 BU_G0201_t8_00651 BU_G0202_t2_00273 BU_G0701_t5_00274 BU_G1905_t3_00275 
ST88_GI-4 * * * * aureus_21343_00928 BU_G0201_t8_00652 BU_G0202_t2_00272 BU_G0701_t5_00273 BU_G1905_t3_00276 
ST88_GI-4 * * * * aureus_21343_00927 BU_G0201_t8_00653 BU_G0202_t2_00271 BU_G0701_t5_00272 BU_G1905_t3_00277 
ST88_GI-4 * * * * aureus_21343_00926 BU_G0201_t8_00654 BU_G0202_t2_00270 BU_G0701_t5_00271 BU_G1905_t3_00278 
ST88_GI-4 * * * * * * * * * 
ST88_GI-4 * * * * aureus_21343_00925 BU_G0201_t8_00655 BU_G0202_t2_00269 BU_G0701_t5_00270 BU_G1905_t3_00279 
ST88_GI-4 * * * * aureus_21343_00924 BU_G0201_t8_00656 BU_G0202_t2_00268 BU_G0701_t5_00269 BU_G1905_t3_00280 
ST88_GI-4 * * * * aureus_21343_01877 BU_G0201_t8_00657 BU_G0202_t2_00267 BU_G0701_t5_00268 BU_G1905_t3_00281 
ST88_GI-4 aureus_str._Newman_00796 * * USA300_FPR3757_00775 aureus_21343_01876 BU_G0201_t8_00658 BU_G0202_t2_00266 BU_G0701_t5_00267 BU_G1905_t3_00282 
ST88_GI-4 * * * * aureus_21343_01875 BU_G0201_t8_00659 BU_G0202_t2_00265 BU_G0701_t5_00266 BU_G1905_t3_00283 
ST88_GI-5 * * * * aureus_21343_01106 BU_G0201_t8_02668 BU_G0202_t2_02575 BU_G0701_t5_02313 BU_G1905_t3_02645 
ST88_GI-5 aureus_str._Newman_01780 MRSA_CVM43477_01485 * USA300_FPR3757_01793 aureus_21343_01107 * BU_G0202_t2_02574 BU_G0701_t5_02312 * 
ST88_GI-5 aureus_str._Newman_01781 MRSA_CVM43477_01486 * USA300_FPR3757_01794 aureus_21343_01108 BU_G0201_t8_02548 BU_G0202_t2_02573 BU_G0701_t5_02311 BU_G1905_t3_02464 
ST88_GI-5 aureus_str._Newman_01783 MRSA_CVM43477_01488 * USA300_FPR3757_01796 aureus_21343_01592 BU_G0201_t8_02547 BU_G0202_t2_02572 BU_G0701_t5_02310 BU_G1905_t3_02463 
ST88_GI-5 * * * * aureus_21343_01593 BU_G0201_t8_02546 BU_G0202_t2_02571 BU_G0701_t5_02309 BU_G1905_t3_02462 
ST88_GI-5 * * * * aureus_21343_01595 BU_G0201_t8_02544 BU_G0202_t2_02569 BU_G0701_t5_02307 BU_G1905_t3_02460 
ST88_GI-5 * * * * aureus_21343_01596 BU_G0201_t8_02543 BU_G0202_t2_02568 BU_G0701_t5_02306 BU_G1905_t3_02459 
ST88_GI-5 aureus_str._Newman_01785 MRSA_CVM43477_01490 * USA300_FPR3757_01798 aureus_21343_01597 BU_G0201_t8_02542 BU_G0202_t2_02567 BU_G0701_t5_02305 BU_G1905_t3_02458 
ST88_GI-5 aureus_str._Newman_01786 MRSA_CVM43477_01491 * USA300_FPR3757_01799 aureus_21343_01598 BU_G0201_t8_02541 BU_G0202_t2_02566 BU_G0701_t5_02304 BU_G1905_t3_02457 
ST88_GI-5 * * * * aureus_21343_01599 BU_G0201_t8_02540 BU_G0202_t2_02565 BU_G0701_t5_02303 BU_G1905_t3_02456 
ST88_GI-5 aureus_str._Newman_01788 MRSA_CVM43477_01493 * USA300_FPR3757_01801 aureus_21343_01600 BU_G0201_t8_02539 BU_G0202_t2_02564 BU_G0701_t5_02302 BU_G1905_t3_02455 
ST88_GI-5 * MRSA_CVM43477_01494 ST772-MRSA-
V_01864 
* aureus_21343_01601 BU_G0201_t8_02538 BU_G0202_t2_02563 BU_G0701_t5_02301 BU_G1905_t3_02454 
ST88_GI-5 * MRSA_CVM43477_01495 ST772-MRSA-
V_01865 
* aureus_21343_01602 BU_G0201_t8_02537 BU_G0202_t2_02562 BU_G0701_t5_02300 BU_G1905_t3_02453 
ST88_GI-5 * * * * aureus_21343_01603 BU_G0201_t8_02536 BU_G0202_t2_02561 BU_G0701_t5_02299 BU_G1905_t3_02452 
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Table  S1 cont’ 
 ST88 ST88 ST88 ST88 ST88 ST88 ST88 ST88 ST88 ST88 ST88 ST88 ST88 ST88  ST88 
Feature BU_W13_t1 HST-
105 
Sa_aus0325 Sa_NOG-
W01 
Sa_NOG-
W02 
Sa_NOG-
W04 
Sa_NOG-
W05 
Sa_NOG-
W06 
Sa_NOG-
W07 
Sa_NOG-
W10 
Sa_NOG-
W11 
Sa_NOG-
W13 
Sa_NOG-
W14 
Sa_NOG-
W24 
Sa_NOG-
W25 
ST88_GI-1 BU_W13_t1_01354 HST-
105_02277 
Sa_aus0325_00029 Sa_NOG-
W01_00264 
Sa_NOG-
W02_01656 
* Sa_NOG-
W05_00596 
* Sa_NOG-
W07_00525 
Sa_NOG-
W10_01168 
Sa_NOG-
W11_00597 
Sa_NOG-
W13_00296 
* Sa_NOG-
W24_01424 
* 
ST88_GI-1 BU_W13_t1_01355 HST-
105_02276 
Sa_aus0325_00030 Sa_NOG-
W01_00265 
Sa_NOG-
W02_01655 
Sa_NOG-
W04_01082 
Sa_NOG-
W05_00595 
Sa_NOG-
W06_00441 
Sa_NOG-
W07_00526 
Sa_NOG-
W10_01169 
Sa_NOG-
W11_00596 
Sa_NOG-
W13_00297 
Sa_NOG-
W14_01014 
Sa_NOG-
W24_01423 
Sa_NOG-
W25_02365 
ST88_GI-1 BU_W13_t1_01356 HST-
105_02275 
Sa_aus0325_00031 Sa_NOG-
W01_00266 
Sa_NOG-
W02_01654 
Sa_NOG-
W04_01083 
Sa_NOG-
W05_00594 
Sa_NOG-
W06_00440 
Sa_NOG-
W07_00527 
Sa_NOG-
W10_01170 
Sa_NOG-
W11_00595 
Sa_NOG-
W13_00298 
Sa_NOG-
W14_01015 
Sa_NOG-
W24_01422 
Sa_NOG-
W25_02364 
ST88_GI-1 * * Sa_aus0325_00032 * * * * * * * * * * * * 
ST88_GI-1 BU_W13_t1_01357 HST-
105_02273 
Sa_aus0325_00033 Sa_NOG-
W01_00267 
Sa_NOG-
W02_01653 
Sa_NOG-
W04_02297 
Sa_NOG-
W05_00593 
Sa_NOG-
W06_02268 
Sa_NOG-
W07_00528 
Sa_NOG-
W10_01171 
Sa_NOG-
W11_00594 
Sa_NOG-
W13_00299 
Sa_NOG-
W14_02313 
Sa_NOG-
W24_01421 
Sa_NOG-
W25_02535 
ST88_GI-1 BU_W13_t1_01358 HST-
105_02272 
Sa_aus0325_00034 Sa_NOG-
W01_00268 
Sa_NOG-
W02_01652 
Sa_NOG-
W04_02296 
Sa_NOG-
W05_00592 
Sa_NOG-
W06_02267 
Sa_NOG-
W07_00529 
Sa_NOG-
W10_01172 
Sa_NOG-
W11_00593 
Sa_NOG-
W13_00300 
Sa_NOG-
W14_02312 
Sa_NOG-
W24_01420 
Sa_NOG-
W25_02534 
ST88_GI-1 BU_W13_t1_01359 HST-
105_02271 
Sa_aus0325_00035 Sa_NOG-
W01_00269 
Sa_NOG-
W02_01651 
Sa_NOG-
W04_02295 
Sa_NOG-
W05_00591 
Sa_NOG-
W06_02266 
Sa_NOG-
W07_00530 
Sa_NOG-
W10_01173 
Sa_NOG-
W11_00592 
Sa_NOG-
W13_00301 
Sa_NOG-
W14_02311 
Sa_NOG-
W24_01419 
Sa_NOG-
W25_02533 
ST88_GI-2 BU_W13_t1_01484 HST-
105_01286 
Sa_aus0325_00229 Sa_NOG-
W01_01752 
Sa_NOG-
W02_01815 
Sa_NOG-
W04_01424 
Sa_NOG-
W05_01462 
Sa_NOG-
W06_01324 
Sa_NOG-
W07_01218 
Sa_NOG-
W10_01556 
Sa_NOG-
W11_01727 
Sa_NOG-
W13_01320 
Sa_NOG-
W14_01354 
Sa_NOG-
W24_00892 
Sa_NOG-
W25_00917 
ST88_GI-2 BU_W13_t1_01485 HST-
105_02651 
Sa_aus0325_00230 Sa_NOG-
W01_01751 
Sa_NOG-
W02_01816 
Sa_NOG-
W04_01425 
Sa_NOG-
W05_01463 
Sa_NOG-
W06_01325 
Sa_NOG-
W07_01219 
Sa_NOG-
W10_01557 
Sa_NOG-
W11_01728 
Sa_NOG-
W13_01321 
Sa_NOG-
W14_01355 
Sa_NOG-
W24_00893 
Sa_NOG-
W25_00918 
ST88_GI-2 BU_W13_t1_01486 HST-
105_02652 
Sa_aus0325_00231 Sa_NOG-
W01_01750 
Sa_NOG-
W02_01817 
Sa_NOG-
W04_01426 
Sa_NOG-
W05_01464 
Sa_NOG-
W06_01326 
Sa_NOG-
W07_01220 
Sa_NOG-
W10_01558 
Sa_NOG-
W11_01729 
Sa_NOG-
W13_01322 
Sa_NOG-
W14_01356 
Sa_NOG-
W24_00894 
Sa_NOG-
W25_00919 
ST88_GI-2 BU_W13_t1_01487 HST-
105_02653 
Sa_aus0325_00232 Sa_NOG-
W01_01749 
Sa_NOG-
W02_01818 
Sa_NOG-
W04_01427 
Sa_NOG-
W05_01465 
Sa_NOG-
W06_01327 
Sa_NOG-
W07_01221 
Sa_NOG-
W10_01559 
Sa_NOG-
W11_01730 
Sa_NOG-
W13_01323 
Sa_NOG-
W14_01357 
Sa_NOG-
W24_00895 
Sa_NOG-
W25_00920 
ST88_GI-2 BU_W13_t1_01488 HST-
105_02640 
Sa_aus0325_00233 Sa_NOG-
W01_01748 
Sa_NOG-
W02_01819 
Sa_NOG-
W04_01428 
Sa_NOG-
W05_01466 
Sa_NOG-
W06_01328 
Sa_NOG-
W07_01222 
Sa_NOG-
W10_01560 
Sa_NOG-
W11_01731 
Sa_NOG-
W13_01324 
Sa_NOG-
W14_01358 
Sa_NOG-
W24_00896 
Sa_NOG-
W25_00921 
ST88_GI-2 BU_W13_t1_01489 HST-
105_02639 
Sa_aus0325_00234 Sa_NOG-
W01_01747 
Sa_NOG-
W02_01820 
Sa_NOG-
W04_01429 
Sa_NOG-
W05_01467 
Sa_NOG-
W06_01329 
Sa_NOG-
W07_01223 
Sa_NOG-
W10_01561 
Sa_NOG-
W11_01732 
Sa_NOG-
W13_01325 
Sa_NOG-
W14_01359 
Sa_NOG-
W24_00897 
Sa_NOG-
W25_00922 
ST88_GI-2 BU_W13_t1_01490 HST-
105_02638 
Sa_aus0325_00235 Sa_NOG-
W01_01746 
Sa_NOG-
W02_01821 
Sa_NOG-
W04_01430 
Sa_NOG-
W05_01468 
Sa_NOG-
W06_01330 
Sa_NOG-
W07_01224 
Sa_NOG-
W10_01562 
Sa_NOG-
W11_01733 
Sa_NOG-
W13_01326 
Sa_NOG-
W14_01360 
Sa_NOG-
W24_00898 
Sa_NOG-
W25_00923 
ST88_GI-2 BU_W13_t1_01491 HST-
105_02637 
Sa_aus0325_00236 Sa_NOG-
W01_01745 
Sa_NOG-
W02_01822 
Sa_NOG-
W04_01431 
Sa_NOG-
W05_01469 
Sa_NOG-
W06_01331 
Sa_NOG-
W07_01225 
Sa_NOG-
W10_01563 
Sa_NOG-
W11_01734 
Sa_NOG-
W13_01327 
Sa_NOG-
W14_01361 
Sa_NOG-
W24_00899 
Sa_NOG-
W25_00924 
ST88_GI-2 BU_W13_t1_01493 HST-
105_02635 
Sa_aus0325_00238 Sa_NOG-
W01_01743 
Sa_NOG-
W02_01824 
Sa_NOG-
W04_01433 
Sa_NOG-
W05_01471 
Sa_NOG-
W06_01333 
Sa_NOG-
W07_01227 
Sa_NOG-
W10_01565 
Sa_NOG-
W11_01736 
Sa_NOG-
W13_01329 
Sa_NOG-
W14_01363 
Sa_NOG-
W24_00901 
Sa_NOG-
W25_00926 
ST88_GI-2 BU_W13_t1_01494 HST-
105_02634 
Sa_aus0325_00239 Sa_NOG-
W01_01742 
Sa_NOG-
W02_01825 
Sa_NOG-
W04_01434 
Sa_NOG-
W05_01472 
Sa_NOG-
W06_01334 
Sa_NOG-
W07_01228 
Sa_NOG-
W10_01566 
Sa_NOG-
W11_01737 
Sa_NOG-
W13_01330 
Sa_NOG-
W14_01364 
Sa_NOG-
W24_00902 
Sa_NOG-
W25_00927 
ST88_GI-2 BU_W13_t1_01495 HST-
105_02633 
Sa_aus0325_00240 Sa_NOG-
W01_01741 
Sa_NOG-
W02_01826 
Sa_NOG-
W04_01435 
Sa_NOG-
W05_01473 
Sa_NOG-
W06_01335 
Sa_NOG-
W07_01229 
Sa_NOG-
W10_01567 
Sa_NOG-
W11_01738 
Sa_NOG-
W13_01331 
Sa_NOG-
W14_01365 
Sa_NOG-
W24_00903 
Sa_NOG-
W25_00928 
ST88_GI-2 BU_W13_t1_01496 HST-
105_02632 
Sa_aus0325_00241 Sa_NOG-
W01_01740 
Sa_NOG-
W02_01827 
Sa_NOG-
W04_01436 
Sa_NOG-
W05_01474 
Sa_NOG-
W06_01336 
Sa_NOG-
W07_01230 
Sa_NOG-
W10_01568 
Sa_NOG-
W11_01739 
Sa_NOG-
W13_01332 
Sa_NOG-
W14_01366 
Sa_NOG-
W24_00904 
Sa_NOG-
W25_00929 
ST88_GI-2 BU_W13_t1_01497 HST-
105_02631 
Sa_aus0325_00242 Sa_NOG-
W01_01739 
Sa_NOG-
W02_01828 
Sa_NOG-
W04_01437 
Sa_NOG-
W05_01475 
Sa_NOG-
W06_01337 
Sa_NOG-
W07_01231 
Sa_NOG-
W10_01569 
Sa_NOG-
W11_01740 
Sa_NOG-
W13_01333 
Sa_NOG-
W14_01367 
Sa_NOG-
W24_00905 
Sa_NOG-
W25_00930 
ST88_GI-3 BU_W13_t1_01587 HST-
105_01550 
Sa_aus0325_00327 Sa_NOG-
W01_01654 
Sa_NOG-
W02_01341 
Sa_NOG-
W04_01523 
Sa_NOG-
W05_01561 
Sa_NOG-
W06_01423 
Sa_NOG-
W07_01317 
Sa_NOG-
W10_01655 
Sa_NOG-
W11_01824 
Sa_NOG-
W13_01419 
Sa_NOG-
W14_01453 
Sa_NOG-
W24_00991 
Sa_NOG-
W25_01015 
ST88_GI-3 BU_W13_t1_01588 HST-
105_01551 
Sa_aus0325_00328 Sa_NOG-
W01_01653 
Sa_NOG-
W02_01340 
Sa_NOG-
W04_01524 
Sa_NOG-
W05_01562 
Sa_NOG-
W06_01424 
Sa_NOG-
W07_01318 
Sa_NOG-
W10_01656 
Sa_NOG-
W11_01825 
Sa_NOG-
W13_01420 
Sa_NOG-
W14_01454 
Sa_NOG-
W24_00992 
Sa_NOG-
W25_01016 
ST88_GI-3 BU_W13_t1_01589 HST-
105_01552 
Sa_aus0325_00329 Sa_NOG-
W01_01652 
Sa_NOG-
W02_01339 
Sa_NOG-
W04_01525 
Sa_NOG-
W05_01563 
Sa_NOG-
W06_01425 
Sa_NOG-
W07_01319 
Sa_NOG-
W10_01657 
Sa_NOG-
W11_01826 
Sa_NOG-
W13_01421 
Sa_NOG-
W14_01455 
Sa_NOG-
W24_00993 
Sa_NOG-
W25_01017 
ST88_GI-3 BU_W13_t1_01590 HST-
105_01553 
Sa_aus0325_00330 Sa_NOG-
W01_01651 
Sa_NOG-
W02_01338 
Sa_NOG-
W04_01526 
Sa_NOG-
W05_01564 
Sa_NOG-
W06_01426 
Sa_NOG-
W07_01320 
Sa_NOG-
W10_01658 
Sa_NOG-
W11_01827 
Sa_NOG-
W13_01422 
Sa_NOG-
W14_01456 
Sa_NOG-
W24_00994 
Sa_NOG-
W25_01018 
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ST88_GI-3 BU_W13_t1_01591 HST-
105_01554 
Sa_aus0325_00331 Sa_NOG-
W01_01650 
Sa_NOG-
W02_01337 
Sa_NOG-
W04_01527 
Sa_NOG-
W05_01565 
Sa_NOG-
W06_01427 
Sa_NOG-
W07_01321 
Sa_NOG-
W10_01659 
Sa_NOG-
W11_01828 
Sa_NOG-
W13_01423 
Sa_NOG-
W14_01457 
Sa_NOG-
W24_00995 
Sa_NOG-
W25_01019 
ST88_GI-3 BU_W13_t1_01592 HST-
105_01555 
Sa_aus0325_00332 Sa_NOG-
W01_01649 
Sa_NOG-
W02_01336 
Sa_NOG-
W04_01528 
Sa_NOG-
W05_01566 
Sa_NOG-
W06_01428 
Sa_NOG-
W07_01322 
Sa_NOG-
W10_01660 
Sa_NOG-
W11_01829 
Sa_NOG-
W13_01424 
Sa_NOG-
W14_01458 
Sa_NOG-
W24_00996 
Sa_NOG-
W25_01020 
ST88_GI-3 BU_W13_t1_01593 HST-
105_01556 
Sa_aus0325_00333 Sa_NOG-
W01_01648 
Sa_NOG-
W02_01335 
Sa_NOG-
W04_01529 
Sa_NOG-
W05_01567 
Sa_NOG-
W06_01429 
Sa_NOG-
W07_01323 
Sa_NOG-
W10_01661 
Sa_NOG-
W11_01830 
Sa_NOG-
W13_01425 
Sa_NOG-
W14_01459 
Sa_NOG-
W24_00997 
Sa_NOG-
W25_01021 
ST88_GI-3 BU_W13_t1_01594 HST-
105_01557 
Sa_aus0325_00334 Sa_NOG-
W01_01647 
Sa_NOG-
W02_01334 
Sa_NOG-
W04_01530 
Sa_NOG-
W05_01568 
Sa_NOG-
W06_01430 
Sa_NOG-
W07_01324 
Sa_NOG-
W10_01662 
Sa_NOG-
W11_01831 
Sa_NOG-
W13_01426 
Sa_NOG-
W14_01460 
Sa_NOG-
W24_00998 
Sa_NOG-
W25_01022 
ST88_GI-3 BU_W13_t1_01595 HST-
105_01558 
Sa_aus0325_00335 Sa_NOG-
W01_01646 
Sa_NOG-
W02_01333 
Sa_NOG-
W04_01531 
Sa_NOG-
W05_01569 
Sa_NOG-
W06_01431 
Sa_NOG-
W07_01342 
Sa_NOG-
W10_01663 
Sa_NOG-
W11_01832 
Sa_NOG-
W13_01427 
Sa_NOG-
W14_01461 
Sa_NOG-
W24_00999 
Sa_NOG-
W25_01023 
ST88_GI-3 BU_W13_t1_01596 HST-
105_01559 
Sa_aus0325_00336 Sa_NOG-
W01_01645 
Sa_NOG-
W02_01332 
Sa_NOG-
W04_01532 
Sa_NOG-
W05_01570 
Sa_NOG-
W06_01432 
Sa_NOG-
W07_01343 
Sa_NOG-
W10_01664 
Sa_NOG-
W11_01833 
Sa_NOG-
W13_01428 
Sa_NOG-
W14_01462 
Sa_NOG-
W24_01000 
Sa_NOG-
W25_01024 
ST88_GI-3 BU_W13_t1_01597 HST-
105_01560 
Sa_aus0325_00337 Sa_NOG-
W01_01644 
Sa_NOG-
W02_01331 
Sa_NOG-
W04_01533 
Sa_NOG-
W05_01571 
Sa_NOG-
W06_01433 
Sa_NOG-
W07_01344 
Sa_NOG-
W10_01665 
Sa_NOG-
W11_01834 
Sa_NOG-
W13_01429 
Sa_NOG-
W14_01463 
Sa_NOG-
W24_01001 
Sa_NOG-
W25_01025 
ST88_GI-3 BU_W13_t1_01598 HST-
105_01561 
Sa_aus0325_00338 Sa_NOG-
W01_01643 
Sa_NOG-
W02_01330 
Sa_NOG-
W04_01534 
Sa_NOG-
W05_01572 
Sa_NOG-
W06_01434 
Sa_NOG-
W07_01345 
Sa_NOG-
W10_01666 
Sa_NOG-
W11_01835 
Sa_NOG-
W13_01430 
Sa_NOG-
W14_01464 
Sa_NOG-
W24_01002 
Sa_NOG-
W25_01026 
ST88_GI-3 BU_W13_t1_01599 HST-
105_01562 
Sa_aus0325_00339 Sa_NOG-
W01_01642 
Sa_NOG-
W02_01329 
Sa_NOG-
W04_01535 
Sa_NOG-
W05_01573 
Sa_NOG-
W06_01435 
Sa_NOG-
W07_01346 
Sa_NOG-
W10_01667 
Sa_NOG-
W11_01836 
Sa_NOG-
W13_01431 
Sa_NOG-
W14_01465 
Sa_NOG-
W24_01003 
Sa_NOG-
W25_01027 
ST88_GI-3 BU_W13_t1_01600 HST-
105_01563 
Sa_aus0325_00340 Sa_NOG-
W01_01641 
Sa_NOG-
W02_01328 
Sa_NOG-
W04_01536 
Sa_NOG-
W05_01574 
Sa_NOG-
W06_01436 
Sa_NOG-
W07_01347 
Sa_NOG-
W10_01668 
Sa_NOG-
W11_01837 
Sa_NOG-
W13_01432 
Sa_NOG-
W14_01466 
Sa_NOG-
W24_01004 
Sa_NOG-
W25_01028 
ST88_GI-3 BU_W13_t1_01601 HST-
105_01564 
Sa_aus0325_00341 Sa_NOG-
W01_01640 
Sa_NOG-
W02_01327 
Sa_NOG-
W04_01537 
Sa_NOG-
W05_01575 
Sa_NOG-
W06_01437 
Sa_NOG-
W07_01348 
Sa_NOG-
W10_01669 
Sa_NOG-
W11_01838 
Sa_NOG-
W13_01433 
Sa_NOG-
W14_01467 
Sa_NOG-
W24_01005 
Sa_NOG-
W25_01029 
ST88_GI-3 BU_W13_t1_01602 HST-
105_01565 
Sa_aus0325_00342 Sa_NOG-
W01_01639 
Sa_NOG-
W02_01326 
Sa_NOG-
W04_01538 
Sa_NOG-
W05_01576 
Sa_NOG-
W06_01438 
Sa_NOG-
W07_01349 
Sa_NOG-
W10_01670 
Sa_NOG-
W11_01839 
Sa_NOG-
W13_01434 
Sa_NOG-
W14_01468 
Sa_NOG-
W24_01006 
Sa_NOG-
W25_01030 
ST88_GI-3 BU_W13_t1_01603 HST-
105_01566 
Sa_aus0325_00343 Sa_NOG-
W01_01638 
Sa_NOG-
W02_01325 
Sa_NOG-
W04_01539 
Sa_NOG-
W05_01577 
Sa_NOG-
W06_01439 
Sa_NOG-
W07_01350 
Sa_NOG-
W10_01671 
Sa_NOG-
W11_01840 
Sa_NOG-
W13_01435 
Sa_NOG-
W14_01469 
Sa_NOG-
W24_01007 
Sa_NOG-
W25_01031 
ST88_GI-3 BU_W13_t1_01604 HST-
105_01567 
Sa_aus0325_00344 Sa_NOG-
W01_01637 
Sa_NOG-
W02_01324 
Sa_NOG-
W04_01540 
Sa_NOG-
W05_01578 
Sa_NOG-
W06_01440 
Sa_NOG-
W07_01351 
Sa_NOG-
W10_01672 
Sa_NOG-
W11_01841 
Sa_NOG-
W13_01436 
Sa_NOG-
W14_01470 
Sa_NOG-
W24_01008 
Sa_NOG-
W25_01032 
ST88_GI-3 BU_W13_t1_01605 HST-
105_01568 
Sa_aus0325_00345 Sa_NOG-
W01_01636 
Sa_NOG-
W02_01323 
Sa_NOG-
W04_01541 
Sa_NOG-
W05_01579 
Sa_NOG-
W06_01441 
Sa_NOG-
W07_01352 
Sa_NOG-
W10_01673 
Sa_NOG-
W11_01842 
Sa_NOG-
W13_01437 
Sa_NOG-
W14_01471 
Sa_NOG-
W24_01009 
Sa_NOG-
W25_01033 
ST88_GI-3 BU_W13_t1_01606 HST-
105_01569 
Sa_aus0325_00346 Sa_NOG-
W01_01635 
Sa_NOG-
W02_01322 
Sa_NOG-
W04_01542 
Sa_NOG-
W05_01580 
Sa_NOG-
W06_01442 
Sa_NOG-
W07_01353 
Sa_NOG-
W10_01674 
Sa_NOG-
W11_01843 
Sa_NOG-
W13_01438 
Sa_NOG-
W14_01472 
Sa_NOG-
W24_01010 
Sa_NOG-
W25_01034 
ST88_GI-3 BU_W13_t1_01607 HST-
105_01570 
Sa_aus0325_00347 Sa_NOG-
W01_01634 
Sa_NOG-
W02_01321 
Sa_NOG-
W04_01543 
Sa_NOG-
W05_01581 
Sa_NOG-
W06_01443 
Sa_NOG-
W07_01354 
Sa_NOG-
W10_01675 
Sa_NOG-
W11_01844 
Sa_NOG-
W13_01439 
Sa_NOG-
W14_01473 
Sa_NOG-
W24_01011 
Sa_NOG-
W25_01035 
ST88_GI-3 BU_W13_t1_01608 HST-
105_01571 
Sa_aus0325_00348 Sa_NOG-
W01_01633 
Sa_NOG-
W02_01320 
Sa_NOG-
W04_01544 
Sa_NOG-
W05_01582 
Sa_NOG-
W06_01444 
Sa_NOG-
W07_01355 
Sa_NOG-
W10_01676 
Sa_NOG-
W11_01845 
Sa_NOG-
W13_01440 
Sa_NOG-
W14_01474 
Sa_NOG-
W24_01012 
Sa_NOG-
W25_01036 
ST88_GI-3 BU_W13_t1_01609 HST-
105_01572 
Sa_aus0325_00349 Sa_NOG-
W01_01632 
Sa_NOG-
W02_01319 
Sa_NOG-
W04_01545 
Sa_NOG-
W05_01583 
Sa_NOG-
W06_01445 
Sa_NOG-
W07_01356 
Sa_NOG-
W10_01677 
Sa_NOG-
W11_01846 
Sa_NOG-
W13_01441 
Sa_NOG-
W14_01475 
Sa_NOG-
W24_01013 
Sa_NOG-
W25_01037 
ST88_GI-3 BU_W13_t1_01610 HST-
105_01573 
Sa_aus0325_00350 Sa_NOG-
W01_02682 
Sa_NOG-
W02_01318 
Sa_NOG-
W04_01546 
Sa_NOG-
W05_01584 
Sa_NOG-
W06_01446 
Sa_NOG-
W07_01357 
Sa_NOG-
W10_01678 
Sa_NOG-
W11_01847 
Sa_NOG-
W13_01442 
Sa_NOG-
W14_01476 
Sa_NOG-
W24_01014 
Sa_NOG-
W25_01038 
ST88_GI-3 BU_W13_t1_01611 HST-
105_01574 
Sa_aus0325_00351 Sa_NOG-
W01_02681 
Sa_NOG-
W02_01317 
Sa_NOG-
W04_01547 
Sa_NOG-
W05_01585 
Sa_NOG-
W06_01447 
Sa_NOG-
W07_01358 
Sa_NOG-
W10_01679 
Sa_NOG-
W11_01848 
Sa_NOG-
W13_01443 
Sa_NOG-
W14_01477 
Sa_NOG-
W24_01015 
Sa_NOG-
W25_01039 
ST88_GI-3 * HST-
105_01575 
Sa_aus0325_00352 * Sa_NOG-
W02_01316 
* * Sa_NOG-
W06_01448 
Sa_NOG-
W07_01359 
Sa_NOG-
W10_01680 
Sa_NOG-
W11_01849 
Sa_NOG-
W13_01444 
Sa_NOG-
W14_01478 
* * 
ST88_GI-3 BU_W13_t1_02323 HST-
105_01576 
Sa_aus0325_00353 Sa_NOG-
W01_02549 
Sa_NOG-
W02_01315 
Sa_NOG-
W04_02379 
Sa_NOG-
W05_02514 
Sa_NOG-
W06_01449 
Sa_NOG-
W07_01360 
Sa_NOG-
W10_01681 
Sa_NOG-
W11_01850 
Sa_NOG-
W13_01445 
Sa_NOG-
W14_01479 
Sa_NOG-
W24_02449 
Sa_NOG-
W25_02623 
ST88_GI-3 BU_W13_t1_02324 HST-
105_01577 
Sa_aus0325_00354 Sa_NOG-
W01_02548 
Sa_NOG-
W02_01314 
Sa_NOG-
W04_02380 
Sa_NOG-
W05_02513 
Sa_NOG-
W06_01450 
Sa_NOG-
W07_01361 
Sa_NOG-
W10_01682 
Sa_NOG-
W11_01851 
Sa_NOG-
W13_01446 
Sa_NOG-
W14_01480 
Sa_NOG-
W24_02450 
Sa_NOG-
W25_02622 
ST88_GI-3 BU_W13_t1_02325 HST-
105_01578 
Sa_aus0325_00355 Sa_NOG-
W01_02547 
Sa_NOG-
W02_01313 
Sa_NOG-
W04_02381 
Sa_NOG-
W05_02512 
Sa_NOG-
W06_01451 
Sa_NOG-
W07_01362 
Sa_NOG-
W10_01683 
Sa_NOG-
W11_01852 
Sa_NOG-
W13_01447 
Sa_NOG-
W14_01481 
Sa_NOG-
W24_02451 
Sa_NOG-
W25_02621 
ST88_GI-3 BU_W13_t1_02326 HST-
105_01579 
Sa_aus0325_00356 Sa_NOG-
W01_02546 
Sa_NOG-
W02_01312 
Sa_NOG-
W04_02382 
Sa_NOG-
W05_02511 
Sa_NOG-
W06_01452 
Sa_NOG-
W07_01363 
Sa_NOG-
W10_01684 
Sa_NOG-
W11_01853 
Sa_NOG-
W13_01448 
Sa_NOG-
W14_01482 
Sa_NOG-
W24_02452 
Sa_NOG-
W25_02620 
ST88_GI-3 BU_W13_t1_02327 HST-
105_01580 
Sa_aus0325_00357 Sa_NOG-
W01_02545 
Sa_NOG-
W02_01311 
Sa_NOG-
W04_02383 
Sa_NOG-
W05_02510 
Sa_NOG-
W06_01453 
Sa_NOG-
W07_02483 
Sa_NOG-
W10_01685 
Sa_NOG-
W11_01854 
Sa_NOG-
W13_01449 
Sa_NOG-
W14_01483 
Sa_NOG-
W24_02453 
Sa_NOG-
W25_02619 
ST88_GI-3 BU_W13_t1_02328 HST-
105_01581 
Sa_aus0325_00358 Sa_NOG-
W01_02544 
Sa_NOG-
W02_01310 
Sa_NOG-
W04_02384 
Sa_NOG-
W05_02509 
Sa_NOG-
W06_01454 
Sa_NOG-
W07_02484 
Sa_NOG-
W10_01686 
Sa_NOG-
W11_01855 
Sa_NOG-
W13_01450 
Sa_NOG-
W14_01484 
Sa_NOG-
W24_02454 
Sa_NOG-
W25_02618 
ST88_GI-3 BU_W13_t1_02329 HST-
105_01582 
Sa_aus0325_00359 Sa_NOG-
W01_02543 
Sa_NOG-
W02_01309 
Sa_NOG-
W04_02385 
Sa_NOG-
W05_02508 
Sa_NOG-
W06_01455 
Sa_NOG-
W07_02485 
Sa_NOG-
W10_01687 
Sa_NOG-
W11_01856 
Sa_NOG-
W13_01451 
Sa_NOG-
W14_01485 
Sa_NOG-
W24_02455 
Sa_NOG-
W25_02617 
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ST88_GI-3 BU_W13_t1_02330 HST-
105_01583 
Sa_aus0325_00360 Sa_NOG-
W01_02542 
Sa_NOG-
W02_01308 
Sa_NOG-
W04_02386 
Sa_NOG-
W05_02507 
Sa_NOG-
W06_01456 
Sa_NOG-
W07_02486 
Sa_NOG-
W10_01688 
Sa_NOG-
W11_01857 
Sa_NOG-
W13_01452 
Sa_NOG-
W14_01486 
Sa_NOG-
W24_02456 
Sa_NOG-
W25_02616 
ST88_GI-3 BU_W13_t1_02331 HST-
105_01584 
Sa_aus0325_00361 Sa_NOG-
W01_02541 
Sa_NOG-
W02_01307 
Sa_NOG-
W04_02387 
Sa_NOG-
W05_02506 
Sa_NOG-
W06_01457 
Sa_NOG-
W07_02487 
Sa_NOG-
W10_01689 
Sa_NOG-
W11_01858 
Sa_NOG-
W13_01453 
Sa_NOG-
W14_01487 
Sa_NOG-
W24_02457 
Sa_NOG-
W25_02615 
ST88_GI-3 BU_W13_t1_02332 HST-
105_01585 
Sa_aus0325_00362 Sa_NOG-
W01_02540 
Sa_NOG-
W02_01306 
Sa_NOG-
W04_02388 
Sa_NOG-
W05_02505 
Sa_NOG-
W06_01458 
Sa_NOG-
W07_02488 
Sa_NOG-
W10_01690 
Sa_NOG-
W11_01859 
Sa_NOG-
W13_01454 
Sa_NOG-
W14_01488 
Sa_NOG-
W24_02458 
Sa_NOG-
W25_02614 
ST88_GI-4 BU_W13_t1_00816 HST-
105_00744 
Sa_aus0325_00793 Sa_NOG-
W01_00676 
Sa_NOG-
W02_00272 
Sa_NOG-
W04_00275 
Sa_NOG-
W05_00275 
Sa_NOG-
W06_00971 
Sa_NOG-
W07_00780 
Sa_NOG-
W10_00275 
Sa_NOG-
W11_00275 
Sa_NOG-
W13_00445 
Sa_NOG-
W14_00475 
Sa_NOG-
W24_00267 
Sa_NOG-
W25_00100 
ST88_GI-4 BU_W13_t1_00817 HST-
105_00743 
Sa_aus0325_00794 Sa_NOG-
W01_00675 
Sa_NOG-
W02_00273 
Sa_NOG-
W04_00274 
Sa_NOG-
W05_00274 
Sa_NOG-
W06_00970 
Sa_NOG-
W07_00781 
Sa_NOG-
W10_00274 
Sa_NOG-
W11_00274 
Sa_NOG-
W13_00444 
Sa_NOG-
W14_00474 
Sa_NOG-
W24_00266 
Sa_NOG-
W25_00099 
ST88_GI-4 BU_W13_t1_00818 HST-
105_00742 
Sa_aus0325_00795 Sa_NOG-
W01_00674 
Sa_NOG-
W02_00274 
Sa_NOG-
W04_00273 
Sa_NOG-
W05_00273 
Sa_NOG-
W06_00969 
Sa_NOG-
W07_00782 
Sa_NOG-
W10_00273 
Sa_NOG-
W11_00273 
Sa_NOG-
W13_00443 
Sa_NOG-
W14_00473 
Sa_NOG-
W24_00265 
Sa_NOG-
W25_00098 
ST88_GI-4 BU_W13_t1_00819 HST-
105_00741 
Sa_aus0325_00796 Sa_NOG-
W01_00673 
Sa_NOG-
W02_00275 
Sa_NOG-
W04_00272 
Sa_NOG-
W05_00272 
Sa_NOG-
W06_00968 
Sa_NOG-
W07_00783 
Sa_NOG-
W10_00272 
Sa_NOG-
W11_00272 
Sa_NOG-
W13_00442 
Sa_NOG-
W14_00472 
Sa_NOG-
W24_00264 
Sa_NOG-
W25_00097 
ST88_GI-4 BU_W13_t1_00820 HST-
105_00740 
Sa_aus0325_00797 Sa_NOG-
W01_00672 
Sa_NOG-
W02_00276 
Sa_NOG-
W04_00271 
Sa_NOG-
W05_00271 
Sa_NOG-
W06_00967 
Sa_NOG-
W07_00784 
Sa_NOG-
W10_00271 
Sa_NOG-
W11_00271 
Sa_NOG-
W13_00441 
Sa_NOG-
W14_00471 
Sa_NOG-
W24_00263 
Sa_NOG-
W25_00096 
ST88_GI-4 BU_W13_t1_00821 HST-
105_00739 
Sa_aus0325_00798 Sa_NOG-
W01_00671 
Sa_NOG-
W02_00277 
Sa_NOG-
W04_00270 
Sa_NOG-
W05_00270 
* Sa_NOG-
W07_00785 
Sa_NOG-
W10_00270 
Sa_NOG-
W11_00270 
Sa_NOG-
W13_00440 
Sa_NOG-
W14_00470 
Sa_NOG-
W24_00262 
Sa_NOG-
W25_00095 
ST88_GI-4 * * Sa_aus0325_00799 * * * * * * * * * * Sa_NOG-
W24_00811 
* 
ST88_GI-4 BU_W13_t1_00822 HST-
105_00738 
Sa_aus0325_00800 Sa_NOG-
W01_00670 
Sa_NOG-
W02_00278 
Sa_NOG-
W04_00269 
Sa_NOG-
W05_00269 
Sa_NOG-
W06_00171 
Sa_NOG-
W07_00786 
Sa_NOG-
W10_00269 
Sa_NOG-
W11_00269 
Sa_NOG-
W13_00439 
Sa_NOG-
W14_00469 
Sa_NOG-
W24_00810 
Sa_NOG-
W25_00094 
ST88_GI-4 BU_W13_t1_00823 HST-
105_00737 
Sa_aus0325_00801 Sa_NOG-
W01_00669 
Sa_NOG-
W02_00279 
Sa_NOG-
W04_00268 
Sa_NOG-
W05_00268 
Sa_NOG-
W06_00172 
Sa_NOG-
W07_00787 
Sa_NOG-
W10_00268 
Sa_NOG-
W11_00268 
Sa_NOG-
W13_00438 
Sa_NOG-
W14_00468 
Sa_NOG-
W24_00809 
Sa_NOG-
W25_00093 
ST88_GI-4 BU_W13_t1_00824 HST-
105_00736 
Sa_aus0325_00802 Sa_NOG-
W01_00668 
Sa_NOG-
W02_00280 
Sa_NOG-
W04_00267 
Sa_NOG-
W05_00267 
Sa_NOG-
W06_00173 
Sa_NOG-
W07_00788 
Sa_NOG-
W10_00267 
Sa_NOG-
W11_00267 
Sa_NOG-
W13_00437 
Sa_NOG-
W14_00467 
Sa_NOG-
W24_00808 
Sa_NOG-
W25_00092 
ST88_GI-4 BU_W13_t1_00825 HST-
105_00735 
Sa_aus0325_00803 Sa_NOG-
W01_00667 
Sa_NOG-
W02_00281 
Sa_NOG-
W04_00266 
Sa_NOG-
W05_00266 
Sa_NOG-
W06_00174 
Sa_NOG-
W07_00789 
Sa_NOG-
W10_00266 
Sa_NOG-
W11_00266 
Sa_NOG-
W13_00436 
Sa_NOG-
W14_00466 
Sa_NOG-
W24_00807 
Sa_NOG-
W25_00091 
ST88_GI-4 BU_W13_t1_00826 HST-
105_00734 
Sa_aus0325_00804 Sa_NOG-
W01_00666 
Sa_NOG-
W02_00282 
Sa_NOG-
W04_00265 
Sa_NOG-
W05_00265 
Sa_NOG-
W06_00175 
Sa_NOG-
W07_00790 
Sa_NOG-
W10_00265 
Sa_NOG-
W11_00265 
Sa_NOG-
W13_00435 
Sa_NOG-
W14_00465 
Sa_NOG-
W24_00806 
Sa_NOG-
W25_00090 
ST88_GI-5 BU_W13_t1_02586 HST-
105_02561 
Sa_aus0325_01715 Sa_NOG-
W01_02274 
Sa_NOG-
W02_02431 
Sa_NOG-
W04_02527 
Sa_NOG-
W05_02614 
Sa_NOG-
W06_02350 
Sa_NOG-
W07_02629 
Sa_NOG-
W10_02058 
Sa_NOG-
W11_02557 
Sa_NOG-
W13_02618 
Sa_NOG-
W14_01854 
Sa_NOG-
W24_02532 
Sa_NOG-
W25_02265 
ST88_GI-5 * HST-
105_02560 
Sa_aus0325_01716 Sa_NOG-
W01_02273 
Sa_NOG-
W02_02430 
* * Sa_NOG-
W06_02349 
* Sa_NOG-
W10_02057 
* Sa_NOG-
W13_02617 
Sa_NOG-
W14_01853 
* Sa_NOG-
W25_02264 
ST88_GI-5 BU_W13_t1_02691 HST-
105_02559 
Sa_aus0325_01717 Sa_NOG-
W01_02272 
Sa_NOG-
W02_02429 
Sa_NOG-
W04_02377 
Sa_NOG-
W05_02474 
Sa_NOG-
W06_02348 
Sa_NOG-
W07_02419 
Sa_NOG-
W10_02056 
Sa_NOG-
W11_02448 
Sa_NOG-
W13_02616 
Sa_NOG-
W14_01852 
Sa_NOG-
W24_02447 
Sa_NOG-
W25_02263 
ST88_GI-5 BU_W13_t1_02690 HST-
105_02329 
Sa_aus0325_01718 Sa_NOG-
W01_02271 
Sa_NOG-
W02_02428 
Sa_NOG-
W04_02376 
Sa_NOG-
W05_02473 
Sa_NOG-
W06_02347 
Sa_NOG-
W07_02418 
Sa_NOG-
W10_02055 
Sa_NOG-
W11_02447 
Sa_NOG-
W13_02615 
Sa_NOG-
W14_01851 
Sa_NOG-
W24_02446 
Sa_NOG-
W25_02262 
ST88_GI-5 BU_W13_t1_02689 HST-
105_02330 
Sa_aus0325_01719 Sa_NOG-
W01_02270 
Sa_NOG-
W02_02427 
Sa_NOG-
W04_02375 
Sa_NOG-
W05_02472 
Sa_NOG-
W06_02346 
Sa_NOG-
W07_02417 
Sa_NOG-
W10_02054 
Sa_NOG-
W11_02446 
Sa_NOG-
W13_02614 
Sa_NOG-
W14_01850 
Sa_NOG-
W24_02445 
Sa_NOG-
W25_02261 
ST88_GI-5 BU_W13_t1_02687 HST-
105_02332 
Sa_aus0325_01720 Sa_NOG-
W01_02268 
Sa_NOG-
W02_02425 
Sa_NOG-
W04_02373 
Sa_NOG-
W05_02470 
Sa_NOG-
W06_02344 
Sa_NOG-
W07_02415 
Sa_NOG-
W10_02052 
Sa_NOG-
W11_02444 
Sa_NOG-
W13_02612 
Sa_NOG-
W14_01848 
Sa_NOG-
W24_02443 
Sa_NOG-
W25_02259 
ST88_GI-5 BU_W13_t1_02686 HST-
105_02333 
Sa_aus0325_01721 Sa_NOG-
W01_02267 
Sa_NOG-
W02_02424 
Sa_NOG-
W04_02372 
Sa_NOG-
W05_02469 
Sa_NOG-
W06_02343 
Sa_NOG-
W07_02414 
Sa_NOG-
W10_02051 
Sa_NOG-
W11_02443 
Sa_NOG-
W13_02611 
Sa_NOG-
W14_01847 
Sa_NOG-
W24_02442 
Sa_NOG-
W25_02258 
ST88_GI-5 BU_W13_t1_02685 HST-
105_02334 
Sa_aus0325_01722 Sa_NOG-
W01_02266 
Sa_NOG-
W02_02423 
Sa_NOG-
W04_02371 
Sa_NOG-
W05_02468 
Sa_NOG-
W06_02342 
Sa_NOG-
W07_02413 
Sa_NOG-
W10_02050 
Sa_NOG-
W11_02442 
Sa_NOG-
W13_02610 
Sa_NOG-
W14_01846 
Sa_NOG-
W24_02441 
Sa_NOG-
W25_02257 
ST88_GI-5 BU_W13_t1_02684 HST-
105_02335 
Sa_aus0325_01723 Sa_NOG-
W01_02265 
Sa_NOG-
W02_02422 
Sa_NOG-
W04_02370 
Sa_NOG-
W05_02467 
Sa_NOG-
W06_02341 
Sa_NOG-
W07_02412 
Sa_NOG-
W10_02049 
Sa_NOG-
W11_02441 
Sa_NOG-
W13_02609 
Sa_NOG-
W14_01845 
Sa_NOG-
W24_02440 
Sa_NOG-
W25_02256 
ST88_GI-5 BU_W13_t1_02683 HST-
105_02336 
Sa_aus0325_01724 Sa_NOG-
W01_02264 
Sa_NOG-
W02_02421 
Sa_NOG-
W04_02369 
Sa_NOG-
W05_02466 
Sa_NOG-
W06_02340 
Sa_NOG-
W07_02411 
Sa_NOG-
W10_02048 
Sa_NOG-
W11_02440 
Sa_NOG-
W13_02608 
Sa_NOG-
W14_01844 
Sa_NOG-
W24_02439 
Sa_NOG-
W25_02255 
ST88_GI-5 BU_W13_t1_02475 HST-
105_02337 
Sa_aus0325_01725 Sa_NOG-
W01_02263 
Sa_NOG-
W02_02420 
Sa_NOG-
W04_02368 
Sa_NOG-
W05_02465 
Sa_NOG-
W06_02339 
Sa_NOG-
W07_02410 
Sa_NOG-
W10_02047 
Sa_NOG-
W11_02439 
Sa_NOG-
W13_02532 
Sa_NOG-
W14_01843 
Sa_NOG-
W24_02438 
Sa_NOG-
W25_02254 
ST88_GI-5 BU_W13_t1_02474 HST-
105_02338 
Sa_aus0325_01726 Sa_NOG-
W01_02262 
Sa_NOG-
W02_02419 
Sa_NOG-
W04_02367 
Sa_NOG-
W05_02464 
Sa_NOG-
W06_02338 
Sa_NOG-
W07_02409 
Sa_NOG-
W10_02046 
Sa_NOG-
W11_02438 
Sa_NOG-
W13_02531 
Sa_NOG-
W14_01842 
Sa_NOG-
W24_02437 
Sa_NOG-
W25_02253 
ST88_GI-5 BU_W13_t1_02473 HST-
105_02339 
Sa_aus0325_01727 Sa_NOG-
W01_02261 
Sa_NOG-
W02_02418 
Sa_NOG-
W04_02366 
Sa_NOG-
W05_02463 
Sa_NOG-
W06_02337 
Sa_NOG-
W07_02408 
Sa_NOG-
W10_02045 
Sa_NOG-
W11_02437 
Sa_NOG-
W13_02530 
Sa_NOG-
W14_01841 
Sa_NOG-
W24_02436 
Sa_NOG-
W25_02252 
ST88_GI-5 BU_W13_t1_02472 HST-
105_02340 
Sa_aus0325_01728 Sa_NOG-
W01_02260 
Sa_NOG-
W02_02417 
Sa_NOG-
W04_02365 
Sa_NOG-
W05_02462 
Sa_NOG-
W06_02336 
Sa_NOG-
W07_02407 
Sa_NOG-
W10_02044 
Sa_NOG-
W11_02436 
Sa_NOG-
W13_02529 
Sa_NOG-
W14_01840 
Sa_NOG-
W24_02435 
Sa_NOG-
W25_02251 
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Table S2: Genomic regions enriched in S. aureusMRSA ST88 from Ghana 
Feature Annotation 
Ghaniaian_GI-1 Replication protein 
Ghaniaian_GI-1 putative tetracycline resistance protein 
Ghaniaian_GI-1 tetracycline resistance protein TetM 
Ghaniaian_GI-1 hypothetical protein 
Ghaniaian_GI-1 hypothetical protein 
Ghaniaian_GI-1 hypothetical protein 
Ghaniaian_GI-1 putative ATP/GTP-binding protein 
Ghaniaian_GI-1 putative antirestriction protein 
Ghaniaian_GI-1 hypothetical protein 
Ghaniaian_GI-1 replication initiation factor 
Ghaniaian_GI-1 DNA segregation ATPase FtsK/SpoIIIE 
Ghaniaian_GI-1 hypothetical protein 
Ghaniaian_GI-1 hypothetical protein 
Ghaniaian_GI-2 AP2 domain protein 
Ghaniaian_GI-2 phage tape measure protein 
Ghaniaian_GI-2 phage protein 
Ghaniaian_GI-2 transcriptional activator 
Ghaniaian_GI-2 hypothetical protein 
Ghaniaian_GI-2 hypothetical protein 
Ghaniaian_GI-2 hypothetical protein 
Ghaniaian_GI-2 hypothetical protein 
Ghaniaian_GI-2 putative phage protein 
Ghaniaian_GI-2 acetyltransferase (GNAT) family protein 
Ghaniaian_GI-2 phage protein 
Ghaniaian_GI-2 phage protein 
Ghaniaian_GI-2 phage protein 
Ghaniaian_GI-2 phage protein 
Ghaniaian_GI-2 hypothetical protein 
Ghaniaian_GI-2 phage protein 
Ghaniaian_GI-3 hypothetical protein 
Ghaniaian_GI-3 hypothetical protein 
Ghaniaian_GI-3 hypothetical protein 
Ghaniaian_GI-3 hypothetical protein 
Ghaniaian_GI-3 hypothetical protein 
Ghaniaian_GI-3 hypothetical protein 
Ghaniaian_GI-3 Phage regulatory protein Rha (Phage_pRha) 
Ghaniaian_GI-3 hypothetical protein 
Ghaniaian_GI-4 pathogenicity island protein  integrase 
Ghaniaian_GI-4 Excisionase from transposon Tn916 
Ghaniaian_GI-4 Helix-turn-helix domain protein 
Ghaniaian_GI-4 Sigma-70 Region 4 protein 
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Ghaniaian_GI-4 putative transcriptional regulator 
Ghaniaian_GI-4 cassette chromosome recombinase B 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 recombinase/resolvase 
Ghaniaian_GI-5 transposase for transposon Tn552 
Ghaniaian_GI-5 major facilitator superfamily multidrug :cation symporter 
Ghaniaian_GI-5 Gram positive anchor 
Ghaniaian_GI-5 Initiator Replication protein 
Ghaniaian_GI-5 putative 27.7 kDa protein 
Ghaniaian_GI-5 Relaxase/Mobilisation nuclease domain protein 
Ghaniaian_GI-5 Bacterial mobilisation protein (MobC) 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 ABC superfamily ATP binding cassette transporter  ABC protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 putative transcriptional regulator 
Ghaniaian_GI-5 fibrinogen-binding protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 fibronectin-binding protein A 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 Replication protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 Replication protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 phage transcriptional regulator 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 Transposase IS116/IS110/IS902 family protein 
Ghaniaian_GI-5 hypothetical protein 
Ghaniaian_GI-5 putative transposase for 
Ghaniaian_GI-5 transposase for IS431mec 
Ghaniaian_GI-5 putative deoxyribose-phosphate aldolase 
Ghaniaian_GI-5 hypothetical protein 
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Antimicrobial drug susceptibility patterns of clinical isolates of Gram-
negative bacteria from two primary health care facilities in Ghana 
 
Grace Kpeli
1,2,3
, Emelia Danso
1
, Julia Hauser
2
, Vladimira Hinic
4
, Evelyn Owusu-Mireku
1
, 
Gerd Pluschke
2,3
, Dorothy Yeboah-Manu
1*
 
1. Noguchi Memorial Institute for Medical Research, Accra Ghana, P. O. Box LG 581, 
Legon, Accra, Ghana 
2. Swiss Tropical and Public Health Institute, Basel Switzerland, Socinstrasse 57, 4051 
Basel, Switzerland 
3. University of Basel, Basel Switzerland, Petersplatz 1, 4003 Basel, Switzerland 
4. Division of Clinical Microbiology, Universitätsspital Basel, Basel Switzerland, 
Spitalstrasse 21, 4056 Basel, Switzerland 
 
 
 
*Corresponding author: dyeboah-manu@noguchi.ug.edu.gh 
 
 
 
 
 
 
  
Article is ready for submission to 
International Journal of Infectious Diseases 
 
 
 
180 
 
Abstract 
Objectives: The upsurge of antibiotic resistant organisms is of concern to global health as it 
is making treatable infections difficult to treat. We characterized the resistant profiles of 
bacteria isolated from wounds of patients attending two health facilities in Ghana. 
Methods: Phenotypic antibiotic susceptibility testing of Pseudomonas aeruginosa (n=89), 
Escherichia coli (n=23), Enterobacter cloacae (n=26), Klebsiella pneumonia (n=25), and 
Proteus mirabilis (n=37) clinical isolates was performed by the Kirby Bauer disc diffusion 
and multidrug-resistance P. aeruginosa identified. Isolates were further investigated for 
Extended Spectrum ß-Lactamase (ESBL) production and metallo ß-lactamase (MBL) 
production. Resistance conferring genes blaCTX-M, blaTEM, blaSHV, blaIMP-1, blaVIM-1, blaOXA-2, 
blaOXA-48, blaNDM, blaKPC and blaSPM were analysed by PCR.  
Results: High frequency of resistance (>50%) to common first line antibiotics and a lower 
frequency (<50%) to aminoglycosides, ciprofloxacin, aztreonam, ceftazidime, imipenem and 
colistin was observed.  ESBL production was confirmed in 26 isolates phenotypically while 
50% of the isolates harboured at least one ESBL-conferring gene. Carbapenem encoding 
genes were detected in 41% of isolates. Eight antibiotic conferring genes were detected. 
Conclusions: The observed frequency of ESBL and carbapenem resistance indicates the need 
to set up surveillance networks and to strictly enforce policies which guide rational use of 
antibiotics in Ghana.  
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Introduction 
Gram-negative bacteria (GNB) are important causes of both nosocomial and community 
acquired infections such as pneumonia, bloodstream infections, wound and surgical site 
infections and meningitis. ß-lactam antibiotics, which include the penicillins, cephalosporins, 
carbapenems and monobactams, are commonly prescribed for treatment of infections due to 
GNB. Extensive use of these antibiotics has led to an increase in resistance mediated by a 
variety of mechanisms [1]; the most common and clinically significant being the production 
of β-lactamase enzymes [2]. These enzymes are usually encoded by genes present on 
plasmids, which have the potential of being horizontally transferred among strains and 
species. These plasmids also frequently carry genes that confer resistance to other classes of 
antibiotics such as aminoglycosides and quinolones, further limiting therapeutic options [3-
4]. 
As resistance increased, many new antibiotics termed as ‘β-lactamase-stable β-lactams’ 
which include the oxyimino cephalosporins, cephamycins, aztreonam, temocillin and 
carbapenems were introduced in the 1970’s [5]. The oxyimino cephalosporins gained 
widespread use and with it came the emergence of resistance due to extended spectrum β-
lactamases (ESBL’s). The first ESBL-producing organisms were detected in Europe in 1983 
[6].
 
Since then, over 1000 ESBL’s have been described worldwide, found in many different 
genera of Enterobacteriaceae and Pseudomonas aeruginosa [7]. ESBL enzymes are 
commonly encoded by TEM, SHV and CTX-M plasmid types and occasionally by OXA, 
PER, VEB, GES, BES, TLA, SFO and IBC types [3]. The treatment of choice for severe 
infections due to ESBL-producing organisms is the carbapenems. However, carbapenem 
resistance has been detected recently, mediated by class A carbapenemases (eg KPC, GES), 
class B metallo-β-lactamases (eg VIM, IMP, NDM, SPM, IMI types) and class D 
carbapenemases (OXA-23, -48, -51, -58 and -143) [8-9].  
Also on the increase is the prevalence of P. aeruginosa isolates with a multidrug-resistant 
(MDR) phenotype. These organisms have been implicated in 13% of all healthcare-associated 
P. aeruginosa infections in the United States and over 400 deaths yearly, leading to their 
classification as a serious threat by the Center for Disease Control (CDC) (www.cdc.gov).  
Surveillance of antimicrobial resistance is crucial to help in the formulation of policies, put in 
place proper interventions to curb the spread of resistant pathogens [10], as well as to guide 
clinicians on retreatment regimens. However, in many African countries, surveillance 
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systems to monitor the occurrence and spread of drug resistant pathogens are lacking [11]. 
Studies on ESBL-producing bacteria and other antibiotic resistant pathogens in Africa have 
been performed in the Northern and Southern regions of the continent [11]. The few studies 
conducted in Ghana have shown high rate of antibiotic resistance, which may be fuelled by 
the misuse and abuse of drugs by both patients and healthcare professionals through 
indiscriminate, partial and improper use [12-15]. Routine detection of ESBLs in primary and 
regional health facilities is absent in Ghana due to lack of both infrastructural capacity and 
expertise to detect these resistant carrying organisms [14]. This poses a great threat to patient 
care and infection control measures as most of the ESBLs are easily transmitted within the 
hospital setting between patients and health care workers [3]. While few studies have been 
done to assess this problem, the available information is scanty. Most of the studies focused 
on the phenotypic detection of ESBLs and the very few which incorporated molecular 
detection, limited their research to the detection of the most common ESBL conferring genes 
blaCTX-M, blaTEM and blaSHV [16-18].
  
Furthermore, no study in Ghana has investigated 
carbapenem resistance.  
This study was initiated to assess antimicrobial resistance among GNB isolated from wounds 
of patients and the environment of two primary health care centers and provides baseline data 
on a broad spectrum of resistance genes for Ghana.  
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Materials and Methods 
Bacterial strains 
Two hundred (n=200) Gram-negative bacterial isolates from wounds of  patients attending 
two health centers in the Ga district of the Greater Accra region of Ghana between May 2010 
and January 2014 were used in the study. The isolates consisted of 81 P. aeruginosa, 37 
Proteus mirabilis, 26 Enterobacter cloacae, 25 Klebsiella pneumoniae and 23 Escherichia 
coli isolates. The isolates were cultured aerobically from swab samples collected from the 
undermined edges of the wounds and inoculated on MacConkey (Oxoid Ltd, Basingstoke, 
UK) and Blood agar (Oxoid blood agar base with 5% sheep blood, Oxoid Ltd Basingstoke, 
UK). Bacterial isolates were identified presumptively based on morphology and oxidase 
reaction and further confirmation was done using the Analytical Profile Index 20E (API20E) 
strips (bio-Mérieux SA, Marcy-l’É’toile, France). 
 
Antibiotic susceptibility testing 
Antibiotic susceptibility of the isolates to the following antibiotics: amikacin (30μg), 
gentamicin (10μg), tobramycin (10μg), ceftriaxone (30μg), cefuroxime (30μg), cefotaxime 
(30μg), ceftazidime (30μg), sulphamethoxazole-trimethoprim (23.75µg/1.25μg), 
ciprofloxacin (5μg), aztreonam (30μg), ticarcillin-clavulanic acid (75µg/10μg), ampicillin 
(10μg), chloramphenicol (30μg), colistin (10μg) and imipenem (10μg) was determined by the 
Kirby-Bauer disc diffusion method according to CLSI standards [19]. Additionally, P. 
aeruginosa isolates were tested against streptomycin (10μg) and rifampicin (5μg). The 
antibiotic discs were purchased from Oxoid (Oxoid Ltd, Basingstoke, UK) and Becton 
Dickinson (Becton, Dickinson and Company, New Jersey, USA). MDR in P. aeruginosa was 
defined as a resistance of ≥ 1 antimicrobial agent in ≥3 antimicrobial classes of 
aminoglycosides (gentamicin, tobramycin, amikacin), antipseudomonal carbapenems 
(imipenem, meropenem doripenem), antipseudomonal cephalosporins (ceftazidime, 
cefepime), antipseudomonal penicillins and β-lactamase inhibitors (ticarcillin-clavulanic acid, 
piperacillin-tazobactam), monobactams (aztreonam) and polymyxins (colistin, polymyxin B).  
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Phenotypic detection of ESBL  
Each bacterial isolate was first screened for ESBL production by the disc diffusion method 
using the antibiotics ceftriaxone (30μg), cefotaxime (30μg), ceftazidime (30μg) and 
aztreonam (30μg)  according to CLSI guidelines [19]. An isolate with reduced susceptibility 
to any of the four antibiotics was subjected to confirmatory testing. 
ESBL confirmation was done in a stepwise manner involving three methods; the 
recommended CLSI double disc confirmatory method [19], the modified CLSI confirmatory 
test [20] and a combination disc method using discs of cefepime alone and in combination 
with clavulanic acid [21]. All screen-positive isolates were first tested with the CLSI 
confirmatory test using discs of ceftazidime and cefotaxime alone and in combination with 
clavulanic acid. Isolates not confirmed by the CLSI method were further tested by the 
modified CLSI ESBL confirmatory test. Furthermore, E. cloacae and P. aeruginosa isolates 
with known chromosomal AmpC’s, which tested negative with both methods were further 
tested with a combination of cefepime (30µg) with and without clavulanic acid (10µg). E.coli 
ATCC 25922 and K. pneumonia ATCC 700603 were used as negative and positive controls 
respectively. 
In addition, isolates of P. mirabilis, K pneumoniae and E. coli were investigated for other 
mechanisms which could contribute to the negative ESBL confirmatory test such as AmpC. 
Discs of cefoxitin (30µg) and an AmpC detection set (D69C, MastGroup Ltd) were employed 
for the confirmation of chromosomal or plasmid acquired AmpC within these isolates. 
Isolates resistant to cefoxitin were suspected of having an AmpC and confirmation was done 
using the AmpC detection test kit. The kit contained three discs of combinations of a 
cephalosporin (cefpodoxime 10µg) with an AmpC inducer (disc A), an AmpC inducer and an 
ESBL inhibitor (disc B) and an AmpC inducer, an ESBL inhibitor and an AmpC inhibitor 
(disc C). An organism was classified AmpC positive if zone sizes of C-A and C-B were 
≥5mm and negative if all zone sizes were within 3mm.  
Phenotypic detection of MBL producers 
The isolates were first screened for MBL production by the disc diffusion method using discs 
of imipenem (10 μg). Isolates with a reduced susceptibility to imipenem were confirmed for 
MBL production using the double disc potentiation method [22]. Briefly, Mueller Hinton 
agar plates were inoculated with 0.5 McFarland bacterial suspensions by streaking evenly. 
 
 
185 
 
Two imipenem (10 μg) discs were then placed 10mm apart on the plate after which 10μl of 
0.5M EDTA was added to one of the imipenem discs to obtain a concentration of 750μg and 
the plates incubated at 37
0C overnight. Isolates with an increase in zone size of ≥ 7mm 
between the imipenem only and imipenem EDTA discs were confirmed as MBL producers. 
 
Detection of ESBL and carbapenem encoding genes 
Crude genomic DNA from isolates was extracted by boiling a loopfull of overnight cultures 
in 200µl sterile distilled water for 20 minutes.  The following genes blaCTX-M, blaTEM, blaSHV, 
blaIMP-1, blaVIM-1, blaOXA-2, blaOXA-48, blaNDM, blaKPC and blaSPM were sought using the 
primers and cycling conditions listed in table 1[23-30]. The PCR reaction mixture contained 
4µl 5x FIREPol
®
 Mastermix (containing FIREPol
®
 DNA Polymerase, 5x Reaction buffer, 
12.5mM MgCl2 and 1mM of each dNTPs), 0.6 µl 10mM concentration of each primer, 
12.8µl nuclease free water and 2µl of template DNA. PCR products (8 µl) were 
electrophoresed in 1% agarose gel, stained in a gel red bath and detected by ultraviolet (UV) 
transillumination. Amplicons were sized by comparing with a 1kb ladder (Promega 
Corporation, Madison, WI).  The blaCTX-M positive isolates were further sub-classified into 
blaCTX-M1, blaCTX-M2 and blaCTX-M9 groups. 
 
 
 
 
 
 
 
 
 
 
  
 
 
186 
 
Results 
Antibiograms of bacterial species 
Among the Enterobacteriaceae tested, resistance to sulphamethoxazole-trimethoprim (82/111, 
73.8%), chloramphenicol (83/99, 84%), cefuroxime (70/111, 63.0%), ticarcillin-clavulanic 
acid (79/111, 71.2%) and ampicillin (57/60, 95.0%) were recorded at high frequency (Table 
2). Resistance rates to gentamicin (22/111, 19.8%), amikacin (28/111, 25.2%) tobramycin 
(40/111, 36.0%) as well as ciprofloxacin (26/111, 23.4%), colistin (36/79, 45.6%) and 
imipenem (6/111, 5.4%) were lower (Table 2).  
The resistance rate for P. aeruginosa to ceftriaxone (70/89, 79.0%), cefotaxime (80/89, 90.0), 
ticarcillin clavulanic acid (61/89, 68.5) and streptomycin (49/89, 55.0) was high and that 
against gentamicin (19/89, 21.3%), amikacin (18/, 20.2%), tobramycin (5/89, 5.6%), 
ciprofloxacin (9/89, 10.1%), aztreonam (30/89, 34.0), colistin (8/89, 8.9) and imipenem 
(2/89, 2.2%) was relatively lower. Twenty four isolates of P. aeruginosa were identified as 
MDR. 
Resistance rates of the Enterobacteriaceae to the third generation cephalosporins; ceftriaxone 
and cefotaxime were lower in contrast to higher rates observed among the P. aeruginosa 
isolates (Table 2). However, resistance to ceftazidime was low among all the bacterial 
groups.  
 
ESBL and MBL strains  
A total of one hundred and forty-nine (149/200) isolates were screen-positive for ESBL 
comprising 84/89 P. aeruginosa, 21/37 P. mirabilis, 15/25 K. pneumonia, 6/23 E. coli and 
23/26 E. cloacae. Out of these, 12 (7.8%) were confirmed as ESBL by the recommended 
CLSI confirmatory test while 98 (65.7%) isolates mostly P. aeruginosa (n=65, 66.3%) 
showed extended-spectrum cephalosporin (ESC) resistance but no synergy between the 
clavulanate and the ESC. 
Further testing of these 98 isolates by other methods confirmed 14 (14.3%) as ESBL 
producers (Table 3) with eight (8.2%) confirmed by the modified CLSI method and 6 (6.1%) 
by the cefepime/cefepime clavulanic acid double disc combination test. Hence out of the 149 
isolates, 26 (17.4%) were confirmed as ESBL producers by the three methods. 
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Among the ESC-resistant isolates of K. pneumoniae, P. mirabilis, and E. coli, AmpC’s were 
detected in 8 including  K. pneumoniae (3), P. mirabilis (4) and E. coli (1) by the Mast Group 
AmpC detection test kit which could account for the negative confirmatory test in these 
isolates (Table 3). MBL production was confirmed in three isolates comprising P. aeruginosa 
(2) and one K. pneumoniae (1) (Table 3). 
 
 
ESBL and carbapenemase encoding genes 
Among the ESBL encoding genes tested, blaCTX-M, blaTEM, blaSHV and blaOXA-2 were detected 
in 36 (24.2%), 33 (22.1%), 14 (10.1%) and 23 (15.4%) of the isolates, respectively. One 
ESBL gene was identified in 44 isolates, two genes in 27 isolates, and all three genes in three 
K. pneumoniae isolates (Table 4). Further classification of CTX-M genes identified Group 1 
(n=7) and Group 9 (n=2). All together, 50% of the analyzed isolates harboured at least one 
ESBL encoding gene. 
The carbapenemase encoding genes detected were blaVIM-1 (34, 17%), blaNDM (50, 25%), 
blaIMP-1 (2, 0.5%) and blaKPC (20, 10%) while no isolate harboured blaSPM and blaOXA-48 
genes. We did not identify any carbapenemase encoding genes in 118 isolates, one gene only 
was detected in 60 isolates, 21 isolates harboured 2 genes each (Table 5) and three genes 
(blaNDM+ blaVIM-1+ blaKPC)  were identified in 1 K. pneumoniae isolate. In total, 82 isolates 
making 41% of total isolates harboured ß-lactam genes coding for carbapenemases. 
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Discussion 
Antibiotics are an essential part of health care in Ghana where the burden of infectious 
diseases requiring antibiotic treatment is very high. This study aimed to 1) determine the 
phenotypic antimicrobial resistance profile of GNB and 2) identify some genes mediating 
resistance to ESBLs and carbapenems. Our analysis revealed that 1) the GNB studied have a 
high rate of resistance to the common first-line drugs and relatively lower rates of resistance 
to the injectables gentamicin, amikacin, tobramycin and carbapenem antibiotic imipenem, 2) 
there is a high level ß-lactam resistance mediated by a wide range of extended spectrum ß-
lactamase and carbapenemase genes 3) phenotypic detection of ESBL’s may be challenging 
and require more than one method for confirmation. 
The high resistance to ampicillin, chloramphenicol, cefuroxime and sulphamethoxazole-
trimethoprim has also been reported by a nationwide surveillance of antimicrobial resistance 
in Ghana recently published by Opintan [31] and studies from Uganda [32], Nigeria [33] and 
Tanzania [34]. These antibiotics are old, cheap and commonly prescribed as first line 
treatment drugs for many bacterial infections. They are also easily acquired over-the-counter 
and without prescription which has contributed to their abuse and misuse due to the non-
existence of a developed regulatory machinery to enforce the National Drug Policy [35]. 
They are also commonly used in animal husbandry as growth supplements to prevent 
infection and increase yield; thus residues are easily passed on to humans when they ingest 
food [36-37]. These results therefore call for the urgent set up of a surveillance system to 
monitor antibiotic use and also the strict enforcement of rules that govern the use of 
antibiotics in the country. 
We however found comparably low resistance to the injectables gentamicin, amikacin and 
tobramycin and this correlates with findings from Opintan [31]. The low rates may be 
attributed to the limited use of these antibiotics due to their mode of administration, high cost 
which discourages self medication and also the fact that they are only prescribed for serious 
and life threatening infections. In contrast, streptomycin, which is also an injectable 
aminoglycoside, recorded high resistance. This finding is not surprising as high resistance of 
different pathogens to streptomycin (>20%) including Mycobacterium tuberculosis (Mtb) 
[38]  and E. coli [39] from both human and animal sources have been recorded in Ghana. 
Streptomycin, which until recently was used as a first-line treatment drug for tuberculosis 
(TB) has been widely used in Ghana where TB prevalence is 282 per 100,000 in the 
population (http://www.who.int/tb/country/data/profiles/en/). It is also widely used in animal 
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husbandry for treatment and disease prevention [40]. Thus the observed high resistance is 
evidence of the selection pressure provided by years of streptomycin use in both human and 
veterinary medicine. Our findings also suggest that there is very little or no possible cross 
resistance among the aminoglycosides analysed in the study. 
 Carbapenem antibiotics are the last choice in treatment of infections due to ESBL producing 
organisms; the low resistance to imipenem detected in this study correlates with findings  by 
Hackman [41] and Adu-Sarkodie [42]. Interestingly meropenem, the only carbapenem 
approved for use in Ghana has also recorded no resistance so far [15] even though it has been 
on the market since 2002. Thus carbapenems may currently be the best choice for treatment 
of infections, however caution should be taken in their use, as prolonged systemic therapy 
would select for resistant strains. 
The proportion of MDR P. aeruginosa isolates detected in this study was high (27.0%) 
compared to 9.5% in an Egyptian study [43]. Infection with MDR P. aeruginosa has been 
associated with adverse clinical outcomes such as increased morbidity and mortality, 
prolonged hospitalization and the need for surgical interventions. Due to the limited 
therapeutic options available in treating infections by MDR strains of P. aeruginosa, it is 
important to optimize infection control and stewardship strategies especially in heath care 
settings where such strains are commonly found. 
Genes implicated in conferring ESBL (50%) and carbapenem resistance (41%) were 
frequently detected in the study. The most prevalent ESBL type in this study was the TEM 
type, which is similar to findings by Feglo [17] in Kumasi, Ghana but in contrast to research 
by Hackman [41] in Accra, Ghana who detected CTX-M as the most predominant type. 
Though CTX-M types are known as the most prevalent ESBL type globally [16-17, 44-50], 
the percentage within our study was very low, which could be explained as due to the low 
levels of the main ESBL producers K. pneumoniae and E. coli [3]  (23.9%) in this study. No 
SHV-type ESBLs were identified among the P. aeruginosa isolates and research has reported 
only rare isolates of P. aeruginosa harbouring these genes [51-52]. TEM genes were detected 
in 50% of P. mirabilis isolates which is consistent with studies that found these bacteria to be 
associated with the production of TEM-type enzymes [53-57]. 
The carbapenemase encoding genes detected in this study were IMP, VIM-1, NDM and KPC 
with NDM being the most prevalent. Of particular concern is the presence of NDM and KPC 
genes, which have become major foci of worldwide attention as the acquisition of KPC is 
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characterized by multi drug resistance with very limited therapeutic options, thus associated 
with significant morbidity and mortality. Its worldwide emergence and the difficulty in 
identifying them in routine susceptibility screening tests poses an infection control challenge 
to the health care system [58]. The NDM gene on the other hand is associated with non 
clonally related isolates and species. The gene encoding this enzyme is also found on 
plasmids of different sizes with significant mobility and could be present in different GNB 
from one patient [59]. It has also been identified as a source of community acquired infection 
[60]. Carbapenemase production is neither associated with the expression of specific 
virulence factors nor specific clinical infection but to difficult-to-treat infections. Due to their 
rapid and global expansion, the epidemic potentials of Enterobacteriaceae producing such 
enzymes cannot be downplayed and more collaboration is needed between clinicians and 
reference or public health laboratories in identifying and preventing infections due to 
carbapenem producers.  
In identifying carbapenemase producers, the molecular detection of carbapenem encoding 
genes was used as the primary result in this study. Though potential carbapenem producers 
could be identified by phenotypic susceptibility testing, many carbapenemase producers do 
not confer obvious resistance levels to carbapenems [61]. Also, MBL detection methods 
which are based on ß-lactam-chelator combinations have been shown to work well for K. 
pneumoniae and E. coli isolates but have not been thoroughly tested for other Enterobacteria 
[62]. In addition, the development of phenotypic tests for the detection of OXA-type 
carbapenemases has been hindered due to their enzymatic properties which prevents their 
inhibition by clavulanic acid, tazobactam, sulbactam or other zinc chelators [62]. Thus the 
molecular method is considered the reference standard and was applied in this study as such. 
 
The study also highlights the challenges encountered with the phenotypic detection of 
ESBLs. Three methods were combined to confirm ESBL production in 26 isolates. ESBLs 
occur in many Enterobacteriaceae but the current confirmatory tests which rely on the 
synergy between the extended-spectrum cephalosporin and clavulanate are recommended 
only for the detection and confirmation of ESBLs in K. pneumoniae spp, E. coli and P. 
Mirabilis [19]. This will lead to non-detection of many producers as no guidelines currently 
exist for the detection and reporting of ESBLs in other members of the Enterobacteriaceae.  
Additionally, the co-existence of ESBLs with other ß-lactamase types (KPC and MBL) and 
other mechanisms of ß-lactam resistance (AmpC, carbapenemases and overproduction of 
cephalosporinases) further complicate their phenotypic detection [20, 63-65]. MBL and KPC 
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hydrolyze ESBL’s while the existence of the other mechanisms masks their presence leading 
to underestimation of their true prevalence in phenotypic screening tests.  Though molecular 
assays may provide accurate results in the detection of ESBL genes, they are inaccessible to 
many laboratories and are also expensive. The confirmatory tests used in this study in 
addition to the standard CLSI method have been proposed by other research groups to 
improve the detection of ESBLs in the presence of other mechanisms and we were able to 
confirm 14 other isolates as ESBLs. Our findings therefore support the suggestion that the 
current CLSI confirmatory method is inadequate in detecting ESBLs in the presence of other 
mechanisms [20, 64, 66-67]. As a single ESBL-producing isolate may have multiple 
mechanisms of resistance, it is important to have an accurate phenotypic detection assay 
capable of detecting ESBLs regardless of the underlying resistant mechanism. In the absence 
of such an assay, we propose the harmonization of different methods to improve ESBL 
detection in the clinical laboratory. 
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Conclusions 
Based on our findings, Ghana needs to put in place mechanisms to regulate the sale of 
antibiotics, as many are easily accessible over the counter. Antimicrobial surveillance 
systems to monitor drug resistance within the country also need to be set up and policies, 
which guide the rationale use of antibiotics, must be strictly enforced. The challenges 
associated with the phenotypic detection and confirmation of ESBL requires a combination of 
methods to confirm the different mechanisms.  
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TABLE 1: Primers for detection of ESBL and Carbapenem genes 
Primer Sequence 5’- 3’ Band size bp PCR Conditions References 
TEM-1 F ATG AGT ATT CAA CAT TTC CG  867 95
0
C–5min,30(950C-30sec,500C1.30min, 720C-
1.30min), 72
0
C-10min, 4
0
C-∞ 
[29] 
TEM-1 R CTG ACA GTT ACC AAT GCT TA  
CTX-F CGCTTTGCGATGTGCAG 550 95
0
C–5min, 30(950C-30sec,500C-1.30min,720C-
1.30min), 72
0
C-10min, 4
0
C-∞ 
[23] 
CTX-R ACCGCGATATCGTTGGT 
SHV 1 GGG TTA TTC TTA TTT GTC GC  900 95
0
C–5min, 30(950C-30sec,560C-1.00min,720C-
1.30min), 72
0
C-10min, 4
0
C-∞ 
[29] 
SHV 2 TTA GCG TTG CCA GTG CTC  
OXA II F  AAG AAA CGC TAC TCG CCT GC  478 95
0
C–5min, 30(950C-30sec,620C-1.00min,720C-
1.00min), 72
0
C-10min, 4
0
C-∞ 
[28] 
OXA II R  CCA CTC AAC CCA TCC TAC CC  
NDM-F ACCGCCTGGACCGATGACCA 263 95
0
C–5min, 30(950C-30sec,620C-1.00min,720C-
1.00min), 72
0
C-10min, 4
0
C-∞ 
[25] 
NDM-R GCCAAAGTTGGGCGCGGTTG 
VIM 1-F AGTGGTGAGTATCCGACA 261 95
0
C–5min, 30(950C-30sec,540C-40sec,720C-
60sec), 72
0
C-10min, 4
0
C-∞ 
[26] 
VIM 1-R ATGAAAGTGCGTGGAGAC 
KPC-F CTTGCTGCCGCTGTGCTG 489 95
0
C–5min, 30(950C-30sec,580C-1.00min,720C-
1.30min), 72
0
C-10min, 4
0
C-∞ 
[24] 
KPC-R GCAGGTTCCGGTTTTGTCTC 
IMP 1-F ACCGCAGCAGAGTCTTTGCC 587 95
0
C–5min, 30(950C-30sec,580C-1.00min,720C-
1.30min), 72
0
C-10min, 4
0
C-∞ 
[26] 
IMP 1-R ACAACCAGTTTTGCCTTACC 
OXA 48-F TTGGTGGCATCGATTATCGG 743 95
0
C–5min, 30(950C-30sec,580C-1.00min,720C- [27] 
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OXA 48-R GAGCACTTCTTTTGTGATGGC 1.30min), 72
0
C-10min, 4
0
C-∞ 
SPM –F GCGTTTTGTTTGTTGCTC 786 950C–5min, 30(950C-30sec,510C-60sec,720C-
1.30min), 72
0
C-10min, 4
0
C-∞ 
[26] 
SPM –R TTGGGGATGTGAGACTAC 
CTX-M1F GCGTGATACCACTTCACCTC 260 95
0
C–5min, 30(950C-30sec,530C-1.00min,720C-
1.00min), 72
0
C-10min, 4
0
C-∞ 
[30] 
CTX-M1R TGAAGTAAGTGACCAGAATC 
CTX-M2F TGATACCACCACGCCGCTC 341 95
0
C–5min, 30(950C-30sec,500C-1.30min,720C-
1.30min), 72
0
C-10min, 4
0
C-∞ 
[30] 
CTX-M2R TATTGCATCAGAAACCGTGGG 
CTX-M9F ATCAAGCCTGCCGATCTGGTTA 293 95
0
C–5min, 30(950C-30sec,610C-1.00min,720C-
1.00min), 72
0
C-10min, 4
0
C-∞ 
[30] 
CTX-M9-R GTAAGCTGACGCAACGTCTGC 
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TABLE 2 Antibiograms of bacterial isolates 
Antibiotics Pseudomonas 
aeruginosa 
N=89   
n ,% 
Enterobacteriaceae 
Klebsiella 
pneumoniae 
N= 25  
n ,% 
Proteus mirabilis  
N= 37 
n ,% 
E. coli  
 
N= 23 
n ,% 
Enterobacter 
cloacae  
N= 26 
 n ,% 
Total 
 
n ,% 
NT
a
 R
b
 NT R NT R NT R NT R NT R 
Ceftriaxone 89 70, 79.0 25 10, 40.0 37 7, 18.9 23 5, 21.7 26 7, 27 111 29, 26.1 
Gentamicin 89 19, 21.3 25 6, 24.0 37 4, 10.8 23 7, 30.4 26 5,19.2 111 22, 19.8 
Tobramycin 89 5, 5.6 25 9, 36.0 37 8, 21.6 23 9, 39.1 26 14, 53.8 111 40, 36.0 
Cefuroxime ND
c
  25 12, 48.0 37 21, 57.0 23 18, 78.3 26 19, 73 111 70, 63.0 
Sulphamethoxazole-
Trimethoprim 
ND  25 15, 60.0 37 30, 81.0 23 19, 82.6 26 18, 69.2 111 82, 73.8 
Cefotaxime 89 80, 90.0 25 15, 60.0 37 11, 30.0 23 5, 21.7 26 15, 57.7 111 46, 41.4 
Ciprofloxacin 89 9, 10.1 25 4, 16.0 37 8, 21.6 23 8, 34.7 26 6, 23.1 111 26, 23.4 
Aztreonam 89 30, 34.0 25 5, 20.0 37 17, 46.0 23 6, 26.1 26 13, 50 111 71, 34.0 
Ticarcillin-clavulanic acid 89 61, 68.5 25 24, 96.0 37 10, 27.0 23 21, 91.3 26 24, 92.3 111 79,71.2 
Ceftazidime 89 10, 11.2 25 6, 24.0 37 6, 16.2 23 6, 26.1 26 11,42.3 111 29, 26.1 
Imipenem 89 2, 2.2 25 1, 4.0 37 4, 10.8 23 1, 4.3 26 0 111 6, 5.4 
Amikacin 89 18, 20.2 25 8, 32.0 37 6, 16.2 23 1, 4.3 26 13, 50 111 28, 25.2 
Colistin 89 8, 8.9 14 6, 43.0 35 22, 62.8 11 4, 36.4 19 4, 21.0 79 36, 45.6 
Chloramphenicol ND  20 15, 75.0 36 35, 97.2 20 17, 85.0 23 16, 69.5 99 83, 84.0 
Ampicillin ND  ND  37 34, 91.8 23 20, 86.9 ND  60 57, 95.0 
Streptomycin 89 49, 55.0           
a (NT)= number tested, b (R) =resistant, c (ND) =Not done; isolates are intrinsically resistant to antibiotics 
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TABLE 3: Phenotypic detection of ESBL, MBL and MDR strains 
Bacterial 
species  
No of 
isolates  
ESBL 
screening 
positive 
n (%)  
ESBL confirmation   n (%) AmpC  
n (%) 
MBL  
n (%)  
MDR  
n (%)  
ESBL+ MDR 
n (%)  
ESBL+ 
MDR+ 
MBL 
n (%)  
a
CLSI 
test 
Modified 
CLSI 
b
Cef/
c
Cef 
Clav 
Total 
Pseudomonas 
aeruginosa  
89 84 (94.5)  4/84 (4.7) 4/65 
(6.2) 
3/65 
(4.6) 
11/84 
(13.1) 
N/AP 2(2.2)  24(27.0)  24 (27.0)  2 (2.2)  
Proteus 
mirabilis  
37 21 (55.0)  1/21(4.8) 2/13 
(15.4) 
N/AP
d
 3/21 
(14.3) 
4 (28.6) 0 N/AP N/AP N/AP 
Klebsiella 
pneumoniae  
25 15 (57.6)  2/15(13.3) 0 N/AP 2/15 
(13.3) 
3 (42.9) 1 (3.8)  N/AP N/AP N/AP 
Enterobacter 
cloacae  
26  23 (88.5)  3/23(13) 2/12 
(16.7) 
3/12 (25) 8/23 
(34.8) 
N/AP 0 N/AP N/AP NA 
Escherichia 
 coli  
23  6 (26.1)  2/6(33.3) 0 N/AP 2/6 
(33.3) 
1 (100) 0 N/AP N/AP N/AP 
Total  200 149 (74.5)  12/149  
(8.0) 
8 (8.2) 6 (7.8) 26/149(
17.4) 
8 (38.1) 3 (2.6) 24(27.0) 24(27.0) 2 (2.2) 
a CLSI = Clinical Laboratory Standards Institute, b Cef =Cefepime, c Cef/Clav= Cefepime-Clavulanic acid, d (N/AP)= not applicable
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TABLE 4: ESBL genes detected in isolates 
Bacterial 
species 
 
N 
Isolates with one gene only n (%) Isolates with two genes identified n (%) 
CTX-M TEM-1  SHV OXA-2  Total CTX+TEM-
1 
CTX+SHV CTX+OXA-2 TEM-
1+SHV 
TEM-
1+OXA-2 
SHV+OXA-2 Total 
Pseudomonas 
aeruginosa 
84 12 
(63.2) 
1 (5.3) 0 6 (31.6) 19 
(22.6) 
5 (33.3) 0 8 (53.3) 0 2 (13.3) 0 15 (18) 
Klebsiella 
pneumoniae 
15 0 1 (25) 3 
(75) 
0 4 
(26.7) 
0 1 (14.3) 1 (14.3) 4 (57.1) 0 1(14.3) 7 (46.7) 
Proteus 
mirabilis 
21 0 9 (100) 0 0 9 (43) 0 0 0 0 0 0 0 
E. coli 6 3 (75) 1 (25) 0 0 4 
(66.7) 
0 0 0 0 0 0 0 
Enterobacter 
cloacae 
23 0 5 (62.5) 0 3 (37.5) 8 
(34.8) 
0 1 (20) 2 (40) 2 (40) 0 0 5 (33.3) 
Total 149 15 
(10.1) 
17 
(11.4) 
3 (2) 9 (6) 44 
(29.5) 
5(3.4) 2 (1.3) 11 (7.4) 6 (4.02) 2 (1.3) 1 (0.7) 27 
(18.1) 
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TABLE 5: Carbapenem genes detected in isolates 
Bacterial species  
N 
Isolates with one gene only n (%) Isolates with two genes identified n (%) 
NDM VIM-1  KPC IMP-1  Total NDM + VIM-1 NDM+KPC VIM 1+KPC Total 
Pseudomonas aeruginosa 89 23 (72) 1 (3.1) 8 (25) 0 32 (36) 5 (45.5) 5 (45.5) 1 (9.1) 11 
(12.4) 
Klebsiella pneumoniae 25 2 (16.7) 7 (58.3) 2(16.7) 1 (8.3) 12 (48) 3 (75) 0 1 (25) 4 (16) 
Proteus mirabilis 37 1 (33.3) 2 (66.7) 0 0 3 (8.1) 0 0 0 0 
E. coli 23 0 2 (100) 0 0 2 (8.7) 0 0 0 0 
Enterobacter cloacae 26 4(36.4) 5 (45.5) 2 (18.2) 0 11 (42.3) 6 (100) 0 0 6 (100) 
Total 200 30 (15) 17 (8.5) 12 (6) 1 (0.5) 60  (30) 14 (7) 5 (2.5) 2 (1) 15 
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Discussion 
The first diagnosis of Buruli ulcer in Ghana was made in the Greater Accra Region in 1969  
in a 7 year old girl admitted at the Korle-Bu Teaching Hospital [1]. Following from this, 
several other cases were identified in people who used the same water supply (River Densu 
and along its tributaries) as the infected patient. Years later, BU has been reported in all 10 
regions of Ghana in over 400 communities with the identification of numerous endemic foci 
[2]. A national crude prevalence of 20.7/100,000 in 1998 makes Ghana the second most 
endemic country reporting BU disease after Cote d’Ivoire [2] and makes BU the second most 
prevalent mycobacterial disease after tuberculosis. A nationwide case study identified ten 
districts in Ghana with the most caseloads of the disease and the highest and lowest 
prevalence of 150.8/100,000 and 57.0/100,000 in the Amansie West District in the Ashanti 
Region and the Kwawu South District of the Eastern Region respectively [2]. BU is found in 
many impoverished communities with low income and very limited access to resources. This, 
coupled with the fact that the treatment of the disease required surgery negatively impacted 
the health seeking behavior of BU patients for many years as the affected and their families 
were unable to shoulder the financial and economic pressure that came with treatment. The 
introduction of antibiotic treatment for BU therefore brought a welcome relief to many 
affected people as the fear of surgery was reduced and patients were more willing to seek 
treatment at the biomedical facilities. However, observations made across several health 
centers showed that despite antibiotic therapy, the healing process was often still associated 
with long hospital stays before wound closure was achieved. Healing delay, wound 
deterioration and skin graft failure was frequently observed among affected patients and the 
quest to understand these observations led to the initiation of the current studies. Within the 
scope of this PhD thesis, we have identified secondary infection of BU lesions by other 
bacteria (Chapter 2) as a possible contributing factor to delayed wound healing in BU 
disease. We also discovered other factors which could challenge the management of the 
disease such as the evolution of the bacterial burden (Chapter 3) and HIV co-infection 
(Chapter 4). Studying the bacteria isolated from the lesions through phenotypic, molecular 
and whole genome sequencing approaches has helped us to gain an understanding of the 
source and diversity of the bacteria causing secondary infection. These analyses revealed 
widespread antibiotic resistance as a serious problem in Ghana which could have major 
detrimental consequences for health care if not addressed promptly (Chapters 5, 6 and 7). 
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Early case detection to achieve fast healing of BU lesions 
The Greater Accra Region where this study was conducted is the third most prevalent BU 
reporting region (18.5/100,000) and the former Ga District in this region was the fifth most 
prevalent BU reporting district (87.7/100,000) in Ghana till it was split into the Ga-South and 
Ga-West Municipalities in 2009. The study was carried out in two main health centers, the 
Obom Health Center in the Obom sub-district of the Ga-South Municipality and the Ga-West 
Municipal Hospital. The most severe forms of BU disease in Ghana is currently reported in 
these two municipalities [3]. With the introduction of antibiotic therapy (SR8) for the 
treatment of BU and the various successes reported by this treatment regimen, we observed in 
these health centers that a number of cases still stayed post SR8 for extended periods of time 
- at times over two years - before complete wound closure was obtained. Clinical 
observations led us to investigate if secondary infection by other bacteria could contribute to 
the frequently observed healing delay. Analysis of BU lesions before, during and after SR8 
revealed that secondary infection is common in BU disease (Results, Chapter 2) despite the 
belief that it was unlikely because of the presence of mycolactone which was thought to exert 
a sterilizing effect on the lesions [4]. However, no antimicrobial activities have been found in 
studies with synthetic mycolactone [5].  
Our study revealed that most cases present at health centers with lesions that are already 
clinically and microbiologically infected (Results chapter 2). Late reporting of cases is 
frequently observed in BU disease with patients presenting with large ulcers [6-7]. Studies 
have revealed that biomedical health facilities are often not the first point of call for BU 
patients [6, 8-10]. The health seeking behaviour of BU affected patients is deeply rooted in 
their socio-cultural beliefs and practices. In many communities, an unhealing wound is 
thought to be caused by spiritual forces, charms, witches, ancestral spirits or even the gods of 
the land [8]. As a result, traditional healers and witch doctors are first consulted to deal with 
the spiritual forces suspected to cause the disease. Some patients will also practice self-
treatment at home. Because the early clinical manifestations of the disease which could be a 
painless nodule, plaque or a small ulcer, will not be perceived as serious, patients will attempt 
to administer ‘first aid’ at home. Thus cases may only report to the biomedical health centers 
after all efforts have been exhausted by these various approaches and no improvement has 
been seen. Large wounds are therefore presented which may have been treated over long 
periods of time with various concoctions usually not prepared under aseptic conditions. 
Secondary infections may therefore contribute to healing delays in such cases. Currently, 
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various strategies including active case search and the engagement of former patients and 
traditional healers in referring cases is being practiced in both Ghana and Cameroon [3, 11] to 
ensure early detection and timely healing. 
Wound bacterial load and HIV can complicate management of BU lesions 
Wound infection is not only dependent on the presence of infecting bacterial species but also 
on their numbers. Various studies on wounds with other etiology have demonstrated that 
levels of bacteria above 10
5
cfu/ml are a critical level in the prediction of wound infection and 
wound healing outcomes [12-16]. Above this level, negative outcomes such as wound healing 
impairment and breaking of grafts has been reported.  We quantified the bacterial load of 86 
BU patients through a cross-sectional study and found that the majority of BU wounds before 
(62%), during (65%) and post treatment (77%) had bacterial levels above this limit (Chapter 
2). We further investigated the evolution of the bacterial load at all three stages in 
longitudinally analysed patients (Chapter 3) and found that the bacterial load was higher pre 
and post treatment when no antibiotic therapy was being taken, but lowered during antibiotic 
treatment. While the Wound Healing Society views the microbial load and the presence of 
beta-hemolytic streptococci as the best predictors of wound infection [17], clinicians usually 
rely on clinical signs and symptoms in their diagnosis of wound infection. However, clinical 
signs are not always expressed in chronic disease states; for example in diabetic foot ulcers, 
inflammatory responses to infection is often impeded by peripheral vascular disease, 
hyperglycemia, oxygenation, neuropathy and anti-inflammatory drug use among others [18-
19]. The immunosuppressive property of mycolactone in BU disease also has the potential to 
dampen first-line inflammatory responses to wound infection [20]. Therefore determining the 
bacterial load appears to be a valuable component of wound management even in the absence 
of overt clinical signs and guidelines for wound care should include practices aimed at 
reducing the bacterial load.  
Apart from the bacterial load, HIV co-infection can also complicate the management of BU 
(Chapter 4). HIV infection and BU epidemiologically overlap in Sub-Saharan Africa which 
accounts for more than 80% of globally reported HIV infections [21]. We reported a higher 
prevalence of HIV among BU patients compared to that of other patients attending the health 
facility and this has also been reported in Cameroon and Benin [22-23]. While it is clearly 
known that HIV/AIDS which leads to reduced CD4 helper T cell activity is a risk factor for 
tuberculosis, immune protection mechanisms in BU disease are not fully understood. There is 
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growing evidence, that HIV infection is affecting the clinical presentation, disease severity 
and mortality of BU cases, but the actual impact of HIV/AIDS on BU disease is not fully 
characterized [21, 23-26]. In this context, we also reported a case of disseminated disease in a 
BU patient co-infected with HIV (Chapter 4). Even though preliminary guidelines exist in the 
management of BU-HIV co-infection [27], there is a lack of information on the impact of 
antiretroviral therapy (ART) on the incidence and severity of paradoxical reactions which 
have been reported in HIV cases on ART co-infected with other microorganisms such as TB 
[28], Cryptococcus [29] and Mycobacterium avium complex [30]. More research is therefore 
needed to fill the knowledge gaps that exist in the interaction between BU and HIV and the 
effect of both ART and SR8 on treatment outcomes. HIV testing is currently standard in BU 
management; therefore integration of HIV treatment centers with BU treatment centers  
should jointly facilitate timely management and the provision of best models of care.  
 
Decentralized treatment of uncomplicated cases to avoid nosocomial infections  
Many different infecting bacterial species which could negatively impact on the healing 
potential of the wounds were isolated from the lesions of our study patients within the course 
of the study. Some of these bacterial species are known nosocomial pathogens and led us to 
investigate the source of these pathogens into the wounds. Through a combination of 
phenotypic, molecular (spa typing) and whole genome sequencing approaches, we identified 
health-center and patient sources of infection 8 (Chapter 5). 
Most health centers in BU endemic areas are low resourced and not adequately equipped to 
manage the wounds presented or the number of patients reporting at a time. The pressure 
placed on the limited available resources leads to compromises in good wound care practices 
ultimately affecting the management of cases. The benefit of improved infection prevention 
and control practices (IPC) in reducing health-care associated infections cannot be over-
emphasized. Though IPC guidelines exist in many health centers, research has shown that 
compliance among health care workers to these guidelines is low. One reason for the non-
compliance is understaffing at health facilities. The doctor-patient ratio in the Greater Accra 
and Northern regions of Ghana has been reported to be 1:3,712 and 1:21,751, respectively. 
The physician density per 1000 population is 0.13 and 0.04 in urban and rural areas of Ghana, 
respectively, while the density of nurses is 0.60 (urban) and 0.20 (rural) per 1000 population. 
Thus health centers are widely understaffed and this imbalance in health worker to patient 
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ratios impacts on access to good health care. There is the need for more health care workers 
to be recruited to health facilities and for adequate materials and equipment to be provided 
for health centers to reduce the occurrence of health-care associated infection of wounds. 
Providing incentives and improving remuneration of health workers will attract more people 
into the sector and greatly help to reduce the problem of understaffing that currently exists. 
Additionally, treatment of BU cases can be decentralized to reduce the pressure usually 
placed on secondary health facilities and health workers in these facilities. Small 
uncomplicated BU cases can be treated at peripheral health centers and CHPs compounds 
instead of the secondary health centers which should only be used as reference centers for 
complicated cases. This will go a long way to reduce pressure on the health workers and 
resources and the fewer patients will receive better care and attention.  
Apart from deficiencies in health care provision, also patient behavior was found to have 
negative effects on wound healing. Patient adherence to biomedical treatment protocols is 
largely influenced by their financial status and their socio-cultural beliefs. Leaders of BU 
endemic countries agreed in the Yamoussoukro declaration that treatment of BU should be 
free. This however, is not entirely the case as the burden of wound management usually falls 
on the patients, leading to considerable costs which they are often unable to shoulder over 
longer periods of time. This has led to practices such as the recycling of bandages used in 
wound dressing. Sampling of some of these bandages showed that they were contaminated 
with the same type of bacterial pathogens as isolated from patient lesions indicating that they 
were not being washed properly before reuse and may be a source of re-infection. 
Consequently, we also identified the same bacterial species in multiple lesions of a patient 
pointing to a common source of infection. Apart from the recycling of bandages, some 
patients also redressed their wounds after health care workers had dressed them. This practice 
is largely influenced by patient’s beliefs and perceptions regarding the management of 
wounds. Koka’s study revealed that many patients know that wound care is delicate; however 
their response to wound management is deeply rooted in community perceptions of who 
qualifies to handle a wound. Pregnant women, breastfeeding mothers, women in their 
menstrual period and promiscuous young women are some of the people believed to be 
unqualified to manage wounds. It is believed that wounds dressed by any of these people will 
not heal or heal fast. Thus patients resorted to redressing their wounds if a health care worker 
fell into this category and this could lead to the infection of wounds through transfer from 
other body sites. To reduce the occurrence of self-infection, significant investment must be 
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made into wound care. Patients also need to be educated on the need to adhere to the 
biomedical treatment provided at the health centers to ensure faster healing of lesions.  
The study also revealed the urgent need for proper wound management guidelines for BU. 
Apart from antibiotic therapy, wound care is very important in the management of affected 
cases; however no clear guidelines exist to guide wound management. The management of 
wounds is therefore left to the discretion of health care workers whose practices may not be 
optimal. This led us to make recommendations for proper wound management. In line with 
this, a wound care manual has been developed to educate health care workers on proper ways 
of managing wounds. Accordingly, training programs for health care workers within these 
two districts have been organized with the assistance of the National Buruli Ulcer Control 
Programme and experts from the Plastics and Burns unit of the Korle-Bu Teaching Hospital. 
However, constant refresher courses and monitoring is needed to ensure that these guidelines 
are adhered to. 
Preference of good wound management over extensive use of additional antibiotics  
No guidelines currently exist for the management of BU wounds secondarily infected with 
other bacterial pathogens. Specific guidelines are needed to know whether infected wounds 
should be treated with antimicrobial agents, the type of antimicrobial agents to use and 
whether topical or systemic antimicrobials should be administered. The definition of infection 
in many cases is subjective. Thus clinicians are unsure of whether antibiotic therapy should 
be administered especially in cases without evident clinical signs and symptoms. However, 
the prescription of antibiotics for secondary infection is widespread among BU patients with 
non-healing wounds [31]. Studies have found no evidence to support the use of systemic 
antibiotics in wound healing and evidence is also lacking on the required duration of 
treatment [32-34]. Therefore the use of antibiotics needs to be minimized as indiscriminate 
antibiotic use will contribute to the increasing problem of drug resistance.  
Guidelines for the management of diabetic foot ulcers specified by the Wound Healing 
Society indicates that a topical antimicrobial agent should be used on wounds with microbial 
loads > 1 x 10
6
 cfu/ml or any level of beta-hemolytic streptococci following adequate 
debridement to decrease the bacterial load as they will be more effective than systemic 
antimicrobials [17]. This treatment is however to be discontinued once the wound reaches 
bacterial balance to minimize cytotoxicity due to the antimicrobial agents and the 
development of resistance to the agent. The therapeutic efficacy of topical treatments is 
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compromised by the presence of necrotic or ischemic tissue. In such cases, surgical 
debridement can be employed and this will also lead to a significant reduction in the 
microbial load and expose healthy tissues needed for healing. This treatment protocol could 
be adapted for the management of BU wounds in the absence of definitive guidelines. 
In the absence of wound infection however, good wound care is adequate to ensure wound 
healing. The choice of the correct type of dressing materials, keeping the wound bed moist at 
all times, irrigating the wound with physiological saline solution during cleansing, managing 
pain and working under aseptic conditions are some of the practices that will promote timely 
wound healing. In addition, adequate nutrition addressing protein-calorie malnutrition and 
deficiencies in minerals and vitamins also helps in wound healing. Over the course of this 
project, to aid in the provision of good wound care in the treatment centers, we provided 
equipment, refurbished a dressing room and aided in feeding of patients by providing 
breakfast after their antibiotic therapy. The impact of these interventions has been seen in a 
reduction of the length of stay in the health centers and an increase in the number of wounds 
healing without surgical interventions (Yeboah-Manu, personal communication) 
 
Monitoring of the antibiotic resistance scenario in Ghana to avoid use of 'useless' 
antibiotics  
The discovery of antibiotics is one of the greatest medical achievements of the 20th century 
which brought transformation to modern medicine and prevented many deaths. Before the 
antibiotic era, wound infections were treated by amputation and an estimated 70% of 
amputations performed during World War 1 were indicated as a result of infection [35]. Also, 
high fatality rates were reported for pneumonia (40%) [36], S. aureus bacteremia (80%) [37] 
and endocarditis (97%) [38]. After the discovery of penicillin in 1928, its introduction into 
the healthcare system in the 1940’s and the subsequent introduction of many new antibiotics 
from the late 60’s to the 80’s fostered the belief that finally all bacterial infections could be 
treated. This victory over bacterial infections however was not to last with the emergence of 
resistant bacterial strains barely a decade after penicillin had been introduced. Bacteria posses 
a countless number of genetic elements for resistance to antimicrobials, which have evolved 
over millions of years. The inheritance of resistance genes, the acquisition of resistance 
elements on mobile genetic elements, horizontal transfer of resistance elements between 
species and the spontaneous occurrence of mutations leading to resistance are a few of the 
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ways by which bacteria develop resistance. Within our study, we reported wide-spread 
resistance among the isolated bacteria to commonly prescribed antibiotics and also identified 
multi-drug resistant strains of S. aureus and P. aeruginosa (Chapters 5, 6 and 7). 
The burden of infectious diseases in Africa is high. As such, consumption of antibiotics is 
also on the increase. In many African countries, a high level of antibiotic resistance has been 
reported to commonly prescribed antibiotics [39]. A direct relationship exists between the use 
of antibiotics and the emergence and dissemination of resistance. Increased consumption of 
antibiotics leads to selection pressure on bacterial populations to survive where the fittest are 
selected for; which in many cases are the resistant strains. In Ghana, antibiotics are prescribed 
for many infections. Antibiotic use however is largely empirical, as many health facilities 
lack laboratory facilities for appropriate diagnostic guidance. Doctors also easily prescribe 
broad spectrum antibiotics for patients they assume cannot wait for diagnosis or who will be 
unwilling to return because of distance and travel costs. Additionally, patients exert pressure 
on medical practitioners to prescribe antibiotics for them as there is a general belief that they 
have only been attended to properly, if antibiotics are prescribed. Thus antibiotics are 
frequently inappropriately prescribed or over-prescribed. The abuse of antibiotics through 
self medication and inappropriate use is also common. Access to antibiotics is largely 
unregulated and many antibiotics are cheaply and easily available over-the-counter without 
prescription (Figure 1).  
 
Figure 1: Easy access to antibiotics in Ghana 
Antibiotics are easily obtainable in market places from unlicensed chemical sellers or 
freelance medecine men. Figure adapted from Asare [40] 
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In many communities, access to antibiotics is through the activities of chemists, roadside 
stalls and freelance medicine men who gain access to higher classes of antibiotics due to 
unregulation of their activities. Antibiotic resistance in Ghana is also driven by the 
availability of poor quality antibiotics on the open market. The prevalence of counterfeit, 
substandard and degraded antimicrobials is a persistent occurrence in Ghana and even though 
various efforts have been made by authorities to cleanse the markets of such products, they 
still find their way back after a while. Antibiotics are also widely used in agriculture to 
increase production and act as supplements for livestock. These are then ingested by humans 
when they consume food products treated with antibiotics which results in the transfer of 
resistant bacteria from livestock to humans. The effect of this unrestricted use of antibiotics 
has been the emergence of multi-drug resistant organisms which have become the current 
threat to health care worldwide. The past 50 years has seen an accelerated increase in the 
evolution and dissemination of multi-drug resistant organisms [41] and whole genome 
analysis of methicillin resistant S. aureus (MRSA) isolates revealed the recent emergence and 
rapid spread of a community-acquired MRSA clone (ST88-IV) in Ghana (Chapter 6).  
The negative effects of antibiotic resistance are extensive and do not impact the affected 
patients alone but stretch to the healthcare system and the society. In patients, it reflects in 
treatment failure, increase in mortality and longer hospital stays. In addition, it also affects 
empiric treatment options for patients who have not been infected with resistant organisms 
who will be treated with broader spectrum antibiotics as a result of pathogen resistance to the 
narrower spectrum antibiotics. These drugs could be more expensive, toxic and sometimes 
less efficacious [41-42]. Within the healthcare system, antimicrobial resistance limits 
therapeutic options, threatens the safety and efficacy of surgeries and immunosuppressive 
procedures, interrupts hospital activity in cases where sections of hospitals have to be closed 
down to contain an outbreak among others [41]. The societal impact occurs when 
considerable financial investments have to be made to the health sector leading to diminished 
resources to other sectors of society. To curb this menace, surveillance programs need to be 
put in place to monitor the use of antibiotics as no active surveillance system currently exists 
in Ghana. Laws governing the distribution of antibiotics within the country need to be 
tightened and the activities of lower level health facilities and over-the-counter medicine 
sellers need to be regulated. Prescribing practices of doctors and healthcare practitioners also 
need to be monitored. 
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Conclusion 
Antibiotic therapy has been successful in the treatment of early limited cases of BU. The 
median time to healing in large ulcers and those that may require some surgical interventions 
is not very well investigated, but is expected to be longer.  Consequently, wound care is very 
vital in BU management.   
In this thesis, we investigated the factors that could contribute to delayed wound healing 
observed in the BU treatment centers Obom Health Center and Ga-West Municipal Hospital 
and identified secondary wound infection, HIV co-infection and poor wound care practices as 
critical features. Our findings demonstrate the need for clear guidelines on wound care in BU 
case management, as we observed a general need for improvement in nursing practices. 
Consequently, with the help of the national BU control programme and other collaborators, 
several interventions were put in place including: the development of a wound management 
protocol and the design and distribution of wound dressing posters and assessment charts, 
equipping the health centers with needed equipment, refurbishment of a new dressing room at 
Ga West Municipal Hospital and providing wound care training for health workers in the 
facilities. Preliminary results from these interventions show an improvement in time to 
healing and a decrease in the duration of hospital stays by patients. Studying the bacteria 
isolated from the lesions of the patients helped us to identify the sources of infection of the 
lesions. The work of this thesis also contributes valuable data to the increasing global 
problem of drug resistance. The identification and characterization of an ST88 CA-MRSA 
clone presents the first genomic description of this ‘African’ MRSA clone and calls for 
vigilance and antibiotic stewardship programs to be put in place to prevent epidemics. 
Overall, our study demonstrated that with coordinated efforts between researchers, clinicians 
and stakeholders in health care, BU disease can be effectively managed.  
 
Future perspectives 
1. Management of BU wounds needs to be improved.  
2. Major investment in BU management is needed. While we provided several 
interventions for the management of the disease during the course of this study, the  
activities were grant funded and these interventions will therefore not be sustainable 
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in the long term. Other means of financing are therefore needed to maintain the 
standards currently laid down in the BU treatment centers.   
3. Health care should be decentralized to reduce the health-worker to patient ratio at the 
secondary health centers and ensure that patients have access to proper care. 
4. Antibiotic resistance is a problem that needs to be tackled. An active surveillance 
system urgently needs to be put in place to monitor drug use and spread of resistant 
pathogens in the country. 
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